

CITATION REPORT

List of articles citing

Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk

DOI: 10.1016/j.jacc.2006.03.042

Journal of the American College of Cardiology, 2006, 48, 193-202.

Source: <https://exaly.com/paper-pdf/39771304/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2297	.		
2296	Platelets in Hematologic and Cardiovascular Disorders: A Clinical Handbook. 2001 ,		2
2295	Antiplatelet therapies in cardiology. 2001 , 407-436		
2294	The molecular mechanisms of congenital hypofibrinogenaemia. 2004 , 61, 1427-38		39
2293	Biomimetic actuators: where technology and cell biology merge. 2004 , 61, 2497-509		43
2292	Promoting vascular regeneration as an alternative to conventional angioplasty-based intervention. 2006 , 13, 431-9		3
2291	Endothelial progenitor cell-coated stents under scrutiny. 2006 , 22, 1117-9		12
2290	Drug-eluting stent thrombosis: increasingly recognized but too frequently overemphasized. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 203-5	15.1	38
2289	Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 2592-5	15.1	17
2288	Clinical benefits of drug-eluting stents: results from RAVEL and beyond. 2006 , 21, 442-50		3
2287	Bibliography. Current world literature. Coronary artery disease. 2006 , 17, 637-56		
2286	Polymers, drug release, and drug-eluting stents. 2006 , 19, 500-6		80
2285	New developments in coronary stent technology. 2006 , 19, 493-9		22
2284	Drug-eluting stents--safety concerns. 2006 , 29, 479-80		1
2283	[The European Society of Cardiology (ESC) guidelines for percutaneous coronary interventions (PCI). Three case reports]. 2006 , 31, 836-46, 848		11
2282	Cause of death with bare metal and sirolimus-eluting stents. 2006 , 27, 2815-22		33
2281	Treatment of in-stent restenosis--back to the future?. 2006 , 35, 2149-51		35

2280	Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. 2006 , 114, 2154-62	120
2279	Cypher versus Taxus: the stent war. 2006 , 15, 1537-44	2
2278	Regulation of smooth muscle cells in development and vascular disease: current therapeutic strategies. 2006 , 4, 789-800	41
2277	Drug-eluting stent thrombosis: it's never too late. 2006 , 3, 638-9	6
2276	Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angiography. 2007 , 93, 1533-6	26
2275	Far-fetched benefit of inflammation. 2007 , 115, 548-9	1
2274	Emerging thrombotic effects of drug eluting stents. 2007 , 27, 261-2	10
2273	Vascular pathology as a result of drug-eluting stents. 2007 , 93, 895-6	2
2272	Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. 2007 , 5, 939-53	1
2271	Drug-eluting stents: can we move beyond stent thrombosis?. 2007 , 5, 155-8	
2270	The pharmacist's role in tobacco cessation: overview and introduction to the series. 2007 , 64, 1434-6	4
2269	Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. 2007 , 116, 2391-8	162
2268	Prevention of restenosis: is angioplasty the answer?. 2007 , 93, 539-41	30
2267	Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent. 2007 , 64, 1432-4	1
2266	Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model. 2007 , 76, 361-72	44
2265	Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angiography. 2007 , 93, 1353-6	22
2264	Late coronary stent thrombosis. 2007 , 116, 1952-65	186
2263	Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. 2007 , 28, 974-9	90

2262	Treatment of restenosis with a paclitaxel-coated balloon catheter. 2007 , 356, 1071; author reply 1072-3	2
2261	Drug-Eluting Stents: Das Ende einer Erfolgsstory?. 2007 , 3, 237-249	
2260	[Acute myocardial infarction after discontinuing aspirin two years after implantation of a drug-eluting coronary stent]. 2007 , 132, 201-4	
2259	Stent thrombosis in the drug-eluting stent age. 2007 , 5, 138-40	
2258	Drug-eluting stents: the continuing controversy -- a perspective on the downside of drug-eluting stents. 2007 , 5, 159-64	
2257	Controversies surrounding the use of drug-eluting stents. 2007 , 5, 141-5	
2256	Lessons learned in the drug-eluting stent era. 2007 , 5, 169-72	
2255	3D motion compensated tomographic reconstruction of coronary stents from X-ray rotational sequence : an experimental study. 2007 , 2007, 735-8	
2254	Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. 2007 , 93, 922-7	46
2253	Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. 2007 , 356, 1030-9	1025
2252	Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. 2007 , 115, 2435-41	1079
2251	Drug-eluting stent update 2007: part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease). 2007 , 116, 1424-32	51
2250	Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. 2007 , 115, 1051-8	751
2249	Response to Letter Regarding Article, Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization□ 2007 , 116,	0
2248	Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REGistro AngiopLastiche dell'Emilia Romagna) multicenter registry. 2007 , 115, 3181-8	118
2247	Response to Letter Regarding Article, Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern□ 2007 , 116,	4
2246	ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American	540
2245	Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys: 2007 , 27; 2563-8 116, e418-99	61

2244	Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. 2007 , 115, 813-8	670
2243	Drug-eluting stent update 2007: part II: Unsettled issues. 2007 , 116, 961-8	50
2242	Vascular responses to drug eluting stents: importance of delayed healing. 2007 , 27, 1500-10	743
2241	Comparison of the incidence of acute coronary event after balloon angioplasty vs. stenting in native coronary arteries. 2007 , 46, 1501-6	
2240	Periprocedural soluble P- and E-selectin levels fail as predictors of clinical restenosis in patients treated with elective coronary stenting. 2007 , 19, 187	
2239	Does clopidogrel each day keep stent thrombosis away?. 2007 , 297, 209-11	8
2238	Current issues in coronary artery stenting in the elderly. 2007 , 3, 105-114	2
2237	Stenting the coronaries and bypassing the evidence in patients with multivessel coronary artery disease: time to set the record straight. 2007 , 8, 362-70	1
2236	Drug-eluting stents or drug-eluting conduits for multivessel disease?. 2007 , 8, 359-61	3
2235	Current World Literature. 2007 , 22, 586-601	
2234	The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. 2007 , 22, 565-71	21
2233	Antiplatelet therapy in patients undergoing coronary stent implantation: Italian Society of Interventional Cardiology consensus document. 2007 , 8, 782-91	4
2232	Long-term health outcome and mortality evaluation after invasive coronary treatment using drug-eluting stents: HOME DES registry. 2007 , 18, 577-81	1
2231	Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. 2007 , 8, 625-8	1
2230	Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. 2007 , 153, 354-9	70
2229	Acute myocardial infarction and drug-eluting stents: a green light for their use or time for measured restraint?. 2007 , 153, 719-21	13
2228	Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. 2007 , 154, 846-51	40
2227	Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. 2007 , 83, S27-86	709

2226	Four-year results after brachytherapy for diffuse coronary in-stent restenosis: will coronary radiation therapy survive?. 2007 , 8, 170-4	2
2225	A tale of two stents: perioperative management of patients with drug-eluting coronary stents. 2007 , 19, 386-96	15
2224	Still a future for the bare metal stent?. 2007 , 121, 1-3	14
2223	A serial ultrasound assessment of neoaneurysm following paclitaxel-eluting stent implantation. 2007 , 123, e21-2	4
2222	Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. 2007 , 369, 667-78	1634
2221	Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. 2007 , 369, 1869-1875	686
2220	Percutaneous coronary interventions and antiplatelet therapy in the perioperative period. 2007 , 21, 436-42	6
2219	The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents. 2007 , 23, 121-3	13
2218	In Vitro and In Vivo Biocompatibility Testing of Absorbable Metal Stents. 2007 , 253, 103-108	33
2217	Delivery of large biopharmaceuticals from cardiovascular stents: a review. 2007 , 8, 3281-93	60
2216	Clinical end points in coronary stent trials: a case for standardized definitions. 2007 , 115, 2344-51	4380
2215	Motion correction for coronary stent reconstruction from rotational X-ray projection sequences. 2007 , 26, 1412-23	18
2214	Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). 2007 , 28, 719-25	64
2213	A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. 2007 , 356, 989-97	568
2212	Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. 2007 , 356, 998-1008	1555
2211	Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. 2007 , 115, 2426-34	662
2210	Therapy insight: diabetes and drug-eluting stents. 2007 , 4, 143-50	12
2209	Drug-eluting stent technologies for vascular regeneration. 2007 , 98, 637-642	5

2208	Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. 2007 , 356, 1009-19		962
2207	Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. 2007 , 115, 1440-55; discussion 1455		603
2206	Pathology of atherosclerosis and stenting. 2007 , 17, 285-301, vii		29
2205	Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. 2007 , 292, H2935-43		53
2204	Local vascular toxicokinetics of stent-based drug delivery. 2007 , 168, 93-102		27
2203	Mechanisms of vascular injury from drug-eluting stents. 2007 , 4, 141-146		1
2202	Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 181-4	15.1	70
2201	Reply. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 627	15.1	
2200	The mortality of late stent thrombosis in the drug-eluting stent era--still underemphasized. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 627; author reply 627	15.1	
2199	Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of	15.1	364
2198	Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1924-30	15.1	190
2197	Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1265-71	15.1	32
2196	Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 176-85	15.1	54
2195	Drug-eluting stents is their future as bright as their past?. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 146-8	15.1	10
2194	Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 138-45	15.1	69
2193	Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 119-27	15.1	104
2192	Thrombosis and drug-eluting stents: an objective appraisal. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 109-18	15.1	98
2191	The year in interventional cardiology. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 270-85	15.1	6

2190	Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 501-8	15.1	174
2189	Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 573-83	15.1	360
2188	President's page: drug-eluting stents in contemporary practice--a call for a real-world, open-entry, device-tracking registry. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 2223-6	15.1	3
2187	"Crying fire in a theater" or a "confirmatory sighting?". <i>Journal of the American College of Cardiology</i> , 2007 , 50, 268-9	15.1	7
2186	A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1373-80	15.1	253
2185	Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 2249-53	15.1	41
2184	ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Anesthesiologists, Society. <i>Journal of the American College of Cardiology</i> , 2007 , 50, e159-241	15.1	409
2183	Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil. <i>Journal of the American College of Cardiology</i> , 2007 , 50, e159-241		10
2182	Effects of Coffee and Napping on Nighttime Highway Driving. 2007 , 146, 229		
2181	Trombose tardia (3 anos e 9 meses) de stent Cypher. 2007 , 15, 164-166		
2180	Estudo inicial com o stent liberador de 17β-estradiol (ETHOS [®]): avaliação clínica, angiográfica e pela ultra-sonografia intracoronária. 2007 , 15, 357-362		
2179	Evolução clínica tardia dos stents farmacológicos: segurança e eficácia at cinco anos do Registro DESIRE. 2007 , 15, 221-227		1
2178	Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. 2007 , 37, 135		7
2177	Very Late Stent Thrombosis Related to Fracture of a Sirolimus-Eluting Stent. 2007 , 37, 385		1
2176	Drug-eluting coronary stents--a note of caution. 2007 , 186, 253-5		23
2175	Perioperative complications in patients with drug-eluting stents: a three-year audit at Geelong Hospital. 2007 , 35, 939-44		14
2174	Effects of coffee and napping on nighttime highway driving. 2007 , 146, 229; author reply 229		1
2173	Correction: Health Insurance Portability and Accountability Act Privacy Rule and Research Consent Documents. 2007 , 146, 232		

2172	Sirolimus-eluting cobalt alloyed stents in treating patients with coronary artery disease: six-month angiographic and one-year clinical follow-up result A prospective, historically controlled, multi-center clinical study. 2007 , 120, 533-538	12
2171	Stent thrombosis with drug-eluting stents: a re-examination of the evidence. 2007 , 69, 782-9	23
2170	Late DES thrombosis: a lot of smoke, very little fire?. 2007 , 69, 609-15	2
2169	Heterogeneity of atherosclerotic plaque characteristics in human coronary artery disease: a three-dimensional intravascular ultrasound study. 2007 , 70, 349-56	23
2168	Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. 2007 , 69, 327-33	77
2167	Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of	45
2166	Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. 2007 , 70, 515-23	124
2165	Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. 2007 , 70, 388-406	15
2164	Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial. 2007 , 70, 654-60	16
2163	Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis?. 2007 , 69, 959-60	4
2162	Efficacy of reduced-dose sirolimus-eluting stents in the human coronary artery: serial IVUS analysis of neointimal hyperplasia and luminal dimension. 2007 , 70, 946-51	10
2161	Late stent thrombosis--the "vulnerable" stent. 2007 , 70, 54-6	3
2160	What kind of stent for you today and how would you like it prepared?. 2007 , 70, 173-4	0
2159	Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: a retrospective cohort study. 2007 , 2, 378-84	30
2158	Rationale and use of near-infrared spectroscopy for detection of lipid-rich and vulnerable plaques. 2007 , 14, 719-28	18
2157	Dual antiplatelet therapy and drug eluting stents: a marriage of convenience. 2007 , 5, 15	3
2156	Cardiovascular gene therapy: current status and therapeutic potential. 2007 , 152, 175-88	63
2155	Clinical use of sirolimus-eluting stents. 2007 , 25, 316-32	7

2154	Drug-eluting stents: trading restenosis for thrombosis?. 2007 , 5 Suppl 1, 238-45	13
2153	Serpins in thrombosis, hemostasis and fibrinolysis. 2007 , 5 Suppl 1, 102-15	248
2152	Late thrombosis a concern with drug-eluting stents. 2007 , 20, 26-9	19
2151	Efficacy and safety of absorbable metallic stents with adjunct intracoronary beta radiation in porcine coronary arteries. 2007 , 20, 367-72	29
2150	Coronary stents, hypersensitivity reactions, and the Kounis syndrome. 2007 , 20, 314-23	64
2149	Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents. 2007 , 20, 307-13	28
2148	FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations. 2007 , 20, 425-46	19
2147	Stent thrombosis following drug-eluting stent implantation. A single-center experience. 2007 , 8, 243-7	12
2146	Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (> or =3.5 mm) coronary arteries. 2007 , 99, 599-602	52
2145	Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. 2007 , 99, 1033-8	169
2144	Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries. 2007 , 99, 1039-43	54
2143	Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). 2007 , 99, 1222-6	35
2142	Late stent thrombosis: problem or not?. 2007 , 99, 1020-3	5
2141	Design criteria for the ideal drug-eluting stent. 2007 , 100, 3M-9M	64
2140	Drug-eluting stent safety. 2007 , 100, 10M-17M	23
2139	The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. 2007 , 100, 36M-44M	99
2138	Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. 2007 , 100, 71M-76M	20
2137	Les stents: une belle histoire. 2007 , 56, S39-S41	

2136 Stents coronaires et anti-agrègants plaquettaires. **2007**, 56, S53-S62

2135 Release profiles in drug-eluting stents: issues and uncertainties. **2007**, 120, 149-60

139

2134 Situación actual de los stents liberadores de fármacos: nuevos desafíos y nuevas dudas. Introducción. **2007**, 7, 1E-7E

2133 Stents recubiertos en el infarto agudo de miocardio. **2007**, 7, 63E-71E

2132 Seguridad a largo plazo de los stents recubiertos. El fenómeno de la trombosis tardía. **2007**, 7, 80E-90E

2131 Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. **2007**, 15, 382-6

8

2130 Coronary stent healing, endothelialisation and the role of co-medication. **2007**, 15, 395-6

9

2129 Contemporary use of clopidogrel in patients with coronary artery disease. **2007**, 9, 257-63

5

2128 Late thrombosis with drug-eluting stents: anatomy of a controversy and lessons learned. **2007**, 9, 429-31

1

2127 Coronary dilatation 10 weeks after paclitaxel-eluting stent implantation. No role of shear stress in lumen enlargement?. **2007**, 22, 268-73

9

2126 [Update cardiology 2006/2007]. **2007**, 102, 647-58

2125 [Stent thrombosis in the era of drug-eluting stents]. **2007**, 32, 411-8

4

2124 Drug-eluting stents, restenosis and revascularization. **2007**, 32, 287-95

12

2123 Angioscopic findings after drug-eluting stent implantation. **2007**, 32, 281-6

6

2122 Vascular pathology of drug-eluting stents. **2007**, 32, 274-80

45

2121 Biological effects of drug-eluting stents in the coronary circulation. **2007**, 32, 268-73

26

2120 [Increased rate of stent thrombosis with DES]. **2007**, 32, 296-300

3

2119 [Treatment after drug-eluting stent placement]. **2007**, 32, 301-6

0

2118	[Drug-eluting stents: breakthrough or time bomb]. 2007 , 32, 265-7	1
2117	A biodegradable slotted tube stent based on poly(L-lactide) and poly(4-hydroxybutyrate) for rapid balloon-expansion. 2007 , 35, 2031-8	66
2116	Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature. 2007 , 96, 86-93	38
2115	Drug-eluting stents: What is the balance of risks and benefits?. 2007 , 1, 279-283	
2114	Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES). 2007 , 1, 84-111	21
2113	Coronary stents: a materials perspective. 2007 , 28, 1689-710	630
2112	Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study. 2008 , 1, 192-201	64
2111	Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. 2008 , 1, 535-44	44
2110	The lack of endothelialization after drug-eluting stent implantation as a cause of fatal late stent thrombosis. 2008 , 26, 154-8	5
2109	Drug-eluting coronary stent very late thrombosis revisited. 2008 , 33, 334-42	22
2108	[Clopidogrel--clinical use and potential therapeutic problems]. 2008 , 33, 280-6	2
2107	[Optimal platelet inhibition after coronary stent implantation. Current status]. 2008 , 33, 244-53	4
2106	Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. 2008 , 64, 227-32	1
2105	Drug-eluting stents: Are they still the answer?. 2008 , 2, 334-341	
2104	Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. 2008 , 97, 773-81	195
2103	Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. 2008 , 71, 333-9	22
2102	Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry. 2008 , 71, 51-7	29
2101	Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients. 2008 , 71, 600-4	75

2100	"Anti-healing" versus "pro-healing". 2008 , 71, 605-6	2
2099	Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. 2008 , 72, 186-94	55
2098	Biodegradable polymers--are they the answer to late stent thrombosis? Too early to tell. 2008 , 72, 184-5	
2097	Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. 2008 , 72, 893-900	23
2096	Enzymatic release of a surface-adsorbed RGD therapeutic from a cleavable peptide anchor. 2008 , 3, 1645-8	9
2095	Intracellular Ca ²⁺ stores are essential for injury induced Ca ²⁺ signaling and re-endothelialization. 2008 , 214, 595-603	16
2094	Coronary artery aneurysms after drug-eluting stent implantation. 2008 , 1, 14-21	138
2093	In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. 2008 , 1, 168-73	110
2092	Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. 2008 , 1, 227-32	11
2091	Drug-eluting stents for ST-segment elevation myocardial infarction: treatment of choice or is discretion the better part of valor?. 2008 , 1, 233-5	1
2090	Biostability and biological performance of a PDMS-based polyurethane for controlled drug release. 2008 , 29, 2987-95	95
2089	Drug delivery from gold and titanium surfaces using self-assembled monolayers. 2008 , 29, 4561-73	88
2088	Improved endothelial cell adhesion and proliferation on patterned titanium surfaces with rationally designed, micrometer to nanometer features. 2008 , 4, 192-201	214
2087	Reprogramming the cell cycle machinery to treat cardiovascular disease. 2008 , 8, 193-201	10
2086	In-stent restenosis in bare metal stents versus sirolimus-eluting stents after primary coronary intervention for acute myocardial infarction and subsequent transcatheter transplantation of autologous stem cells. 2008 , 31, 356-9	4
2085	Assessing the current role of platelet function testing. 2008 , 31, 110-6	24
2084	Short-term effects of biocorrosible iron stents in porcine coronary arteries. 2008 , 21, 15-20	187
2083	Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study. 2008 , 21, 388-94	4

2082	Near-infrared spectroscopy for plaque characterization. 2008 , 21, 452-8	18
2081	Comparison of vasa vasorum after intravascular stent placement with sirolimus drug-eluting and bare metal stents. 2008 , 52, 570-5	11
2080	Study comparing the double kissing (DK) crush with classical crush for the treatment of coronary bifurcation lesions: the DKCRUSH-1 Bifurcation Study with drug-eluting stents. 2008 , 38, 361-71	84
2079	Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. 2008 , 101, 293-9	35
2078	Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry. 2008 , 101, 1105-11	34
2077	Comparison of neointimal coverage by optical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation. 2008 , 102, 27-31	62
2076	Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. 2008 , 102, 298-303	43
2075	Comparison of the impact of short (or =1 year) clopidogrel use following percutaneous coronary intervention on mortality. 2008 , 102, 1159-62	29
2074	Very late thrombosis of paclitaxel-eluting stent. 2008 , 9, 275-7	4
2073	Optical coherence tomography and intravascular ultrasound imaging of bioabsorbable magnesium stent degradation in porcine coronary arteries. 2008 , 9, 248-54	56
2072	Will carotid angioplasty become the preferred alternative to staged or synchronous carotid endarterectomy in patients undergoing cardiac surgery?. 2008 , 36, 379-84	20
2071	Stent farmacoactivo y antiagregaci3n. Actitud preoperatoria. 2008 , 15, 21-26	
2070	Adjustable paclitaxel release kinetics and its efficacy to inhibit smooth muscle cells proliferation. 2008 , 130, 9-14	38
2069	The future of drug-eluting stents. 2008 , 57, 171-80	97
2068	Micropatterned structural control suppresses mechanotaxis of endothelial cells. 2008 , 95, 3066-78	27
2067	[Stents and thrombosis]. 2008 , 130, 175-6	1
2066	Beyond Oncogenesis: The Role of S-Phase Kinase-Associated Protein-2 (SKP2) In Vascular Restenosis. 2008 , 2, 158-166	2
2065	Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases. 2008 , 101, 100-7	7

2064	Use of drug eluting stents: expert consensus of the French Society of Cardiology. 2008 , 101, 190-3		4
2063	Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 618-26	15.1	130
2062	Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 885-92	15.1	117
2061	Drug-eluting stent implantation may not affect vasomotor function in early phase. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1124-5; author reply 1125	15.1	2
2060	Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2123-9	15.1	131
2059	A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1543-52	15.1	97
2058	Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2011-6	15.1	44
2057	Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2220-7	15.1	95
2056	The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2228-9	15.1	11
2055	The "vulnerable" stent why so dreadful?. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2403-6	15.1	16
2054	Endothelial cell recovery between comparator polymer-based drug-eluting stents. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 333-42	15.1	531
2053	Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1134-40	15.1	404
2052	Stent thrombosis in 2008: definition, predictors, prognosis and treatment. 2008 , 101, 769-77		41
2051	Enhanced cellular mobility guided by TiO ₂ nanotube surfaces. 2008 , 8, 786-93		242
2050	Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. 2009 , 30, 321-9		99
2049	Impact of blood circulation on reendothelialization, restenosis and atorvastatin's restenosis prevention effects. 2008 , 128, 261-8		4
2048	Functional result following direct coronary artery stenting with drug eluting stents in chronic stable angina is similar to stenting after balloon predilatation. 2008 , 128, 374-7		1
2047	Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents. 2008 , 130, 444-8		14

2046 [New antiplatelet drugs]. **2008**, 37, 1055-68

2045	Thiazolidinediones may be effective in the prevention of stent thrombosis with DES. 2008 , 70, 329-32	3
2044	Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?. 2008 , 70, 512-4	13
2043	Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. 2008 , 155, 108-13	73
2042	Local catheter-based delivery of antithrombotic or antiproliferative drugs: a new concept for prevention of restenosis. 2008 , 123, 236-43	11
2041	Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents. 2008 , 34, 62-7	6
2040	Drug-eluting stents: patient understanding of the risks of premature cessation of antiplatelet drugs. 2008 , 22, 806-10	6
2039	Coronary stents and noncardiac surgery: treat the patient, not the stent!. 2008 , 22, 803-5	
2038	Introducing the first polymer-free leflunomide eluting stent. 2008 , 200, 126-34	21
2037	Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. 2008 , 371, 2134-43	96
2036	Drug-eluting stents - what should be improved?. 2008 , 40, 242-52	36
2035	Safety of drug-coated stents. 2008 , 7, 597-606	4
2034	Drug-eluting stent thrombosis: A lesson in vascular biology. 2008 , 24, 50C-55C	2
2033	Efficacy of a polyphosphazene nanocoat in reducing thrombogenicity, in-stent stenosis, and inflammatory response in porcine renal and iliac artery stents. 2008 , 19, 427-37	18
2032	Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. 2009 , 30, 16-24	87
2031	Safety of drug-eluting stents. 2008 , 5, 316-28	17
2030	The effects of vinblastine on endothelial cells. 2008 , 15, 9-15	12
2029	Meta-analysis shows similar risk of thrombosis after drug-eluting stent, bare-metal stent, or angioplasty. 2008 , 15, 93-100	6

2028	Cardiac optical coherence tomography. 2008 , 94, 1200-10	37
2027	Dual antiplatelet therapy with clopidogrel and aspirin. 2008 , 65, 1134-43	8
2026	Local delivery of 17-beta-estradiol modulates collagen content in coronary porcine arteries after PTCA and stent implantation. 2008 , 45, 503-11	8
2025	Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. 2008 , 1, 193-200	78
2024	Meta-iodobenzylguanidine, an inhibitor of arginine-dependent mono(ADP-ribosyl)ation, prevents neointimal hyperplasia. 2008 , 326, 717-24	5
2023	Very late stent thrombosis after dual antiplatelet therapy discontinuation in a patient with a history of acute stent thrombosis. 2008 , 42, 708-12	7
2022	Cardiovascular Toxicology. 2008 ,	
2021	Does prior PCI increase the risk of subsequent CABG?. 2008 , 29, 573-5	9
2020	ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. 2009 , 30, 152-61	25
2019	Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. 2008 , 29, 2868-76	81
2018	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. 2008 , 29, 1975-82	158
2017	Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction: a new red flag is raised. 2008 , 118, 1117-9	37
2016	Thrombosis after stent implantation: how much of a problem is there?. 2008 , 4, 261-7	6
2015	Numerical study of the uniformity of balloon-expandable stent deployment. 2008 , 130, 021018	34
2014	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. 2008 , 337, a1331	209
2013	Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. 2008 , 94, 322-8	60
2012	Coronary artery bypass grafting versus stenting for unprotected left main coronary artery disease: where lies the body of proof?. 2008 , 118, 2326-9	8
2011	Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. 2008 , 118, 1138-45	701

2010	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely. 2008 , 1, 226-32	3
2009	The safety of drug-eluting stents. 2008 , 2, 43-52	6
2008	Drug-eluting stents: a review of current evidence on clinical effectiveness and late complications. 2008 , 53, 16-24	3
2007	In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. 2008 , 78, 563-71	88
2006	Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease. 2008 ,	
2005	Lack of association between large angiographic late loss and low risk of in-stent thrombus: angioscopic comparison between paclitaxel- and sirolimus-eluting stents. 2008 , 1, 20-7	31
2004	High incidence of intramural thrombus after overlapping paclitaxel-eluting stent implantation: angioscopic and histopathologic analysis in porcine coronary arteries. 2008 , 1, 28-35	20
2003	Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. 2008 , 117, 923-30	57
2002	Revealing the silver and red lining in drug-eluting stents with angioscopy. 2008 , 1, 7-9	2
2001	Primary percutaneous coronary intervention for acute myocardial infarction: long-term outcome after bare metal and drug-eluting stent implantation. 2008 , 1, 103-10	36
2000	Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent. 2008 , 117, 1603-8	22
1999	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. 2009 , 30, 923-31	104
1998	Effects of stent design and atherosclerotic plaque composition on arterial wall biomechanics. 2008 , 15, 643-54	44
1997	Late incomplete stent apposition after drug-eluting stent implantation: a true risk factor or "an innocent bystander"?. 2008 , 94, 253-4	10
1996	Physiological evaluation of the provisional side-branch intervention strategy for bifurcation lesions using fractional flow reserve. 2008 , 29, 726-32	185
1995	Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. 2008 , 118, 1155-62	58
1994	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely. 2008 , 1, 217-25	13
1993	Temperature measurement of Ho:YAG laser induced bubble in water using silver halide IR optical fiber. 2008 ,	

1992	Drug-eluting stent safety: findings from preclinical studies. 2008 , 6, 1379-91	62
1991	Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. 2008 , 28, 1960-6	76
1990	Drug release kinetics from stent device-based delivery systems. 2008 , 51, 118-25	27
1989	Comparison of long-term angiographic follow-up after sirolimus-eluting stent and bare-metal stent implantation. 2008 , 47, 201-4	5
1988	Efficacy and safety of drug-eluting stents in long-term follow-up. 2008 , 47, 987-8	
1987	Heavily calcified coronary lesions preclude strut apposition despite high pressure balloon dilatation and rotational atherectomy: in-vivo demonstration with optical coherence tomography. 2008 , 72, 157-60	60
1986	Sirolimus-eluting stents suppress neointimal formation irrespective of metallic allergy. 2008 , 72, 893-6	19
1985	Reply to Letter Regarding Article, "Sirolimus-Eluting Stents Suppress Neointimal Formation Irrespective of Metallic Allergy". 2008 , 72, 1722	
1984	Vitamin A: a drug for prevention of restenosis/reocclusion after percutaneous coronary intervention?. 2008 , 114, 19-25	10
1983	Pro-healing drug-eluting stents: a role for antioxidants?. 2008 , 114, 265-73	13
1982	Antiplatelet Therapy in Chronic Coronary Artery Disease. 178-195	
1981	Coronary artery stents: Part I. Evolution of percutaneous coronary intervention. 2008 , 107, 552-69	52
1980	Drug eluting stents: friend or foe? A review of cellular mechanisms behind the effects of Paclitaxel and sirolimus eluting stents. 2008 , 9, 554-66	21
1979	Systemic immunosuppressive therapy with oral Sirolimus after bare metal stent implantation: the missing alternative in the prevention of coronary restenosis after percutaneous coronary interventions. 2008 , 3, 201-8	3
1978	Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy. 2008 , 9, 737-41	17
1977	Progress is precarious. 2008 , 107, 362-4	2
1976	Intimal hyperplasia in murine models. 2008 , 9, 251-60	64
1975	Coronary artery stents: II. Perioperative considerations and management. 2008 , 107, 570-90	87

1974	A more than 2-year follow-up of incomplete apposition after drug-eluting stent implantation. 2008 , 121, 498-502	6
1973	. 2008 ,	1
1972	Full Metal Jackets (Ø0 mm) of Drug-Eluting Stents: Short- and Long-term Clinical and Angiographic Outcomes. 2008 , 38, 87	2
1971	Análise volumétrica tardia após implante de stents eluidores de sirolimus versus biolimus A9. 2008 , 16, 37-43	
1970	Gene therapy for coronary and peripheral artery disease. 2008 , 18, 903-927	0
1969	A Sirolimus-Eluting Stent Fracture Combined with a Coronary Artery Aneurysm. 2008 , 38, 69	3
1968	Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers. 2009 , 2, 47-55	3
1967	Nueva generación de Stents, con polímero bio-compatibile: resultados y seguimiento clínico. 2009 , 28,	
1966	Long-term effects of novel biodegradable, polymer-coated, sirolimus-eluting stents on neointimal formation in a porcine coronary model. 2009 , 50, 811-22	14
1965	A planned hybrid culotte stenting procedure in the setting of an acute STEMI. 2009 , 2, 9104	
1964	Incredibly late thromboses in first generation drug eluting stents: a case series. 2009 , 2, 9303	1
1963	Luminal flow amplifies stent-based drug deposition in arterial bifurcations. 2009 , 4, e8105	50
1962	Non-cardiac surgery and antiplatelet therapy following coronary artery stenting. 2009 , 95, 1303-8	17
1961	Percutaneous coronary intervention in perspective: drug-eluting stents as a model for regulatory review. 2009 , 2, 574-9	3
1960	Estrogen receptor alpha expression in both endothelium and hematopoietic cells is required for the accelerative effect of estradiol on reendothelialization. 2009 , 29, 1543-50	41
1959	Development of biodegradable drug releasing polymeric cardiovascular stents and in vitro evaluation. 2009 , 26, 501-12	12
1958	Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. 2009 , 95, 1489-94	78
1957	Drug-eluting stents in animals and patients: where do we stand today?. 2009 , 120, 101-3	14

1956	Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. 2009 , 119, 2986-94	382
1955	Bioabsorbable coronary stents. 2009 , 2, 255-60	198
1954	Xience V everolimus-eluting coronary stent. 2009 , 6, 219-29	28
1953	Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation. 2009 , 105, 1003-12	22
1952	Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. 2009 , 120, 141-9, 1-2	166
1951	Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis. 2009 , 29, 857-62	16
1950	Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. 2009 , 119, 687-98	154
1949	The drug-eluting stent saga. 2009 , 119, 653-6	6
1948	Rapamycin-eluting stents in the arterial duct: experimental observations in the pig model. 2009 , 119, 2078-85	27
1947	Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT study. 2009 , 112, 191-9	21
1946	Assessment of the intimal response to a protein-modified stent in a tissue-engineered blood vessel mimic. 2009 , 15, 3869-76	13
1945	Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents. 2009 , 30, 1340-7	41
1944	MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. 2009 , 30, 1477-85	19
1943	Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. 2009 , 30, 2095-101	24
1942	Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety?. 2009 , 30, 1828-30	9
1941	The quest for a 'better mousetrap'. 2009 , 30, 2431-2	1
1940	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. 2009 , 30, 2714-21	199
1939	Novel high-throughput polymer biocompatibility screening designed for SAR (structure-activity relationship): application for evaluating polymer coatings for cardiovascular drug-eluting stents. 2009 , 12, 664-76	11

1938	Genous endothelial progenitor cell-capturing stent system: a novel stent technology. 2009 , 6, 365-75	33
1937	Intracoronary optical coherence tomography and the evaluation of stents. 2009 , 6, 157-67	13
1936	Important role of TNF-alpha in inhibitory effects of Radix Sophorae Flavescentis extract on vascular restenosis in a rat carotid model of balloon dilatation injury. 2009 , 75, 1293-9	4
1935	Time does not heal every wound: coronary stent thrombosis of a bare-metal stent more than one decade after its implantation. 2009 , 20, 594-7	1
1934	Current issues in coronary stent technology. 2009 , 223, 515-24	18
1933	Rapamycin enhances platelet aggregation induced by adenosine diphosphate in vitro. 2009 , 20, 428-31	8
1932	Drug transport in artery walls: a sequential porohyperelastic-transport approach. 2009 , 12, 263-76	27
1931	Treatment of acute myocardial infarction with sirolimus-eluting stents results in chronic endothelial dysfunction in the infarct-related coronary artery. 2009 , 2, 384-91	19
1930	Off-label use and the spectre of drug-eluting stent thrombosis. 2009 , 2, 273-6	2
1929	Long-term outcomes of patients receiving drug-eluting stents. 2009 , 180, 167-74	7
1928	Restenosis revisited. 2009 , 104, 823-5	7
1927	Drug-eluting stent thrombosis. 2009 , 3, 45-52	20
1926	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. 2009 , 30, 2441-9	180
1925	2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. 2009 , 126, e169-276	226
1924	Luminal flow patterns dictate arterial drug deposition in stent-based delivery. 2009 , 133, 24-30	88
1923	Tailored drug release from biodegradable stent coatings based on hybrid polyurethanes. 2009 , 137, 224-33	100
1922	Coronary aneurysm associated with coronary perforation after sirolimus-eluting stents implantation: close follow-up exceeding 2 years by coronary 3-dimensional computed tomography. 2009 , 54, 115-20	3
1921	A case of a newly developed yellow neointima at stent implanted site 1 year after sirolimus-eluting stent placement: angioscopic findings. 2009 , 54, 153-7	13

1920	Effect of alpha lipoic acid in a porcine in-stent restenosis model. 2009 , 54, 375-85	14
1919	The problem of stent thrombosis associated with drug-eluting stents and the optimal duration of dual antiplatelet therapy. 2009 , 12, 59-64	
1918	Relation of drug-eluting stent strut distribution to stent thrombosis in coronary arteries. 2009 , 104, 343-8	4
1917	Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 2009 , 104, 525-30	46
1916	Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. 2009 , 104, 1660-7	48
1915	Anaesthesia and coronary artery stents. 2009 , 20, 150-154	
1914	Metal allergic reaction in chronic refractory in-stent restenosis. 2009 , 10, 17-22	41
1913	Recurrent very late drug-eluting stent thrombosis. 2009 , 10, 130-5	3
1912	Preliminary observations using optical coherence tomography to assess neointimal coverage of a metal stent in a porcine model. 2009 , 10, 229-35	3
1911	Late-acquired incomplete stent apposition: morphologic characterization. 2009 , 10, 236-46	17
1910	Drug-eluting stent fracture and acute coronary syndrome. 2009 , 10, 166-71	29
1909	The Current Status of Coronary Drug-Eluting Stents. 2009 , 21, 18-27	1
1908	Strategies for drug-eluting stent treatment of bifurcation coronary artery disease in the United States: insights from the e-Cypher S.T.L.L.R.trial. 2009 , 73, 890-7	5
1907	Neointimal regression-induced incomplete coverage of a bare-metal stent in the left main trunk: serial angiographic and angioscopic evidence obtained by 5-year follow-up. 2009 , 73, 787-90	4
1906	The incidence and predictors of postprocedural incomplete stent apposition after angiographically successful drug-eluting stent implantation. 2009 , 74, 58-63	16
1905	The risk of cardiac complications following noncardiac surgery in patients with drug eluting stents implanted at least six months before surgery. 2009 , 74, 837-43	29
1904	Failure of drug eluting stents presented as definite stent thrombosis. 2010 , 76, 93-7	1
1903	Improving endothelial cell adhesion and proliferation on titanium by sol-gel derived oxide coating. 2010 , 92, 754-65	9

1902	Evaluation of self-expandable, FK506-coated, covered stents in canine animal model. 2009 , 90, 647-52	3
1901	Interaction of endothelial cells with self-assembled monolayers for potential use in drug-eluting coronary stents. 2009 , 90, 789-801	26
1900	Absorbable polymer stent technologies for vascular regeneration. 2009 , 85, 744-751	40
1899	Echocardiographic identification of ventricular septal rupture caused by acute stent thrombosis. 2010 , 38, 218-21	
1898	The risk of definitive stent thrombosis is increased after "off-label" stent implantation irrespective of drug-eluting stent or bare-metal stent use. 2009 , 98, 549-54	18
1897	Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing. 2009 , 2, 284-90	27
1896	The pre-clinical animal model in the translational research of interventional cardiology. 2009 , 2, 373-83	43
1895	Optimal stent-sizing with intravascular ultrasound contributes to complete neointimal coverage after sirolimus-eluting stent implantation assessed by angioscopy. 2009 , 2, 989-94	20
1894	Use of a novel anti-proliferative compound coated on a biopolymer to mitigate platelet-derived growth factor-induced proliferation in human aortic smooth muscle cells: comparison with sirolimus. 2009 , 26, 721-32	1
1893	Estrogen-eluting stents. 2009 , 2, 240-4	9
1892	Near-infrared spectroscopy for the detection of lipid core coronary plaques. 2009 , 2, 307-315	8
1891	[Perioperative management of patients with coronary stents in non-cardiac surgery]. 2009 , 58, 971-85	30
1890	[Patients with coronary artery stents: when and how should operations be carried out?]. 2009 , 80, 515-8	
1889	Effect of balloon inflation time on expansion of sirolimus-eluting stent. 2009 , 24, 335-9	17
1888	Are drug-eluting stents safe?: Definitely! Or probably... possibly? Or maybe not yet. 2009 , 86, 127-30	1
1887	Drug packaging and delivery using perfluorocarbon nanoparticles for targeted inhibition of vascular smooth muscle cells. 2009 , 30, 1577-84	7
1886	Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing. 2009 , 22, 37-48	27
1885	Long-term clinical follow-up after sirolimus-eluting stent versus bare metal stent implantation in patients with acute coronary syndrome. 2009 , 22, 216-21	3

1884	XIENCE V Everolimus-Eluting Coronary Stent System: A Preclinical Assessment. 2009 , 22, S28-S40	29
1883	Choice of DES: A European Clinician's Perspective. 2009 , 22, S86-S95	
1882	Endothelialization of nonapposed stent struts located over the origin of a side branch: results with different carbofilm-coated stents. 2009 , 22, 222-7	16
1881	Incomplete stent apposition after coronary stent implantation: myth or reality?. 2009 , 22, 341-9	8
1880	Experimental evaluation of a new antithrombogenic stent using ion beam surface modification. 2009 , 33, 456-63	6
1879	A nanoscale drug-entrapment strategy for hydrogel-based systems for the delivery of poorly soluble drugs. 2009 , 30, 2102-11	69
1878	Assessment of tissue prolapse after balloon-expandable stenting: influence of stent cell geometry. 2009 , 31, 441-7	56
1877	Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. 2009 , 2, 312-20	140
1876	Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. 2009 , 2, 253-62	55
1875	Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?. 2009 , 2, 300-2	34
1874	Baseline fractional flow reserve and stent diameter predict optimal post-stent fractional flow reserve and major adverse cardiac events after bare-metal stent deployment. 2009 , 2, 357-63	31
1873	A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. 2009 , 2, 437-44	55
1872	Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. 2009 , 2, 445-52	147
1871	Drug-eluting stent thrombosis: the Kounis hypersensitivity-associated acute coronary syndrome revisited. 2009 , 2, 583-93	94
1870	Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. 2009 , 2, 779-84	37
1869	Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy. 2009 , 2, 861-70	38
1868	A generation 2.5 drug-eluting stent?. 2009 , 2, 986-8	4
1867	Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. 2009 , 2, 977-85	113

1866	Optimal stent expansion and complete neointimal coverage: does this association make sense?. 2009 , 2, 995-6	0
1865	Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results. 2009 , 2, 1017-24	6
1864	The first-generation drug-eluting stents and coronary endothelial dysfunction. 2009 , 2, 1169-77	74
1863	Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De	46
1862	The characteristics and in vivo suppression of neointimal formation with sirolimus-eluting polymeric stents. 2009 , 30, 79-88	62
1861	The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. 2009 , 30, 632-7	52
1860	The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. 2009 , 30, 2276-83	210
1859	Late stent thrombosis, endothelialisation and drug-eluting stents. 2009 , 17, 177-80	13
1858	Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents. 2009 , 32, 164-8	8
1857	Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Libert [®] paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. 2009 , 2, 188-95	125
1856	Retrospective on the future of polyelectrolyte multilayers. 2009 , 25, 14007-10	122
1855	Nitric oxide treatment reduces neo-intimal formation and modulates osteopontin expression in an ex-vivo human model of intimal hyperplasia. 2009 , 46, 228-35	5
1854	A practical method to rapidly dissolve metallic stents. 2009 , 18, 127-33	38
1853	Paclitaxel induces up-regulation of tissue factor in human aortic endothelial cells. 2009 , 9, 144-7	7
1852	A novel drug-eluting stent using bioabsorbable polymer technology: two-year follow-up of the CURAMI registry. 2009 , 131, 272-4	8
1851	Effect of blood flow on drug release from DES: an experimental study. 2009 , 131, 415-7	4
1850	Hypereosinophilic syndrome associated with multiple coronary aneurysms. 2009 , 133, e43-5	17
1849	An angiographic evaluation of restenosis rate at a six-month follow-up of patients with ST-elevation myocardial infarction submitted to primary percutaneous coronary intervention. 2009 , 131, 362-9	5

1848	Consecutively developed late stent malappositions following the implantation of two different kinds of drug-eluting stents associated with spontaneous healing. 2009 , 134, e7-10		3
1847	Distribution pattern of neointimal hyperplasia following sirolimus-eluting stent implantation assessed by 3-dimensional intravascular ultrasound. 2009 , 135, 243-5		2
1846	HVJ-AVE liposome-mediated Tissue Factor Pathway Inhibitor (TFPI) gene transfer with recombinant TFPI (rTFPI) irrigation attenuates restenosis in atherosclerotic arteries. 2009 , 135, 245-8		11
1845	Use of multiple overlapping sirolimus-eluting stents for treatment of long coronary artery lesions: results from a single-center registry in 318 consecutive patients. 2009 , 134, 231-7		14
1844	Low-dose paclitaxel elution by novel bioerodible sol-gel coating on stents inhibits neointima with low toxicity in porcine coronary arteries. 2009 , 135, 93-101		12
1843	Intraoperative drug-eluting stent thrombosis in a patient undergoing robotic prostatectomy. 2009 , 21, 517-20		6
1842	Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study). 2009 , 157, 149-55		45
1841	Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice. 2009 , 157, 883-8		17
1840	Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents. 2009 , 158, 271-6		33
1839	Design and rationale of the TRI-stent adjudication study (TRIAS) program. 2009 , 158, 527-532.e1		11
1838	Rationale and design of the Patient Related Outcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. 2009 , 158, 902-909.e5		38
1837	Simultaneous very late angiographic stent thrombosis of 2 drug-eluting stents: a case report. 2009 , 27, 131.e5-131.e8		2
1836	Comparative analysis of neointimal coverage with paclitaxel and zotarolimus drug-eluting stents, using optical coherence tomography 6 months after implantation. 2009 , 102, 617-24		15
1835	The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. 2009 , 134, 180-8		116
1834	Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 2053-60	15.1	117
1833	Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 2298-305	15.1	57
1832	Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1924-31	15.1	205
1831	2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. <i>Journal of the American College of Cardiology</i> , 2009 , 54, e13-e118	15.1	223

1830	Drug-eluting stent fracture promise and performance. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1932-4	15.1	9
1829	One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. 2009 , 2, 625-8		137
1828	Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. 2009 , 32, 749-70		54
1827	Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. 2009 , 7, 42		9
1826	Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. 2009 , 120, 391-9		388
1825	Interventional Treatment of Advanced Ischemic Heart Disease. 2009 ,		
1824	A review of current devices and a look at new technology: drug-eluting stents. 2009 , 6, 33-42		50
1823	Preparation of a dual-drug-eluting stent by grafting of ALA with abciximab on a bare metal stent. 2009 , 19, 8135		8
1822	The bioabsorbable stent as a virtual prosthesis. 2009 , 373, 869-70		3
1821	Advances in stent drug delivery: the future is in bioabsorbable stents. 2009 , 6, 113-26		56
1820	Advanced neointimal growth is not associated with a low risk of in-stent thrombus. Optical coherence tomographic findings after first-generation drug-eluting stent implantation. 2009 , 73, 1627-34		24
1819	Molecular basis of restenosis and novel issues of drug-eluting stents. 2009 , 73, 615-21		146
1818	Chest pain without significant coronary stenosis after implantation of sirolimus-eluting stents. 2009 , 48, 213-7		3
1817	Latest on the pathology of drug-eluting stents. 2009 , 1, 165-174		3
1816	Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography. 2009 , 73, 2300-7		58
1815	Clinical outcomes of sirolimus-eluting stenting after rotational atherectomy. 2009 , 73, 2042-9		30
1814	Role of endothelial progenitor cell mobilization after percutaneous angioplasty procedure. 2009 , 15, 1107-22		14
1813	Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions. 2009 , 2009, 294-297		1

1812	Use of optical coherence tomography in interventional cardiology. 2009 , 1, 63-71	3
1811	Stent thrombosis and duration of dual antiplatelet therapy. 2010 , 16, 4052-63	6
1810	Animal models for studying neointima formation. 2010 , 8, 198-219	16
1809	Biodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial. 2010 , 2, 267-273	1
1808	The effects of vinblastine on smooth muscle cells in vitro: evaluation of a therapeutic window for the treatment of restenosis. 2010 , 55, 399-407	1
1807	Percutaneous coronary intervention for ST-elevation myocardial infarction: drug-eluting stents or bare metal stents?. 2010 , 17, 516-22	
1806	The patient with coronary stents and antiplatelet agents: what to do and how to deal?. 2010 , 27, 406-10	6
1805	Short- and mid-term intravascular ultrasound analysis of the new zotarolimus-eluting stent with durable polymer [results from the RESOLUTE trial] 2010 , 74, 2097-102	16
1804	ISAR--a story of trials with impact on practice. 2010 , 74, 1771-8	6
1803	[Drug-eluting balloon in the treatment of a recurrent in-stent restenosis of drug-eluting stent]. 2010 , 151, 1509-14	
1802	DESIGN IMPLICATIONS FOR ENDOVASCULAR STENTS AND THE ENDOTHELIUM. 2010 , 291-312	2
1801	Coronary angioscopic evaluation for serial changes of luminal appearance after pharmacological and catheter interventions. 2010 , 74, 240-5	14
1800	Late progression after sirolimus-eluting stent implantation for de novo lesions--comparison with bare metal stent implantation. 2010 , 74, 1104-10	7
1799	Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials. 2010 , 74, 2334-9	11
1798	Drug-eluting stents are not indicated for patients with acute coronary syndrome [should drug-eluting stents be indicated for patients with acute coronary syndrome? (Con)] 2010 , 74, 2232-8	9
1797	STELLIUM 1: First-in-man follow-up evaluation of bioabsorbable polymer-coated paclitaxel-eluting stent. 2010 , 74, 2089-96	8
1796	Noncardiac surgery following percutaneous coronary intervention. 2010 , 2, 841-850	
1795	Liposomal simvastatin attenuates neointimal hyperplasia in rats. 2010 , 12, 181-7	22

1794	One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent. 2010 , 18, 486-92	2
1793	Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. 2010 , 62, 1023-30	54
1792	Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-choice stent compared to the paclitaxel-eluting TAXUS Stent. 2010 , 33, E33-8	1
1791	Long-term clinical outcomes of drug-eluting stents vs bare-metal stents in Chinese patients. 2010 , 33, E22-9	3
1790	Recurrent stent fracture in the right coronary artery. 2010 , 33, E70-2	6
1789	Comparison of sirolimus- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. 2010 , 33, 583-90	3
1788	Drug-eluting stent endothelium: presence or dysfunction. 2010 , 3, 76-7	25
1787	Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. 2010 , 3, 531-9	135
1786	Left atrial appendage obliteration: mechanisms of healing and intracardiac integration. 2010 , 3, 870-7	83
1785	Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. 2010 , 3, 1043-50	83
1784	Plasma-induced nanopillars on bare metal coronary stent surface for enhanced endothelialization. 2010 , 6, 4589-95	39
1783	A nitric oxide releasing, self assembled peptide amphiphile matrix that mimics native endothelium for coating implantable cardiovascular devices. 2010 , 31, 1502-8	135
1782	The immobilization of recombinant human tropoelastin on metals using a plasma-activated coating to improve the biocompatibility of coronary stents. 2010 , 31, 8332-40	84
1781	Pathology of cardiovascular interventions and surgery. 2010 , 16, 17-30	5
1780	Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. 2010 , 99, 165-74	143
1779	Serial changes of minimal stent malapposition not detected by intravascular ultrasound: follow-up optical coherence tomography study. 2010 , 99, 639-44	18
1778	Catheter-Based Near-Infrared Spectroscopy for Imaging of Lipid-Rich Plaques. 2010 , 3, 403-411	216
1777	Coronary stent thrombosis in the current era: challenges and opportunities for treatment. 2010 , 12, 46-57	3

1776	Acute infection-inflammation and coronary stent thrombosis: an observational study. 2010 , 5, 121-6	9
1775	Spectroscopy to improve identification of vulnerable plaques in cardiovascular disease. 2010 , 26, 111-9	7
1774	Managing coronary artery disease in the cancer patient. 2010 , 53, 149-56	25
1773	Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. 2010 , 127, 95-107	15
1772	Autonomic denervation using magnetic nanoparticles. 2010 , 20, 268-72	2
1771	Activation of prostanoid EP receptors by prostacyclin analogues in rabbit iliac artery: implications for anti-restenotic potential. 2010 , 641, 160-7	12
1770	Neointimal coverage on drug-eluting stent struts crossing side-branch vessels using optical coherence tomography. 2010 , 105, 1565-9	8
1769	Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry). 2010 , 106, 504-10	14
1768	Fibrinolytic therapy for very late stent thrombosis--is it a viable option?. 2010 , 11, 264.e13-5	
1767	Stent-based release of a selective PDGF-receptor blocker from the bis-indolylmethanon class inhibits restenosis in the rabbit animal model. 2010 , 52, 55-62	14
1766	Greater endothelial cell responses on submicron and nanometer rough titanium surfaces. 2010 , 94, 1042-9	12
1765	Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS. 2010 , 75, 578-83	108
1764	A case of newly demonstrated coronary spasm 4 months after paclitaxel-eluting stent implantation for in-stent restenosis. 2010 , 1, e33-e36	0
1763	Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. 2010 , 3, 68-75	115
1762	The DESIRE-Late registry: what is left to be desired?. 2010 , 3, 19-21	2
1761	Perioperative management of patients with drug-eluting stents. 2010 , 3, 131-42	59
1760	A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. 2010 , 3, 431-8	40
1759	Insurance type influences the use of drug-eluting stents. 2010 , 3, 773-9	36

1758	Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation: optical coherence tomographic analysis. 2010 , 3, 1074-9	33
1757	Delivery of paclitaxel from cobalt-chromium alloy surfaces without polymeric carriers. 2010 , 31, 5372-84	30
1756	Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. 2010 , 31, 648-57	63
1755	In vitro and in vivo changes to PLGA/sirolimus coating on drug eluting stents. 2010 , 31, 5151-8	54
1754	A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study. 2010 , 8, 6	1
1753	Recent perspective on coronary bifurcation intervention: statement of the "Bifurcation Club in KOKURA". 2010 , 23, 295-304	10
1752	Nanomedicine for the reduction of the thrombogenicity of stent coatings. 2010 , 5, 239-48	21
1751	New stent design for use in small coronary arteries during percutaneous coronary intervention. 2010 , 3, 57-66	2
1750	Are drug-eluting stents safe and effective in the long term?. 2010 , 95, 663-70	3
1749	Effectiveness and safety of drug-eluting stents in a cardiology clinic in Curitiba, PR, Brazil. 2010 , 95, 3-11	
1748	Sirolimus Eluting Stents. 2010 , 2, CMT.S2094	
1747	Drug-eluting medical implants. 2010 , 299-341	33
1746	Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. 2010 , 3, 468-75	73
1745	Lipoic acid prevents neointimal hyperplasia via induction of p38 mitogen-activated protein kinase/Nur77-mediated apoptosis of vascular smooth muscle cells and accelerates postinjury reendothelialization. 2010 , 30, 2164-72	41
1744	Smooth muscle cells orchestrate the endothelial cell response to flow and injury. 2010 , 121, 2192-9	43
1743	The management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery. 2010 , 14, 256-73	13
1742	Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. 2010 , 3, 174-83	115
1741	Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. 2010 , 122, 1077-84	139

1740	Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). 2010 , 122, 52-61	197
1739	Duration of dual antiplatelet therapy following percutaneous coronary intervention with drug-eluting stents: a review of recent evidence. 2010 , 9, 203-6	8
1738	Altered plasma fibrin clot properties are associated with in-stent thrombosis. 2010 , 30, 276-82	49
1737	Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. 2010 , 122, 2288-300	248
1736	Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents?. 2010 , 1, 20-24	9
1735	Letter by Virmani et al regarding article, "Drug-eluting stents in animals and patients: where do we stand today?". 2010 , 121, e246; author reply e247	3
1734	Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. 2010 , 122, 2301-12	268
1733	Modeling of Deformation-Accelerated Breakdown of Polylactic Acid Biodegradable Stents. 2010 , 4,	29
1732	Clinical Guide to Primary Angioplasty. 2010 ,	
1731	Development and performance of the zotarolimus-eluting Endeavor coronary stent. 2010 , 7, 449-59	7
1730	Late vascular responses from 2 to 4 years after implantation of sirolimus-eluting stents: serial observations by intracoronary optical coherence tomography. 2010 , 3, 476-83	39
1729	Drug-eluting stents: a reappraisal. 2010 , 96, 489-93	18
1728	Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Libert [®] paclitaxel-eluting stent in de novo native coronary artery lesions. 2010 , 3, 556-64	46
1727	Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3beta inhibitor. 2010 , 86, 338-45	42
1726	Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems. 2010 , 47, 58-76	39
1725	Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. 2010 , 31, 1055-64	96
1724	Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. 2010 , 31, 1172-80	209
1723	An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. 2010 , 31, 165-76	210

1722	Endothelial progenitor cell capture stents: will this technology find its niche in contemporary practice?. 2010 , 31, 1032-5		24
1721	Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. 2010 , 31, 1792-801		90
1720	Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. 2010 , 31, 2625-32		31
1719	Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. 2010 , 27, 999-1015		348
1718	Pathobiology of stent thrombosis after drug-eluting stent implantation. 2010 , 16, 4064-71		29
1717	Second-generation drug-eluting coronary stents. 2010 , 362, 1728-30		35
1716	Current status of the Xience V [®] everolimus-eluting coronary stent system. 2010 , 8, 1363-74		9
1715	Decision-making: stenting in acute myocardial infarction. 2010 , 6, 301-14		1
1714	Drug-eluting stents: the next generation. 2010 , 2, 341-350		5
1713	Benefits of and safety concerns associated with drug-eluting coronary stents. 2010 , 8, 449-70		20
1712	The effect of aging on deformations of the superficial femoral artery resulting from hip and knee flexion: potential clinical implications. 2010 , 21, 195-202		63
1711	Coronary stents: looking forward. <i>Journal of the American College of Cardiology</i> , 2010 , 56, S43-78	15.1	239
1710	Drug-eluting stents: issues of late stent thrombosis. 2010 , 28, 97-105		16
1709	A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 543-54	15.1	193
1708	Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 810-4	15.1	68
1707	Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1936-42	15.1	115
1706	Pathological findings at bifurcation lesions: the impact of flow distribution on atherosclerosis and arterial healing after stent implantation. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1679-87	15.1	188
1705	Coronary stents: current status. <i>Journal of the American College of Cardiology</i> , 2010 , 56, S1-42	15.1	371

1704	The evolving role of inflammatory biomarkers in risk assessment after stent implantation. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1783-93	15.1	79
1703	Stent thrombosis. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1357-65	15.1	312
1702	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. 2010 , 103, 13-28		232
1701	Drug Delivery. 2010 ,		22
1700	Intravascular ultrasound and histology findings in very late bare-metal stent thrombosis. 2010 , 63, 1492-6		
1699	Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. 2010 , 183, 2128-36		56
1698	Quantitative analysis of intracoronary optical coherence tomography measurements of stent strut apposition and tissue coverage. 2010 , 141, 151-6		48
1697	Clinical outcomes of drug-eluting stent use in patients with ST elevation myocardial infarction. 2010 , 143, 283-8		6
1696	Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway. 2010 , 129, 273-9		38
1695	Coronary ischemia and percutaneous intervention. 2010 , 19, 12-21		1
1694	Composition of thrombi in late drug-eluting stent thrombosis versus de novo acute myocardial infarction. 2010 , 126, 254-7		17
1693	Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound. 2010 , 159, 271-7		21
1692	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). 2010 , 160, 804-11		54
1691	Degradable, Multifunctional Cardiovascular Implants: Challenges and Hurdles. 2010 , 35, 607-613		97
1690	In vitro and in vivo characterization of novel biodegradable polymers for application as drug-eluting stent coatings. 2010 , 21, 529-52		24
1689	Stent thrombosis--risk assessment and prevention. 2010 , 28, e92-100		17
1688	Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. 2010 , 208, 285-9		32
1687	Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model. 2010 , 208, 97-103		25

1686	Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation. 2010 , 210, 503-9	19
1685	Coronary bare metal stent implantation in homozygous LDL receptor deficient swine induces a neointimal formation pattern similar to humans. 2010 , 213, 518-24	26
1684	Hallazgos de ecografía intravascular e histológicos de trombosis muy tardías de stents convencionales. 2010 , 63, 1492-1496	3
1683	Nuevos avances en cardiología intervencionista. 2010 , 22, 42-47	
1682	Pyrrole-imidazole polyamide: a novel gene silencer and its potential use in drug-eluting stents. 2010 , 109, 91-3	
1681	Controversies in the use of drug-eluting stents for acute myocardial infarction: a critical appraisal of the data. 2010 , 61, 215-31	6
1680	Handbook of Angioplasty and Stenting Procedures. 2010 ,	4
1679	Pharmacological prevention and management of restenosis. 2010 , 11, 1855-72	3
1678	Vigorous exercise as a triggering mechanism for late stent thrombosis: A description of three cases. 2010 , 21, 72-6	10
1677	The comparative safety of bare-metal and drug-eluting intracoronary stents. 2010 , 7, 611-24	4
1676	Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents. 2010 , 10, 49-61	3
1675	Protective effect of trapidil and l-arginine against renal and hepatic toxicity induced by cyclosporine in rats. 2010 , 32, 959-68	7
1674	How safe and how good are drug-eluting stents?. 2011 , 7, 251-70	14
1673	Detection of very early stent healing after primary angioplasty: an optical coherence tomographic observational study of chromium cobaltum and first-generation drug-eluting stents. The DETECTIVE study. 2011 , 97, 1841-6	23
1672	Chitosan for Biomaterials I. 2011 ,	10
1671	Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?. 2011 , 123, 779-97	327
1670	Outcomes of drug-eluting stents compared to bare-metal stents in ST-segment elevation acute myocardial infarction. 2011 , 30, 813-9	
1669	Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Libert [®] stents in de novo native coronary artery lesions. 2011 , 4, 146-54	13

1668	Clopidogrel therapy in ophthalmic procedures: a survey of subspecialty ophthalmologists and review of current guidelines. 2011 , 46, 528-30		1
1667	Perioperative Considerations and Management in Patients with Intravascular Stents. 2011 , 29, 85-112		
1666	Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 390-8	15.1	245
1665	Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 538-45	15.1	306
1664	Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase C α activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2527-38	15.1	36
1663	The magic of disappearing stents. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1589-91	15.1	6
1662	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Journal of the American College of Cardiology</i> , 2011 , 58, e44-122	15.1	1703
1661	Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. 2011 , 4, 992-1001		71
1660	1-year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. 2011 , 4, 896-904		40
1659	Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. 2011 , 4, 1057-66		302
1658	Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents. 2011 , 4, 1067-74		22
1657	Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation?. 2011 , 4, 1129-32		10
1656	Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial. 2011 , 4, 1281-9		17
1655	Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. 2011 , 4, 1271-80		49
1654	Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography. 2011 , 104, 147-54		3
1653	Current and future drug-eluting coronary stent technology. 2011 , 9, 485-503		19
1652	Novel Coating Technologies of Drug Eluting Stents. 2011 , 87-125		3
1651	Chitosan: Its Applications in Drug-Eluting Devices. 2011 , 185-230		24

1650	Management of antiplatelet therapy inpatients at risk for coronary StentThrombosis undergoing non-cardiac surgery. 2011 , 71, 1797-806	6
1649	Lactide and Glycolide Polymers. 2011 , 317-365	2
1648	Paclitaxel delivery from cobalt-chromium alloy surfaces using self-assembled monolayers. 2011 , 6, 33-42	22
1647	Active Implants and Scaffolds for Tissue Regeneration. 2011 ,	11
1646	Intravascular Ultrasound: Principles, Image Interpretation, and Clinical Applications. 2011 , 145-171	
1645	Bioactive stent surface coating that promotes endothelialization while preventing platelet adhesion. 2011 , 12, 533-9	49
1644	Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries. 2011 , 22, 603-10	53
1643	Qualitative assessment of neointimal tissue after drug-eluting stent implantation: comparison between follow-up optical coherence tomography and intravascular ultrasound. 2011 , 161, 367-72	18
1642	The possibility of delayed arterial healing 5 years after implantation of sirolimus-eluting stents: serial observations by coronary angiography. 2011 , 161, 1200-6	14
1641	Proximal atherosclerotic lesion as a cause of very late stent thrombosis. 2011 , 76, 500-2	3
1640	Intracoronary optical coherence tomography for the assessment of in-stent restenosis. 2011 , 20, 332-5	
1639	Determining clinical benefits of drug-eluting coronary stents according to the population risk profile: a meta-regression from 31 randomized trials. 2011 , 148, 23-9	5
1638	Long-term clinical outcomes after drug eluting stent implantation in women with de novo coronary lesions. Results from the REAL (REgistro Regionale AngiopLastiche Emilia-Romagna) multicenter registry. 2011 , 149, 55-62	3
1637	Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: an optical coherence tomography study. 2011 , 151, 155-9	15
1636	Optical coherence tomography analysis for restenosis of drug-eluting stents. 2011 , 146, 100-3	9
1635	Pre-procedural use of statins for all patients undergoing percutaneous coronary intervention. 2011 , 146, 103-4	3
1634	Significant intimal hyperplasia regression between 6 and 18 months following Genous [®] Endothelial progenitor cell capturing stent placement. 2011 , 147, 289-91	6
1633	Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials. 2011 , 150, 84-9	30

1632	Acute myocardial infarction late following stent implantation: Incidence, mechanisms and clinical presentation. 2011 , 152, 295-301	2
1631	Effect of recombinant human SDF-1a on re-endothelialization after sirolimus-eluting stent implantation in rabbit aorta abdominalis. 2011 , 89, 926-30	6
1630	Scanning electron microscopy analysis of luminal inflammation induced by different types of coronary stent in an animal model. 2011 , 64, 159-62	8
1629	Intravascular imaging of vulnerable coronary plaque: current and future concepts. 2011 , 8, 131-9	68
1628	Mesenchymal stem cell seeding promotes reendothelialization of the endovascular stent. 2011 , 98, 442-9	23
1627	In-stent restenosis. 2011 , 29, 190-8	82
1626	Local drug delivery for treatment of coronary and peripheral artery disease. 2011 , 29, e54-66	13
1625	Quadratic Models to Fit Experimental Data of Paclitaxel Release Kinetics from Biodegradable Polymers. 2011 , 71, 2269-2286	6
1624	Scanning Electron Microscopy Analysis of Luminal Inflammation Induced by Different Types of Coronary Stent in an Animal Model. 2011 , 64, 159-162	
1623	Outcomes of drug-eluting stents compared to bare-metal stents in ST-segment elevation acute myocardial infarction. 2011 , 30, 813-819	
1622	The emerging role of allergic inflammation in adverse reactions after coronary stent implantation. 2011 , 217, 70-1	5
1621	A dietary approach to increase in-stent stenosis and face validity of a rat model for arterial angioplasty and stenting. 2011 , 219, 484-91	2
1620	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. 2011 , 378, 1940-8	283
1619	Safety and Efficacy of Clopidogrel before Surgery. 2011 , 3, CMT.S2334	2
1618	Very Late Stent Thrombosis due to Neointimal Rupture After Paclitaxel-Eluting Stent Implantation. 2011 , 41, 754-8	1
1617	A case of stent thrombosis occurred at 5 years after sirolimus-eluting stent implantation. 2011 , 47, 124-6	1
1616	Are Paclitaxel-Eluting Stents Better in Unprotected Left Main Coronary Artery Disease? Three-Year Clinical and Intravascular Imaging Results From a Randomized Study. 2011 , 47, 77	2
1615	Comparação randomizada entre o stent eluidor de paclitaxel de nova geração sem polímero e o stent eluidor de paclitaxel com polímero durável em pacientes com doença arterial coronária: resultados da análise angiográfica e ultrassonográfica seriada do estudo PAX-A. 2011 , 19, 379-391	2

1614	Novel drug-eluting stents in the treatment of de novo coronary lesions. 2011 , 7, 103-18	15
1613	Advantages and disadvantages of biodegradable platforms in drug eluting stents. 2011 , 3, 84-92	26
1612	Serial clinical and angiographic follow-up after phosphorylcholine-coated stent implantation. 2011 , 52, 88-91	3
1611	Drug-Eluting Stents. 2011 , 427-448	5
1610	Evaluation of a novel paclitaxel-eluting stent with a bioabsorbable polymeric surface coating in the porcine artery injury model. 2011 , 66, 765-72	1
1609	Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. 2011 , 105, 864-72	56
1608	Designing multifunctional polymers for cardiovascular implants. 2011 , 49, 347-55	12
1607	Dual oral antiplatelet therapy and unplanned surgery: possible role for intravenous platelet glycoprotein receptor inhibitors. 2011 , 12, 673-4	0
1606	Bioactive stents for percutaneous coronary intervention: a new forerunner on the track. 2011 , 3, 527-529	0
1605	Predictors of stent fracture in patients treated with closed-cell design stents: sirolimus-eluting stent and its bare-metal counterpart, the BX velocity stent. 2011 , 22, 40-4	4
1604	Flow Control in Biomedical Microdevices using Thermally Re- sponsive Fluids. 2011 , 125-152	
1603	Local delivery of therapeutics for percutaneous coronary intervention. 2011 , 8, 534-56	9
1602	Rather anaesthetise a patient with CABG than a stent. 2011 , 17, 9-12	
1601	Coronary stent thrombosis: incidence, predictors and triggering mechanisms. 2011 , 3, 581-588	2
1600	Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study. 2011 , 75, 306-14	6
1599	Angioscopic assessment of arterial repair following biodegradable polymer-coated biolimus A9-eluting stent implantation. - Comparison with durable polymer-coated sirolimus-eluting stent-. 2011 , 75, 1113-9	16
1598	Long-term benefit of the TAXUS Libert`stent in small vessels and long lesions. TAXUS ATLAS program. 2011 , 75, 1120-9	9
1597	Bioresorbable scaffold technologies. 2011 , 75, 509-20	93

1596	Neointimal coverage over coronary stent struts crossing the side branch Ostia. 2011 , 75, 51-2	1
1595	Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. 2011 , 75, 1287-96	197
1594	Drug-eluting stent: importance of clinico-pathological correlations. 2011 , 75, 1548-58	18
1593	Mechanisms of non-fatal stent-related myocardial infarction late following coronary stenting with drug-eluting stents and bare metal stents. Insights from optical coherence tomography. 2011 , 75, 2789-97	8
1592	Assessment by optical coherence tomography of stent struts across side branch. -Comparison of bare-metal stents and drug-elution stents.-. 2011 , 75, 106-12	30
1591	Clinical outcomes and the risk factors of coronary artery aneurysms that developed after drug-eluting stent implantation. 2011 , 75, 861-7	20
1590	Outcomes following coronary stenting and a role for eosinophils: evidence from eosinophil cationic protein. 2011 , 3, 421-423	
1589	The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial. 2011 , 3, 451-460	1
1588	The SeQuent>Please drug-coated balloon system for percutaneous transluminal coronary angioplasty. 2011 , 3, 133-147	2
1587	A comparison of drug-eluting stents versus bare metal stents in saphenous vein graft PCI outcomes: a meta-analysis. 2011 , 24, 172-80	15
1586	Low stent thrombosis risk with the XIENCE V Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials. 2011 , 24, 326-41	8
1585	Drug-eluting stents during ST-segment elevation acute myocardial infarction: a critical analysis. 2011 , 24, 416-23	
1584	Three-year clinical follow-up of an unselected patient population treated with the genous endothelial progenitor cell capturing stent. 2011 , 24, 442-9	9
1583	Three-year clinical outcome with the EndeavorZotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the EndeavorPrimary PCI study (E-PPCI). 2011 , 24, 542-8	3
1582	Increased artery wall stress post-stenting leads to greater intimal thickening. 2011 , 91, 955-67	86
1581	Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. 2011 , 57, 231-8	20
1580	Restenosis after implantation of sirolimus-eluting stent begins suddenly, shows short term progression, and stops suddenly. 2011 , 58, 26-31	
1579	Stent thrombosis of drug eluting stent: pathological perspective. 2011 , 58, 84-91	59

1578	Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. 2011 , 107, 186-94	100
1577	Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). 2011 , 107, 841-8	18
1576	Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. 2011 , 107, 1597-603	20
1575	Comparison of angioscopic findings and three-year cardiac events between sirolimus-eluting stent and bare-metal stent in acute myocardial infarction. 2011 , 108, 1238-43	9
1574	Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial). 2011 , 108, 1387-94	24
1573	Stent-related cardiac events beyond three years after implantation of the sirolimus-eluting stent (from the EVASTENT Patients). 2011 , 108, 1401-7	8
1572	Comparison of usefulness of percutaneous coronary intervention guided by angiography plus computed tomography versus angiography alone using intravascular ultrasound end points. 2011 , 108, 1728-34	18
1571	[Decreasing incidence of stent thrombosis]. 2011 , 60, 338-46	
1570	Selective adhesion and growth of vascular endothelial cells on bioactive peptide nanofiber functionalized stainless steel surface. 2011 , 32, 8797-805	128
1569	Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery. 2011 , 32, 9504-14	54
1568	Effects of local intracoronary paclitaxel delivery using the Remedy transport catheter on neointimal hyperplasia after stent implantation in a porcine model. 2011 , 12, 82-9	2
1567	Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Libert ^{vs} . TAXUS Express: the importance of stent platform design for drug-eluting stents. 2011 , 12, 247-57	5
1566	Evaluation of neointimal morphology of lesions with or without in-stent restenosis: an optical coherence tomography study. 2011 , 34, 633-9	20
1565	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2013 , 82, E266-355	81
1564	In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis. 2011 , 22, 1615-23	7
1563	Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. 2011 , 27, 859-66	17
1562	Long-term (2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results. 2011 , 27, 875-81	22
1561	Optical coherence tomography endpoints in stent clinical investigations: strut coverage. 2011 , 27, 271-87	27

1560	Dedicated bifurcation analysis: dedicated devices. 2011 , 27, 181-8	4
1559	The 5352 A allele of the pro-inflammatory caspase-1 gene predicts late-acquired stent malapposition in STEMI patients treated with sirolimus stents. 2011 , 26, 235-41	3
1558	Recent developments in drug-eluting stents. 2011 , 89, 545-53	13
1557	Biocompatibility of implants: lymphocyte/macrophage interactions. 2011 , 33, 221-33	164
1556	Second- and third-generation drug-eluting coronary stents: progress and safety. 2011 , 36, 190-6	38
1555	New strategies in the treatment of coronary bifurcations. 2011 , 36, 198-212	14
1554	Opportunities and limitations of drug-coated balloons in interventional therapies. 2011 , 36, 232-9	20
1553	[Coronary stent thrombosis: what's new in 2011?]. 2011 , 36, 241-53	2
1552	How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?. 2011 , 13, 46-56	1
1551	Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter. 2011 , 5, 411-435	11
1550	Prediction of late restenosis after sirolimus-eluting stent implantation using serial quantitative angiographic and intravascular ultrasound analysis. 2011 , 26, 26-32	2
1549	Comparison of neointimal morphology of in-stent restenosis with sirolimus-eluting stents versus bare metal stents: virtual histology-intravascular ultrasound analysis. 2011 , 26, 186-92	1
1548	Clinical usefulness of the Driver() stent in a retrospective, collaborative, multicenter, open-label study in Japanese real-world patients with coronary artery disease and the drug-eluting stent era. 2011 , 26, 131-7	
1547	Calcified plaque rupture and very late stent thrombosis after bare-metal stent implantation. 2011 , 26, 252-9	3
1546	Fabrication and controlled release of electrosprayed ReoPro-loaded metal surface for vascular stent. 2011 , 19, 501-506	6
1545	Efficacy of dual antiplatelet therapy combined with Naoxintong capsules [see text] following coronary microembolization induced by homologous microthrombi in rats. 2011 , 17, 917-24	14
1544	Microfabrication and nanotechnology in stent design. 2011 , 3, 256-68	63
1543	Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. 2011 , 3, 400-20	49

1542	Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. 2011 , 3, 620-46	14
1541	Coronary stenting after failure of conservative treatment for spontaneous coronary dissection: Usefulness of the intravascular ultrasound. 2011 , 39, 175-8	1
1540	In vitro and in vivo degradation of poly(D, L-lactide-co-glycolide)/amorphous calcium phosphate copolymer coated on metal stents. 2011 , 96, 632-8	22
1539	A novel polymer-free paclitaxel-eluting stent with a nanoporous surface for rapid endothelialization and inhibition of intimal hyperplasia: Comparison with a polymer-based sirolimus-eluting stent and bare metal stent in a porcine model. 2011 , 98, 629-37	9
1538	Inorganic coatings for cardiovascular stents: In vitro and in vivo studies. 2011 , 96, 333-41	13
1537	Long-term stability of self-assembled monolayers on electropolished L605 cobalt chromium alloy for stent applications. 2011 , 98, 280-9	22
1536	Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. 2011 , 77, 494-501	12
1535	One-year clinical outcome in an unselected patient population treated with the Genous [®] endothelial progenitor cell capturing stent. 2011 , 77, 809-17	10
1534	Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. 2011 , 78, 161-6	12
1533	Rationale and design of the randomized, multicenter EREMUS trial, a study that investigates how to achieve low restenosis and early reendothelialization after percutaneous coronary interventions. 2011 , 78, 32-7	
1532	Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. 2011 , 78, 3-12	94
1531	Nevo stent: a successful stent makeover. 2011 , 77, 52-3	1
1530	Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. 2011 , 78, 1078-85	9
1529	Very late stent thrombosis due to DES fracture: description of a case and review of potential causes. 2011 , 78, 1101-5	7
1528	Genous [®] endothelial progenitor cell capturing stent: thrombus-resistant but vulnerable to restenosis. 2011 , 78, 196-7	4
1527	Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies. 2011 , 54, 807-11	48
1526	Drug-eluting stents for coronary artery disease: a review. 2011 , 33, 148-63	90
1525	Vasomotor function after paclitaxel-coated balloon post-dilation in porcine coronary stent model. 2011 , 4, 247-55	14

1524	Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. 2011 , 4, 149-54	176
1523	Autopsy validation study of the academic research consortium stent thrombosis definition. 2011 , 4, 554-9	30
1522	Microarray applications in occlusive vascular disease. 2011 , 9, 84-94	0
1521	Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature. 2011 , 39, 32-40	10
1520	Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. 2011 , 123, 2382-91	100
1519	Delayed coverage in malapposed and side-branch struts with respect to well-apposed struts in drug-eluting stents: in vivo assessment with optical coherence tomography. 2011 , 124, 612-23	104
1518	Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. 2011 , 4, 495-504	424
1517	How to Implement a Clinical Pathway For Intensive Glucose Regulation in Acute Coronary Syndromes: Erratum. 2011 , 10, 192	
1516	Use of endothelial progenitor capture cell stent during percutaneous treatment of coronary bifurcations: a prospective angiographic registry. 2011 , 10, 189-92	3
1515	Dual antiplatelet therapy duration: what are the drivers?. 2011 , 26 Suppl 1, S4-14	5
1514	Restenosis: delineating the numerous causes of drug-eluting stent restenosis. 2011 , 4, 195-205	129
1513	Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: insights from the RESOLUTE trial. 2011 , 4, 248-55	19
1512	Response gene to complement 32 promotes vascular lesion formation through stimulation of smooth muscle cell proliferation and migration. 2011 , 31, e19-26	50
1511	Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. 2011 , 4, 239-47	156
1510	Time course of reendothelialization of stents in a normal coronary swine model: characterization and quantification. 2011 , 48, 1109-17	23
1509	Five-year outcomes of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: are they equally good (or bad)?. 2011 , 123, 2779-81	2
1508	Stent coated with antibody against vascular endothelial-cadherin captures endothelial progenitor cells, accelerates re-endothelialization, and reduces neointimal formation. 2011 , 31, 2798-805	53
1507	Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. 2011 , 4, 38-46	67

1506	Stent-induced coronary artery stenosis characterized by multimodal nonlinear optical microscopy. 2011 , 16, 021110	4
1505	Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. 2011 , 32, 2454-63	107
1504	Enhanced efficacy of sirolimus-eluting bioabsorbable magnesium alloy stents in the prevention of restenosis. 2011 , 18, 407-15	32
1503	Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. 2011 , 123, 274-81	131
1502	Vascular responses to drug-eluting and bare metal stents in diabetic/hypercholesterolemic and nonatherosclerotic porcine coronary arteries. 2011 , 4, 438-46	15
1501	Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. 2011 , 4, 577-84	34
1500	The complementary role of microCT and histopathology in characterizing the natural history of stented arteries. 2011 , 9, 939-48	5
1499	Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. 2011 , 18, 613-23	133
1498	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2011 , 124, e574-651	1039
1497	The representative porcine model for human cardiovascular disease. 2011 , 2011, 195483	63
1496	Neutrophil-derived cathelicidin protects from neointimal hyperplasia. 2011 , 3, 103ra98	81
1495	Fatal very late stent thrombosis in a paclitaxel-eluting stent after treatment of gastrointestinal bleeding: a case report. 2011 , 11, 48-52	
1494	Drug eluting stents: current status and new developments. 2012 , 12, 676-83	1
1493	Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. 2012 , 5, 296-304	6
1492	Femtosecond Laser Nanotexturing of Drug-Eluting Stents. 2012 , 134,	3
1491	Comparison of acute recoil between bioabsorbable poly-L-lactic acid XINSORB stent and metallic stent in porcine model. 2012 , 2012, 413956	14
1490	Serial assessment of coronary artery response to paclitaxel-eluting stents using optical coherence tomography. 2012 , 5, 30-8	24
1489	From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?. 2012 , 33, 16-25b	235

1488	Impact of drug-eluting stents on distal vessels. 2012 , 5, 211-9	8
1487	Long-term follow-up of attenuated plaques in patients with acute myocardial infarction: an intravascular ultrasound substudy of the HORIZONS-AMI trial. 2012 , 5, 185-92	16
1486	Nanosecond Laser Induced Periodic Surface Structures on Drug Elution Profiles in Stents. 2012 , 6,	0
1485	Stent selection in patients with myocardial infarction: drug eluting, biodegradable polymers or bare metal stents?. 2012 , 7, 105-20	1
1484	Impact of preinterventional plaque composition and eccentricity on late-acquired incomplete stent apposition after sirolimus-eluting stent implantation: an intravascular ultrasound radiofrequency analysis. 2012 , 23, 432-7	2
1483	Very late stent thrombosis: current concepts. 2012 , 27, 634-41	21
1482	Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents. 2012 , 11, 152-9	8
1481	The long-term effect of coronary stenting on epicardial and microvascular endothelial function. 2012 , 5, 523-9	13
1480	Recurrent angina after coronary angioplasty: mechanisms, diagnostic and therapeutic options. 2012 , 1, 158-69	28
1479	New-generation drug-eluting stents for patients with myocardial infarction. 2012 , 308, 814-5	4
1478	Impact of parallel micro-engineered stent grooves on endothelial cell migration, proliferation, and function: an in vivo correlation study of the healing response in the coronary swine model. 2012 , 5, 499-507	30
1477	Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. 2012 , 125, 2343-53	171
1476	Vascular stents with rationally-designed surface patterning. 2012 , 2012, 1639-42	5
1475	Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). 2012 , 33, 606-13	267
1474	Late drug-eluting stent thrombosis: optical coherence tomography and intravascular ultrasound insights. 2012 , 5, 615-6	1
1473	Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. 2012 , 33, 1214-22	296
1472	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. 2012 , 10, 1273-85	6
1471	Incidence and clinical impact of stent fracture after everolimus-eluting stent implantation. 2012 , 5, 663-71	72

1470	Assessment of atherosclerotic plaques at coronary bifurcations with multidetector computed tomography angiography and intravascular ultrasound-virtual histology. 2012 , 13, 635-42	17
1469	Impact of frequency-domain optical coherence tomography guidance for optimal coronary stent implantation in comparison with intravascular ultrasound guidance. 2012 , 5, 193-201	88
1468	Very late stent thrombosis and late target lesion revascularization: no end in sight. 2012 , 125, 562-4	11
1467	Intracoronary Imaging and Histopathology of Late Phase In-Stent Restenosis after Coronary Stent Implantation. 2012 , 2012, 1-11	2
1466	Targeted Treatments for Restenosis and Vein Graft Disease. 2012 , 2012, 1-23	1
1465	Grabbing the horns of a dilemma: the duration of dual antiplatelet therapy after stent implantation. 2012 , 125, 1967-70	13
1464	Long-term treatment with nifedipine suppresses coronary hyperconstricting responses and inflammatory changes induced by paclitaxel-eluting stent in pigs in vivo: possible involvement of Rho-kinase pathway. 2012 , 33, 791-9	25
1463	Biodegradable polymer and permanent polymer drug-eluting stents: at the crossroads of evidence and expectation. 2012 , 4, 147-150	
1462	Temporal Evolution of Neointimal Proliferation After Implantation of Two Types of Drug-eluting Stents with Biodegradable Polymers in a Porcine Model: Qualitative Assessment by Sequential Optical Coherence Tomography. 2012 , 20, 413-419	
1461	Long-term Clinical and Angiographic Follow-up of the New Non-Polymeric Paclitaxel-Eluting Stent for the Treatment of De Novo Coronary Lesions: Outcomes of the PAX-B Study. 2012 , 20, 146-154	2
1460	Smooth muscle and endothelial cell behaviour on degradable copolyetheresterurethane films. 2012 , 52, 313-23	6
1459	The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation. 2012 , 107, 356-68	20
1458	Human Umbilical Vein Endothelial Cell Interaction with Fluorine-Incorporated Amorphous Carbon Films. 2012 , 51, 090129	3
1457	Accelerating endothelialization of coronary stents by capturing circulating endothelial progenitor cells. 2012 , 4, 169-181	7
1456	Coronary artery stents: approved first-generation drug-eluting stents. 2012 , 18-30	
1455	Drug-eluting stent malapposition and its relationship to drug-eluting stent thrombosis. 2012 , 4, 521-525	1
1454	Research Highlights: Highlights from the latest articles in interventional cardiology. 2012 , 4, 513-516	
1453	Mechanisms of late stent-related myocardial infarction: insights from optical coherence tomography. 2012 , 4, 645-651	

- 1452 Biolimus-eluting stent with biodegradable polymer: one step forward in the fight against stent thrombosis vulnerability?. **2012**, 4, 11-25 1
- 1451 Devices and Sensors for Bioelectric Monitoring and Stimulation. **2012**, 287-320
- 1450 Nobori drug-eluting stent system: current data on a novel stent. **2012**, 4, 309-318
- 1449 Endovascular Stents. **2012**, 89-116 1
- 1448 In vivo optical coherence tomography of very late drug-eluting stent thrombosis compared with late in-stent restenosis. **2012**, 76, 390-8 20
- 1447 Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion--CATHOLIC Total Occlusion Study (CATOS) trial. **2012**, 76, 868-75 42
- 1446 Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. **2012**, 379, 1393-402 727
- 1445 In-stent neoatherosclerosis: a final common pathway of late stent failure. *Journal of the American College of Cardiology*, **2012**, 59, 2051-7 15.1 285
- 1444 Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. **2012**, 167, 313-23 82
- 1443 Drug-Eluting Stents. **2012**, 383-407 2
- 1442 Stents and antiplatelet therapy. **2012**, 47, 114-24 3
- 1441 Stent thrombosis: no longer an issue with newer-generation drug-eluting stents?. **2012**, 5, 332-5 13
- 1440 Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. **2012**, 380, 1396-405 124
- 1439 The battle against stent thrombosis--to protect and to serve. **2012**, 380, 1365-7
- 1438 Surface chemical and physical modification in stent technology for the treatment of coronary artery disease. **2012**, 100, 1989-2014 47
- 1437 Assessment of an asymmetrical coating stent with sirolimus released from abluminal matrix in porcine model. **2012**, 101, 917-27 10
- 1436 Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. **2012**, 28, 1307-14 12
- 1435 Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?. **2012**, 221, 106-12 96

1434	In vivo assessment of intraplaque and endothelial fibrin in ApoE(-/-) mice by molecular MRI. 2012 , 222, 43-9	36
1433	Endothelial progenitor cell response to antiproliferative drug exposure. 2012 , 225, 91-8	15
1432	Pathogenesis of late in-stent thrombosis after treatment with drug-eluting stents. 2012 , 6, e158-e160	
1431	New Evidence, New Controversies: a Critical Review of the European Society of Cardiology 2010 Clinical Practice Guidelines on Atrial Fibrillation. 2012 , 65, 7-13	
1430	Giant coronary artery aneurysm following implantation of Endeavour stent presenting with fever. 2012 , 64, 198-9	3
1429	Repetitive angioscopic observations of a sirolimus-eluting stent deployed in a patient with silent chronic thrombotic occlusion. 2012 , 27, 201-4	3
1428	Reducing In-Stent Restenosis Through Novel Stent Flow Field Augmentation. 2012 , 3, 353-373	24
1427	Stenting in Acute STEMI Intervention. 2012 , 1, 507-520	1
1426	Time-dependent conformational changes in adsorbed albumin and its effect on platelet adhesion. 2012 , 28, 2745-52	46
1425	New evidence, new controversies: a critical review of the European Society of Cardiology 2010 clinical practice guidelines on atrial fibrillation. 2012 , 65, 7-13	23
1424	Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. 2012 , 125, 1110-21	280
1423	Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. 2012 , 33, 2513-20	286
1422	A novel regimen of alternate day clopidogrel would provide a cost-effective strategy to prevent very late stent thrombosis. 2012 , 78, 166-70	5
1421	Evaluation of the peri-strut low intensity area following sirolimus- and paclitaxel-eluting stents implantation: insights from an optical coherence tomography study in humans. 2012 , 157, 38-42	45
1420	An optical coherence tomography study of two new generation stents with biodegradable polymer carrier, eluting paclitaxel vs. biolimus-A9. 2012 , 157, 341-6	19
1419	"Angiographic late catch-up" phenomenon after sirolimus-eluting stent implantation. 2012 , 160, 48-52	21
1418	Eosinophilic responses to stent implantation and the risk of Kounis hypersensitivity associated coronary syndrome. 2012 , 156, 125-32	42
1417	Histological confirmation of hypersensitivity as a contributor to very-late coronary stent thrombosis. 2012 , 157, e29-30	7

1416	Pathological features of in-stent restenosis after sirolimus-eluting stent versus bare metal stent placement. 2012 , 21, e19-22	7
1415	Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. 2012 , 38, 473-83	142
1414	Freeing the vessel from metallic cage: what can we achieve with bioresorbable vascular scaffolds?. 2012 , 27, 141-54	21
1413	Introduction of a high-throughput double-stent animal model for the evaluation of biodegradable vascular stents. 2012 , 100, 2023-8	2
1412	Combination coating of chitosan and anti-CD34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formation. 2012 , 12, 96	17
1411	Intimal hyperplasia evaluated by OCT in de novo coronary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO): study protocol for a randomized controlled trial. 2012 , 13, 55	5
1410	Microrough cobalt-chromium alloy surfaces for paclitaxel delivery: preparation, characterization, and in vitro drug release studies. 2012 , 28, 11511-26	23
1409	A fibronectin-fibrinogen-tropoelastin coating reduces smooth muscle cell growth but improves endothelial cell function. 2012 , 16, 2117-26	21
1408	Value of a new post-procedural intravascular ultrasound score in predicting target vessel revascularization after coronary drug-eluting stents implantation. 2012 , 13, 624-30	1
1407	The important role of inflammatory biomarkers pre and post bare-metal and drug-eluting stent implantation. 2012 , 28, 700-5	19
1406	Stent thrombosis in patients with chronic kidney disease. 2012 , 10, 617-26	
1405	ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease. 2012 , 111, 151-63	105
1404	Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study. 2012 , 164, 810-6.e3	16
1403	A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. 2012 , 64, 547-52	11
1402	Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1337-49	15.1 211
1401	Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1752-9	15.1 48
1400	First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. <i>Journal of</i>	15.1 96
1399	Kissing balloon or sequential dilation of the side branch and main vessel for provisional stenting of bifurcations: lessons from micro-computed tomography and computational simulations. 2012 , 5, 47-56	101

1398	Angiographic stent thrombosis at coronary bifurcations: short- and long-term prognosis. 2012 , 5, 57-63	15
1397	Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients. 2012 , 5, 182-90	21
1396	Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. 2012 , 5, 131-40	127
1395	Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent. 2012 , 5, 436-44	48
1394	Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process. 2012 , 5, 428-35	30
1393	Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions. 2012 , 5, 666-74	41
1392	Multiple interstrut cavities: a potential mechanism for very late stent thrombosis? Insights from optical coherence tomography. 2012 , 5, 995-6	3
1391	3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. 2012 , 5, 812-8	42
1390	Coronary endothelial dysfunction distal to stent of first-generation drug-eluting stents. 2012 , 5, 966-73	34
1389	Evaluation of efficacy and dose response of different paclitaxel-coated balloon formulations in a novel swine model of iliofemoral in-stent restenosis. 2012 , 5, 1081-8	22
1388	On OCT and finding the uncovered tracks. 2012 , 5, 83-6	2
1387	Quantitative and qualitative changes in DES-related neointimal tissue based on serial OCT. 2012 , 5, 1147-55	51
1386	Adverse cardiac events in patients with coronary stents undergoing noncardiac surgery: a systematic review. 2012 , 204, 494-501	20
1385	Direct thrombin inhibitor-bivalirudin functionalized plasma polymerized allylamine coating for improved biocompatibility of vascular devices. 2012 , 33, 7959-71	82
1384	In vivo biocompatibility of a plasma-activated, coronary stent coating. 2012 , 33, 7984-92	53
1383	Hemocompatibility of drug-eluting coronary stents coated with sulfonated poly(styrene-block-isobutylene-block-styrene). 2012 , 33, 8204-12	25
1382	Drug-coated balloons--the new gold standard for treatment of coronary in-stent restenosis?. 2012 , 13, 257-9	4
1381	Eosinophils and risk stratification of patients treated by coronary stenting. 2012 , 130, 571-3	2

1380	Bioabsorbable stents [Has the concept really translated to clinical benefits? [Concept to clinical Update: 2012. 2012 , 2, 156-159		1
1379	Extracellular matrix molecules facilitating vascular biointegration. 2012 , 3, 569-87		15
1378	Gene-eluting stents: non-viral, liposome-based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model. 2012 , 19, 321-8		33
1377	Current perspectives of biodegradable drug-eluting stents for improved safety. 2012 , 17, 912-924		6
1376	The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2005-16	15.1	31
1375	Drug-coated balloons for coronary and peripheral interventional procedures. 2012 , 14, 635-41		15
1374	Long Acting Injections and Implants. 2012 ,		14
1373	Clopidogrel. 2012 , 12, 361-374		8
1372	Drug-Eluting Stents. 2012 , 405-421		
1371	OCT in Coronary Bifurcations. 2012 , 103-120		
1370	Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. 2012 , 33, 3078-87		102
1369	Drug-eluting stent coatings. 2012 , 4, 73-83		19
1368	Pathological perspective of drug-eluting stent thrombosis. 2012 , 2012, 219389		11
1367	Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement. 2012 , 2012, 608593		41
1366	Stent thrombosis: incidence, predictors and new technologies. 2012 , 2012, 956962		44
1365	Towards personalized medicine based on platelet function testing for stent thrombosis patients. 2012 , 2012, 617098		9
1364	Impact of stenting and oral sirolimus on endothelium-dependent and independent coronary vasomotion. 2012 , 98, 290-8		2
1363	Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation. 2012 , 107, 1161-71		38

1362	DES Overview: A Historical and Current Review of Pivotal Clinical Trial Programs. 2012,	
1361	Effect of cytochrome P450-dependent epoxyeicosanoids on Ristocetin-induced thrombocyte aggregation. 2012, 52, 403-16	22
1360	Coronary stent thrombosis: current insights into new drug-eluting stent designs. 2012, 48, 141-9	6
1359	Everolimus-eluting stents in interventional cardiology. 2012, 8, 393-404	12
1358	Absorbable stent: focus on clinical applications and benefits. 2012, 8, 125-32	24
1357	Novel nanostructured biomaterials: implications for coronary stent thrombosis. 2012, 7, 6063-76	25
1356	Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. 2012, 125, 2873-91	417
1355	The importance of the endothelium in atherothrombosis and coronary stenting. 2012, 9, 439-53	258
1354	Development of a probucol-releasing antithrombogenic drug eluting stent. 2012, 100, 1068-77	7
1353	A nonelutable low-molecular weight heparin stent coating for improved thromboresistance. 2012, 100, 1274-82	9
1352	Controlled Release of Antiproliferative Drugs From Polymeric Systems for Stent Applications and Local Cancer Treatment. 2012, 14, B294-B310	2
1351	Antibody-targeted drug delivery to injured arteries using layered double hydroxide nanoparticles. 2012, 1, 669-73	36
1350	Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study. 2012, 80, 408-16	6
1349	Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience. 2012, 80, E15-22	8
1348	Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stents. 2012, 80, 524-30	8
1347	Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials. 2012, 80, 507-13	5
1346	In vivo comparison of a polymer-free Biolimus A9-eluting stent with a biodegradable polymer-based Biolimus A9 eluting stent and a bare metal stent in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries. 2012, 80, 429-36	14
1345	Comparison of vascular remodeling in patients treated with sirolimus-versus zotarolimus-eluting stent following acute myocardial infarction. 2012, 35, 49-54	4

1344	[Perioperative management of antiplatelet therapy in thoracic surgery. A survey of German hospitals]. 2012 , 83, 576-82	1
1343	Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation. 2012 , 28, 705-14	13
1342	Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. 2012 , 28, 715-23	22
1341	Thromboresistant and endothelialization effects of dopamine-mediated heparin coating on a stent material surface. 2012 , 23, 1259-69	44
1340	Magnetic stents retain nanoparticle-bound antirestenotic drugs transported by lipid microbubbles. 2012 , 29, 1295-307	24
1339	Late stent thrombosis: the last remaining obstacle in coronary interventional therapy. 2012 , 14, 408-17	12
1338	Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles. 2012 , 5, 519-27	23
1337	Optical Coherence Tomography Imaging: Novel Insights into the Vascular Response After Coronary Stent Implantation. 2012 , 5, 231-238	8
1336	Optical Coherence Tomography: Potential Clinical Applications. 2012 , 5, 206-220	31
1335	How Do OCT and IVUS Compare to Histology in Coronary Atherosclerosis and Stenting?. 2012 , 5, 249-263	1
1334	Applying the National Institute for Clinical Excellence criteria to patients treated with the Genous [®] Bio-engineered R stent—a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. 2012 , 27, 360-9	7
1333	Intravascular ultrasound guided percutaneous coronary intervention: a practical approach. 2012 , 25, 86-94	5
1332	Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents following successful PCI in non-ST-elevation myocardial infarction: findings from the Guthrie Health Off-Label Stent (GHOST) Registry. 2012 , 25, 28-36	5
1331	Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevation myocardial infarction: findings from the Guthrie Health Off-label Stent (GHOST) Registry. 2012 , 25, 118-25	4
1330	Relationship between stent malapposition and incomplete neointimal coverage after drug-eluting stent implantation. 2012 , 25, 270-7	9
1329	One-year clinical outcome of a randomized trial of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based rapamycin-eluting stents in patients with coronary heart disease. 2012 , 25, 604-10	13
1328	Bridging therapy after recent stent implantation: case report and review of data. 2012 , 13, 30-8	9
1327	Intravascular ultrasound insights from the Cobalt Chromium Stent With Antiproliferative for Restenosis II (COSTAR II) trial comparing CoStar and Taxus paclitaxel-eluting stents. 2012 , 13, 111-8	1

1326	Symptomatic abnormal vessel wall reaction after implantation of the first generation sirolimus-eluting stent: a case series. 2012 , 13, 196-200	2
1325	Manganese superoxide dismutase inhibits neointima formation through attenuation of migration and proliferation of vascular smooth muscle cells. 2012 , 52, 173-81	32
1324	Endothelial progenitor cell capture stent: safety and effectiveness. 2012 , 25, 493-500	31
1323	Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. 2012 , 25, 482-92	18
1322	Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization. 2012 , 159, 27-33	37
1321	An analytical solution for the stress state at stent-coating interfaces. 2012 , 10, 183-96	10
1320	The Genous [®] Endothelial progenitor cell capture stent accelerates stent re-endothelialization but does not affect intimal hyperplasia in porcine coronary arteries. 2012 , 79, 231-42	46
1319	Duration of dual antiplatelet therapy and outcomes after coronary stenting with the Genous [®] bio-engineered R stent [™] in patients from the e-HEALING registry. 2012 , 79, 243-52	7
1318	Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro. 2012 , 100, 41-50	42
1317	Biomaterial testing for covered stent membranes: evaluating thrombosis and restenosis potential. 2012 , 100, 103-10	8
1316	Polymer-free immobilization of a cyclic RGD peptide on a nitinol stent promotes integrin-dependent endothelial coverage of strut surfaces. 2012 , 100, 637-45	15
1315	Stent thrombosis: understanding and managing a critical problem. 2012 , 14, 91-107	5
1314	Diffuse in-stent restenosis of CYPHER [®] stent due to hypersensitivity reaction confirmed by pathohistological findings. 2012 , 27, 110-3	13
1313	Short-term effects of fully bioabsorbable PLLA coronary stents in a porcine model. 2012 , 68, 1171-1181	14
1312	Drug Release Kinetics from Biodegradable Polymers via Partial Differential Equations Models. 2012 , 118, 161-183	11
1311	Optical coherence tomography evaluation of drug-eluting stents: a systematic review. 2013 , 81, 481-7	18
1310	Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. 2013 , 81, E23-8	42
1309	Initial findings of impact of strut width on stent coverage and apposition of sirolimus-eluting stents assessed by optical coherence tomography. 2013 , 81, 776-81	13

1308	Shear- vs. nanotopography-guided control of growth of endothelial cells on RGD-nanoparticle-nanowell arrays. 2013 , 7, 11	5
1307	Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial. 2013 , 14, 38	1
1306	Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats. 2013 , 167, 126-33	15
1305	In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release. 2013 , 24, 2589-600	22
1304	Blood compatibility of a new zwitterionic bare metal stent with hyperbranched polymer brushes. 2013 , 1, 5036-5044	20
1303	Progress in treatment by percutaneous coronary intervention: the stent of the future. 2013 , 66, 483-96	13
1302	Design and evaluation of mixed self-assembled monolayers for a potential use in everolimus eluting coronary stents. 2013 , 112, 330-6	7
1301	First in vitro and in vivo results of an anti-human CD133-antibody coated coronary stent in the porcine model. 2013 , 102, 413-25	25
1300	Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. 2013 , 102, 371-81	10
1299	System Modeling and Optimization. 2013 ,	1
1298	Nanostructured poly(L-lactide) matrix as novel platform for drug delivery. 2013 , 448, 175-88	19
1297	Impact of kissing balloon inflation on the main vessel stent volume, area, and symmetry after side-branch dilation in patients with coronary bifurcation lesions: a serial volumetric intravascular ultrasound study. 2013 , 6, 923-31	42
1296	Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. 2013 , 6, 504-12	46
1295	Modelos animales de reparaci3n vascular y reendotelizaci3n. 2013 , 13, 20-28	
1294	Safety and efficacy of drug-eluting stents in patients with acute myocardial infarction--from first generation to second generation of drug-eluting stents. 2013 , 61, 378-9	2
1293	Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2406-2416	15.1 59
1292	Clinical Efficacy and Safety of SeQuent Please Paclitaxel-Eluting Balloon in a Real-World Single-Center Registry of South-East Asian Patients. 2013 , 1, 37-41	6
1291	Endopr3tesis coronarias bioabsorbibles. 2013 , 13, 29-39	

1290	Fabrication of Mg alloy tubes for biodegradable stent application. 2013 , 33, 4746-50	44
1289	Evaluation of neointimal coverage and apposition with various drug-eluting stents over 12 months after implantation by optical coherence tomography. 2013 , 162, 166-71	15
1288	Public health science: a call for abstracts. 2013 , 381, 789	
1287	Poly-(L-lactic acid) and citric acid-crosslinked gelatin composite matrices as a drug-eluting stent coating material with endothelialization, antithrombogenic, and drug release properties. 2013 , 101, 2049-57	8
1286	Fabrication of a novel polymer-free nanostructured drug-eluting coating for cardiovascular stents. 2013 , 5, 10337-45	52
1285	The effects of stenting on shear stress: relevance to endothelial injury and repair. 2013 , 99, 269-75	90
1284	OCT analysis in patients with very late stent thrombosis. 2013 , 6, 695-703	69
1283	New drug-eluting stents: polymer-free, biodegradable polymers or bioabsorbable scaffolds?. 2013 , 66, 423-6	
1282	A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. 2013 , 166, 527-33	95
1281	Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. 2013 , 102, 785-97	117
1280	Endothelial dysfunction following drug-eluting stent implantation: a systematic review of the literature. 2013 , 165, 222-8	34
1279	Macroscale delivery systems for molecular and cellular payloads. 2013 , 12, 1004-17	217
1278	Questions and answers on proper peri-operative management of antiplatelet therapy after coronary stent implantation to prevent stent thrombosis. 2013 , 112, 1046-50	4
1277	Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds. 2013 , 6, 211-21	25
1276	Use of IVUS guided coronary stenting with drug eluting stent: a systematic review and meta-analysis of randomized controlled clinical trials and high quality observational studies. 2013 , 170, 54-63	44
1275	Advanced stent coating for drug delivery and in vivo biocompatibility. 2013 , 15, 1	8
1274	Accelerated endothelialization with a polymer-free sirolimus-eluting antibody-coated stent. 2013 , 24, 2601-9	4
1273	Treatment of a coronary bifurcation lesion with drug-coated balloons: lumen enlargement and plaque modification after 6 months. 2013 , 102, 469-72	13

1272	Evolution of Coronary Stents: From Bare-Metal Stents to Fully Biodegradable, Drug-Eluting Stents. 2013 , 3, 9-24	20
1271	Are there sufficient standards for the in vitro hemocompatibility testing of biomaterials?. 2013 , 8, 33	45
1270	Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial. 2013 , 29, 1693-703	11
1269	Evaluation neointimal coverage in patients with coronary artery aneurysm formation after drug-eluting stent implantation by optical coherence tomography. 2013 , 29, 1677-83	9
1268	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. 2013 , 5, 179-201	
1267	Local insulin application on the carotid artery inhibits neointima formation. 2013 , 91, 1086-94	4
1266	Reproducibility of qualitative assessment of stent struts coverage by optical coherence tomography. 2013 , 29, 5-11	12
1265	Long-term serial angiographic outcomes after sirolimus-eluting stent implantation. 2013 , 81, E29-35	2
1264	Triple, simultaneous, very late coronary stent thrombosis. 2013 , 32, 247-252	3
1263	[Very late bare-metal stent thrombosis 10 years after the implantation: a case report]. 2013 , 62, 435-7	1
1262	Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions--a meta-analysis of randomized controlled trials. 2013 , 167, 2126-33	8
1261	Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. 2013 , 6, 1267-74	216
1260	The Optimal Duration of Dual Combination Antiplatelet Therapy After Stent Implantation and Perioperative Management Issues. 2013 , 2, 585-594	
1259	Frequency domain optical coherence tomography for guidance of coronary stenting. 2013 , 166, 722-8	26
1258	Triple, simultaneous, very late coronary stent thrombosis. 2013 , 32, 247-52	5
1257	Disappearing stents--DREAMS of a sorcerer's apprentice?. 2013 , 381, 787-9	
1256	A stent for co-delivering paclitaxel and nitric oxide from abluminal and luminal surfaces: Preparation, surface characterization, and in vitro drug release studies. 2013 , 279, 216-232	21
1255	Effects of the simultaneous use of drug-eluting stents and statins in an atherosclerotic animal model. 2013 , 25, 16-24	

1254	Safety and efficacy of biodegradable polymer-coated biolimus-eluting stents. 2013 , 65, 207-212	3
1253	Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. 2013 , 168, 5162-6	28
1252	De novo pseudoaneurysm formation after angioplasty and stenting of posterior circulation intracranial atherosclerotic disease: mechanism, characterization with intravascular ultrasound and management considerations. 2013 , 5, 447-51	3
1251	Comparisons of detailed arterial healing response at seven months following implantation of an everolimus- or sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction. 2013 , 168, 960-6	19
1250	The relationship between eosinophil and nondipper hypertension. 2013 , 55, e487-e491	2
1249	Novel paclitaxel-coated angioplasty balloon catheter based on cetylpyridinium salicylate: preparation, characterization and simulated use in an in vitro vessel model. 2013 , 33, 4244-50	24
1248	Nuevos stents farmacoactivos: ¿sin polímero, con polímeros biodegradables o dispositivos completamente bioabsorbibles?. 2013 , 66, 423-426	11
1247	Avances en el tratamiento mediante intervención coronaria percutánea: el stent del futuro. 2013 , 66, 483-496	47
1246	Optical coherence tomography and histopathological assessment of delayed arterial healing after drug-eluting stent implant in a pig coronary model. 2013 , 170, 152-9	5
1245	Intra-individual head-to-head comparison of Sirolimus [®] - and Paclitaxel [®] -eluting stents for coronary revascularization. A randomized, multi-center trial. 2013 , 167, 1552-9	4
1244	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. 2013 , 381, 661-9	152
1243	Six-month follow-up evaluation for everolimus-eluting stents by intracoronary optical coherence tomography: comparison with paclitaxel-eluting stents. 2013 , 166, 181-6	24
1242	Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus Biodegradable Stent Coating) randomized, noninferiority trial. 2013 , 6, 777-89	254
1241	Serial assessment by optical coherence tomography of early and late vascular responses after implantation of an absorbable-coating Sirolimus-Eluting stent (from the first-in-human DESSOLVE I trial). 2013 , 112, 1557-64	15
1240	Current applications of optical coherence tomography for coronary intervention. 2013 , 165, 7-16	42
1239	The efficacy and safety of drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction (KAMIR). 2013 , 163, 1-4	21
1238	An update on drug-eluting stents. 2013 , 15, 61-78	2
1237	New concepts in the design of drug-eluting coronary stents. 2013 , 10, 248-60	92

1236	New generation coronary stent technology--is the future biodegradable?. 2013 , 22, 495-506	37
1235	Recent advances in drug eluting stents. 2013 , 441, 665-79	117
1234	Eosinophils in Human Disease. 2013 , 431-536	2
1233	Drug-eluting coronary-artery stents. 2013 , 368, 254-65	499
1232	Biocompatibility studies of low temperature nitrided and collagen-I coated AISI 316L austenitic stainless steel. 2013 , 24, 1501-13	15
1231	Newly available and recent advances in drug-eluting stents. 2013 , 11, 555-66	4
1230	Development and characterization of a coronary polylactic acid stent prototype generated by selective laser melting. 2013 , 24, 241-55	33
1229	Late and very late coronary stent thrombosis: Intravascular ultrasound findings and associations with antiplatelet therapy. 2013 , 82, 1056-65	9
1228	Surface modification of cardiovascular materials and implants. 2013 , 233, 80-90	84
1227	Nanomedicine highlights in atherosclerosis. 2013 , 15, 1	7
1226	Bioresorbable scaffolds: current knowledge, potentialities and limitations experienced during their first clinical applications. 2013 , 167, 11-21	45
1225	A randomized comparison of sirolimus- vs. paclitaxel-eluting stents for treatment of bifurcation lesions by single stent and kissing balloon: results of the SINGLE KISS trial. 2013 , 166, 187-92	7
1224	Oxidative stress and pathological changes after coronary artery interventions. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1471-81	15.1 76
1223	Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies. 2013 , 6, 687-95	61
1222	Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. 2013 , 381, 651-60	243
1221	Current status of research and application in vascular stents. 2013 , 58, 4362-4370	10
1220	Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. 2013 , 34, 3304-13	69
1219	Nanomedicine in diagnostics and therapy of cardiovascular diseases: beyond atherosclerotic plaque imaging. 2013 , 2, 449-472	15

1218	Enhanced visualization of biodegradable polymeric vascular scaffolds by incorporation of gold, silver and magnetite nanoparticles. 2013 , 28, 219-31	17
1217	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. 2013 , 99, 1267-74	30
1216	Tissue characterization after drug-eluting stent implantation using optical coherence tomography. 2013 , 33, 1376-83	61
1215	Resolute and Xience V polymer-based drug-eluting stents compared in an atherosclerotic rabbit double injury model. 2013 , 81, E259-68	11
1214	Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. 2013 , 34, 872-4	2
1213	The invasive assessment of coronary atherosclerosis and stents using optical coherence tomography: a clinical update. 2013 , 5, 154-161	6
1212	Biolimus-eluting stent with biodegradable polymer (Nobori [®]): an overview of recent clinical results, SORT OUT V and COMPARE II trials. 2013 , 11, 1293-6	3
1211	Drug-coated balloons in interventional cardiology. 2013 , 11, 1379-91	5
1210	A selective peroxisome proliferator-activated receptor- γ agonist attenuates neointimal hyperplasia after wire-mediated arterial injury. 2013 , 22, 1095-106	2
1209	Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification. 2013 , 34, 3378-88	50
1208	Coronary artery stents and surgery; the basis of sound perioperative management. 2013 , 05, 1730-1736	2
1207	Influence of fibre diameter and orientation of electrospun copolyetheresterurethanes on smooth muscle and endothelial cell behaviour. 2013 , 55, 513-22	13
1206	Experience with biodegradable polymer coated sirolimus-eluting coronary stent system in "real-life" percutaneous coronary intervention: 24-month data from the manipal-s registry. 2013 , 7, 1959-63	3
1205	Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model. 2013 , 2013, 937936	9
1204	Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. 2013 , 2013, 748736	13
1203	Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease. 2013 , 14, 24492-500	86
1202	Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study. 2013 , 24, 431-9	13
1201	Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents. 2013 , 24, 217-23	5

1200	Late-phase inflammatory response as a feature of in-stent restenosis after drug-eluting stent implantation. 2013 , 24, 368-73	26
1199	Difference in neointimal appearance between early and late restenosis after sirolimus-eluting stent implantation assessed by optical coherence tomography. 2013 , 24, 95-101	10
1198	Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy. 2013 , 127, 2047-55	53
1197	Novel small leucine-rich repeat protein podocan is a negative regulator of migration and proliferation of smooth muscle cells, modulates neointima formation, and is expressed in human atheroma. 2013 , 128, 2351-63	18
1196	Impact of stent surface on thrombogenicity and vascular healing: a comparative analysis of metallic and polymeric surfaces. 2013 , 6, 370-7	33
1195	Automatic characterization of neointimal tissue by intravascular optical coherence tomography. 2014 , 19, 21104	21
1194	Development of a sirolimus-eluting poly (L-lactide)/poly(4-hydroxybutyrate) absorbable stent for peripheral vascular intervention. 2013 , 58, 429-37	10
1193	Advances in Coronary Revascularization. 2013 , 214-239	
1192	Impact of stent mis-sizing and mis-positioning on coronary fluid wall shear and intramural stress. 2013 , 115, 285-92	12
1191	Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. 2013 , 310, 1462-72	220
1190	Implant-associated local drug delivery systems based on biodegradable polymers: customized designs for different medical applications. 2013 , 58, 417-27	15
1189	Preclinical evaluation of a novel drug-eluting balloon in an animal model of in-stent stenosis. 2013 , 27, 717-26	14
1188	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. 2013 , 347, f6530	166
1187	Pathologic findings of coronary stents: a comparison of sudden coronary death versus non-cardiac death. 2013 , 58, 1542-8	3
1186	Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation. 2013 , 54, 1360-8	17
1185	Bioresorbable vascular scaffolds: the promise of transience. 2013 , 43, 615-8	2
1184	A meta-analysis of the impact of EPC capture stent on the clinical outcomes in patients with coronary artery disease. 2013 , 26, 228-38	7
1183	Application of a rotating bioreactor consisting of low-cost and ready-to-use medical disposables for in vitro evaluation of the endothelialization efficiency of small-caliber vascular prostheses. 2013 , 101, 1061-8	10

1182	Stent apposition in late and very late stent thrombosis: the apposing views. 2013 , 82, 1066-7	
1181	Fibronectin/fibrinogen/tropoelastin on a stent to promote CD34+cell growth does not reduce neointima formation. 2013 , 5, 359-367	
1180	Stent-based drug-delivery systems: current challenges and future trends. 2013 , 4, 1079-82	2
1179	Crush, culotte, T and protrusion: which 2-stent technique for treatment of true bifurcation lesions? - insights from in vitro experiments and micro-computed tomography. 2013 , 77, 73-80	41
1178	Incidence and predictors for late target lesion revascularization after sirolimus-eluting stent implantation. 2013 , 77, 988-94	9
1177	Coronary arterial remodeling and out-stent plaque change after drug-eluting stent implantation--comparison between zotarolimus-eluting stents and paclitaxel-eluting stents. 2013 , 77, 363-71	9
1176	Qualitative and quantitative assessment of stent restenosis by optical coherence tomography: comparison between drug-eluting and bare-metal stents. 2013 , 77, 652-60	34
1175	Usefulness of functional assessment in the treatment of patients with moderate angiographic paclitaxel-eluting stent restenosis. 2013 , 77, 1180-5	10
1174	Difference in clinical and angiographic characteristics of very late stent thrombosis between drug-eluting and bare-metal stent implantations. 2013 , 77, 1453-60	10
1173	Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model. 2013 , 81, 698-708	10
1172	A murine model of stent implantation in the carotid artery for the study of restenosis. 2013 , e50233	3
1171	Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry. 2013 , 82, E155-62	6
1170	One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology. 2013 , 81, 268-73	7
1169	Early vessel healing of the Avantgarde cobalt-chromium coronary stent: the ON-GARDE OCT study. 2013 , 14, 276-80	4
1168	Preclinical Evaluation of Coronary Stents: Focus on Safety Issues. 2013 , 11, 74-99	12
1167	Immediate results of bifurcational stenting assessed with optical coherence tomography. 2013 , 81, 519-28	21
1166	Membranous diaphragm formation after simultaneous kissing stenting with sirolimus-eluting stents for the left main bifurcation: insight from optical coherence tomography findings. 2013 , 82, E221-4	3
1165	One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study. 2013 , 82, E428-36	5

1164	Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents. 2013 , 8, 59-66	
1163	A randomized, open-label clinical trial using optical coherence tomography to compare two sirolimus-eluting stents, one with a biodegradable polymer and the other with a permanent polymer. 2013 , 7, 1191-6	1
1162	Potential benefit of final kissing balloon inflation after single stenting for the treatment of bifurcation lesions--insights from optical coherence tomography observations. 2013 , 77, 1193-201	44
1161	Five years on dual-antiplatelet therapy. DES thrombosis after clopidogrel withdrawal. 2013 , 54, 234-6	0
1160	Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model. 2013 , 49, 7-13	16
1159	Inflammation: a key mechanism of adverse reactions to coronary stent and a target for future therapies. 2013 , 11, 377-8	3
1158	Endovascular Gene Delivery from a Stent Platform: Gene- Eluting Stents. 2013 , 1,	4
1157	Clinical significance of low signal intensity area surrounding stent struts identified by optical coherence tomography. 2013 , 54, 7-10	4
1156	Knockout of CD8 delays reendothelialization and accelerates neointima formation in injured arteries of mouse via TNF- α inhibiting the endothelial cells migration. 2013 , 8, e62001	13
1155	Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. 2013 , 8, e78667	10
1154	An anti-CD34 antibody-functionalized clinical-grade POSS-PCU nanocomposite polymer for cardiovascular stent coating applications: a preliminary assessment of endothelial progenitor cell capture and hemocompatibility. 2013 , 8, e77112	35
1153	ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS?. 2013 , 9, 682-689	2
1152	Clinical and Research Applications of Optical Coherence Tomography Imaging in Coronary Artery Disease. 2013 ,	1
1151	Impaired digital reactive hyperemia and the risk of restenosis after primary coronary intervention in patients with acute coronary syndrome. 2014 , 21, 957-65	7
1150	Optical Coherence Tomography: A Journey from Clinical Research to Daily Interventional Practice. 2014 , 4, 16-21	
1149	Promoting endothelial recovery and reducing neointimal hyperplasia using sequential-like release of acetylsalicylic acid and paclitaxel-loaded biodegradable stents. 2014 , 9, 4117-33	15
1148	Role of the latest endovascular technology in the treatment of intermittent claudication. 2014 , 10, 467-74	2
1147	The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view. 2015 , 8, 37-45	2

1146	Advances in stent technologies and their effect on clinical efficacy and safety. 2014 , 7, 165-78	5
1145	Oxido-reductive regulation of vascular remodeling by receptor tyrosine kinase ROS1. 2014 , 124, 5159-74	30
1144	Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. 2014 , 66, 345-9	5
1143	Drug-eluting stents in unprotected left main coronary artery disease. 2014 , 12, 1349-68	1
1142	Bioresorbable scaffolds in peripheral arterial disease. 2014 , 12, 443-50	4
1141	Everolimus-eluting stents improve vascular response in a diabetic animal model. 2014 , 7, 526-32	10
1140	Rapamycin attenuates endothelial apoptosis induced by low shear stress via mTOR and sestrin1 related redox regulation. 2014 , 2014, 769608	22
1139	Incomplete stent apposition causes high shear flow disturbances and delay in neointimal coverage as a function of strut to wall detachment distance: implications for the management of incomplete stent apposition. 2014 , 7, 180-9	151
1138	Cardiovascular therapy through nanotechnology [how far are we still from bedside?]. 2014 , 6,	12
1137	Biocompatibility of Coronary Stents. 2014 , 7, 769-786	25
1136	Neointimal patterns obtained by optical coherence tomography correlate with specific histological components and neointimal proliferation in a swine model of restenosis. 2014 , 15, 292-8	43
1135	Frequency-domain optical coherence tomography findings in patients with bifurcated lesions undergoing provisional stenting. 2014 , 15, 547-55	25
1134	Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. 2014 , 1, e000117	79
1133	A Randomized Comparison between Everolimus-Eluting Stent and Cobalt Chromium Stent in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Using Routine Intravenous Eptifibatid: The X-MAN (Xience vs. Multi-Link Stent in Acute Myocardial Infarction) Trial, A Pilot Study. 2014 , 23, 93-100	
1132	Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent. 2014 , 84, 720-6	12
1131	A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents. 2014 , 7, 1352-60	27
1130	The relationship between re-endothelialization and endothelial function after DES implantation: comparison between paclitaxel eluting stent and zotarolims eluting stent. 2014 , 83, 412-7	9
1129	First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial. 2014 , 83, 405-11	13

1128	Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale. 2014 , 84, 368-74		2
1127	Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. 2014 , 168, 862-8.e1		6
1126	Impact of stent strut design in metallic stents and biodegradable scaffolds. 2014 , 177, 800-8		106
1125	Biodegradable polymer brush as nanocoupled interface for improving the durability of polymer coating on metal surface. 2014 , 122, 808-817		22
1124	Three-Dimensional Quadratic Model of Paclitaxel Release from Biodegradable Polymer Films. 2014 , 74, 1354-1374		5
1123	Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent. 2014 , 84, 323-31		21
1122	Current status of bioresorbable scaffolds in the treatment of coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2541-51	15.1	184
1121	Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. 2014 , 35, 795-807		51
1120	RAPSTROM™ First-in-man study long-term results of a biodegradable polymer sustained-release sirolimus-eluting stent in de novo coronary stenoses. 2014 , 27, 373-80		2
1119	The integrin ligand c(RGDf(NMe)Nal) reduces neointimal hyperplasia in a polymer-free drug-eluting stent system. 2014 , 9, 1413-8		6
1118	Healing the injured vessel wall using microRNA-facilitated gene delivery. 2014 , 124, 3694-7		10
1117	[Antithrombotic therapy and PCI. Duration of therapy after DCB/stents/scaffolds]. 2014 , 39, 819-21		2
1116	Predictors of coronary artery aneurysm after stent implantation in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 2014 , 30, 1435-44		1
1115	Inhibitory effects of roscovitine on proliferation and migration of vascular smooth muscle cells in vitro. 2014 , 34, 791-795		2
1114	Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome. 2014 , 84, 1053-60		9
1113	Stent selection to minimize the risk of stent thrombosis. 2014 , 29, 578-85		9
1112	Electrochemical Hydroxyapatite Coatings on Nitinol Stents for the Reduction of Metal Ions Elution. 2014 , 1626, 1		
1111	Next-generation DES: the COMBO dual therapy stent with Genous endothelial progenitor capturing technology and an abluminal sirolimus matrix. 2014 , 11, 121-35		15

1110	Vascular Pathology and Interventional Treatments. 2014 , 1-25	
1109	Clinical use of optical coherence tomography to identify angiographic silent stent thrombosis. 2014 , 48, 156-60	2
1108	Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients. 2014 , 21, 411-24	20
1107	Randomized comparison between polymer-free versus polymer-based paclitaxel-eluting stent: two-year final clinical results. 2014 , 7, 312-21	12
1106	Bioresorbable scaffolds for percutaneous coronary interventions. 2014 , 2014, 409-27	11
1105	A Survey of Surface Modification Techniques for Next-Generation Shape Memory Polymer Stent Devices. 2014 , 6, 2309-2331	60
1104	Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical results. 2014 , 7, 35-43	4
1103	Safety and efficacy of first-generation and second-generation drug-eluting stents in the setting of acute coronary syndromes. 2014 , 15, 532-42	2
1102	Coronary artery stents: advances in technology. 2014 , 42, 83-91	8
1101	Análisis de la eficacia y la seguridad de distintos balones liberadores de paclitaxel en un modelo animal. 2014 , 67, 456-462	8
1100	Clinical significance of non-slip element balloon angioplasty for patients of coronary artery disease: a preliminary report. 2014 , 63, 19-23	14
1099	African-American patients are less likely to receive drug-eluting stents during percutaneous coronary intervention. 2014 , 15, 214-8	14
1098	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. 2014 , 383, 2047-2056	80
1097	Polymeric stent materials dysregulate macrophage and endothelial cell functions: implications for coronary artery stent. 2014 , 174, 688-95	7
1096	Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. 2014 , 30, 495-504	28
1095	Relationship between endothelial vasomotor function and strut coverage after implantation of drug-eluting stent assessed by optical coherence tomography. 2014 , 30, 263-70	11
1094	Impact of angiographic peri-stent contrast staining (PSS) on late adverse events after sirolimus-eluting stent implantation: an observation from the multicenter j-Cypher registry PSS substudy. 2014 , 29, 226-36	11
1093	Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. 2014 , 103, 141-8	46

1092	Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial. 2014 , 167, 445-51		26
1091	Clinical and angiographic outcomes of patients undergoing entrapped guidewire retrieval in stent-jailed side branch using a balloon catheter. 2014 , 84, 750-6		11
1090	Recent perspective on coronary artery bifurcation interventions. 2014 , 6, 18-25		6
1089	Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INFArction) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute Myocardial Infarction) studies. 2014 , 116, 100-10		75
1088	Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations. 2014 , 83, 889-95		6
1087	Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome. 2014 , 113, 888-96		7
1086	Effects of polydopamine functionalized titanium dioxide nanotubes on endothelial cell and smooth muscle cell. 2014 , 116, 553-60		39
1085	Evolving management of patients treated by drug-eluting stent: prevention of late events. 2014 , 15, 100-8		1
1084	Causes of early stent thrombosis in patients presenting with acute coronary syndrome: an ex vivo human autopsy study. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2510-2520	15.1	82
1083	Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. 2014 , 35, 777-86		93
1082	New stent surface materials: the impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets. 2014 , 10, 688-700		55
1081	Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 299-307	15.1	217
1080	Drug-coated balloon therapy in coronary and peripheral artery disease. 2014 , 11, 13-23		133
1079	Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis. 2014 , 103, 21-7		8
1078	The evolution of coronary stents: a brief review. 2014 , 30, 35-45		101
1077	Fabrication of nonbiofouling metal stent and in vitro studies on its hemocompatibility. 2014 , 29, 14-25		10
1076	Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. 2014 , 384, 2111-22		184
1075	Healing course of acute vessel wall injury after drug-eluting stent implantation assessed by optical coherence tomography. 2014 , 15, 800-9		27

1074	Vascular endothelial growth factor-bound stents: application of in situ capture technology of circulating endothelial progenitor cells in porcine coronary model. 2014 , 27, 63-72	19
1073	Permanent polymer of drug eluting stents increases eosinophil cationic protein levels following percutaneous coronary intervention independently of C-reactive protein. 2014 , 237, 816-20	2
1072	Intracoronary Optical Coherence Tomography: Insights from Clinical Research—What Do We Need to Learn?. 2014 , 7, 1	2
1071	Stent thrombosis: a clinical perspective. 2014 , 7, 1081-92	107
1070	Gallic acid and gallic acid-loaded coating involved in selective regulation of platelet, endothelial and smooth muscle cell fate. 2014 , 4, 212-221	12
1069	Polymer-free drug-eluting stent in unselected patient population: a single center experience. 2014 , 15, 350-3	6
1068	Non-cardiac surgery after percutaneous coronary intervention. 2014 , 114, 1613-20	6
1067	ORAL iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: a patient-level meta-analysis of randomized trials. 2014 , 237, 410-7	11
1066	Current and future perspectives on drug-eluting bioresorbable coronary scaffolds. 2014 , 10, 409-20	5
1065	Bioresorbable scaffolds for the treatment of coronary artery disease: current status and future perspective. 2014 , 11, 467-80	5
1064	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. 2014 , 1, e000064	70
1063	Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel. 2014 , 19, 201-8	12
1062	The effects of eosinophil on the left atrial thrombus in patients with atrial fibrillation. 2014 , 20, 285-9	8
1061	Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells. 2014 , 177, 266-75	29
1060	Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: network meta-analysis of primary percutaneous coronary intervention trials in ST-segment Elevation myocardial infarction [corrected]. 2014 , 7, 49-61	30
1059	Stent thrombosis following drug-eluting stents in STEMI: "Much ado about nothing?". <i>Journal of the American College of Cardiology</i> , 2014 , 64, 25-7	15.1 1
1058	Cell-specific expression of uptake transporters—a potential approach for cardiovascular drug delivery devices. 2014 , 11, 665-72	4
1057	Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. 2014 , 175, 484-91	9

1056	A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. 2014 , 35, 2021-31	124
1055	Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. 2014 , 35, 1147-58	134
1054	Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. 2014 , 7, 330-42	125
1053	Reinforcement of interfacial adhesion of a coated polymer layer on a cobalt-chromium surface for drug-eluting stents. 2014 , 30, 8020-8	20
1052	Circulating soluble LR11, a novel marker of smooth muscle cell proliferation, is enhanced after coronary stenting in response to vascular injury. 2014 , 237, 374-8	16
1051	Nitinol-based nanotubular coatings for the modulation of human vascular cell function. 2014 , 14, 5021-8	36
1050	Mechanisms, pathophysiology, and clinical aspects of incomplete stent apposition. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1355-67	15.1 90
1049	Recent advances in micro/nanoscale biomedical implants. 2014 , 189, 25-45	48
1048	Choosing the right coronary stent in the modern era. 2014 , 16, 469	1
1047	Coronary vasomotion one year after drug-eluting stent implantation: comparison of everolimus-eluting and paclitaxel-eluting coronary stents. 2014 , 7, 406-12	10
1046	Comparison of sirolimus loaded PLGA-PEG Co-polymer coronary stent and bare metal stent in a porcine coronary restenosis model. 2014 , 22, 639-646	8
1045	Elsibucol inhibits atherosclerosis following arterial injury: multifunctional effects on cholesterol levels, oxidative stress and inflammation. 2014 , 237, 194-9	11
1044	Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation. 2014 , 220-228	
1043	Covalent co-immobilization of heparin/laminin complex that with different concentration ratio on titanium surface for selectively direction of platelets and vascular cells behavior. 2014 , 317, 776-786	18
1042	Mortality after presentation with stent thrombosis is associated with time from index percutaneous coronary intervention: a report from the VA CART program. 2014 , 168, 560-7	13
1041	Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention. 2014 , 15, 2825-32	10
1040	Long-term coronary arterial response to biodegradable polymer biolimus-eluting stents in comparison with durable polymer sirolimus-eluting stents and bare-metal stents: five-year follow-up optical coherence tomography study. 2014 , 237, 23-9	14
1039	Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents. 2014 , 113, 1968-76	18

1038	Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. 2014 , 7, 688-95	58
1037	A novel coating of type IV collagen and hyaluronic acid on stent material-titanium for promoting smooth muscle cell contractile phenotype. 2014 , 38, 235-43	41
1036	An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. 2014 , 67, 65-70	21
1035	Neo-atherosclerosis in very late stent thrombosis of drug eluting stent. 2014 , 26, 226-30	
1034	Analysis by optical coherence tomography of long-term arterial healing after implantation of different types of stents. 2014 , 30, 904-11	3
1033	The molecular mechanism for effects of TiN coating on NiTi alloy on endothelial cell function. 2014 , 35, 6195-205	32
1032	Safety and efficacy of different paclitaxel-eluting balloons in a porcine model. 2014 , 67, 456-62	2
1031	Stent malapposition, as a potential mechanism of very late stent thrombosis after bare-metal stent implantation: a case report. 2014 , 15, 178-81	1
1030	Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. 2014 , 233, 224-31	24
1029	Interactions of anti-proliferative and anti-platelet drugs with self-assembled monolayers: a future strategy in stent development. 2014 , 4, 4218-4224	2
1028	Numerical modelling of the physical factors that affect mass transport in the vasculature at early time periods. 2014 , 36, 308-17	3
1027	The late-phase inflammatory response after drug-eluting stent implantation. 2014 , 29, 213-9	14
1026	Comparison of long-term outcome after percutaneous coronary intervention for stent thrombosis between early, late, and very late stent thrombosis. 2014 , 78, 101-9	25
1025	Drug-coated percutaneous balloon catheters. 2014 , 42, 193-212	3
1024	Is There a Role for Drug-Eluting Balloons in Treatment of Acute Coronary Syndromes?. 2014 , 146-151	
1023	New Stents for Acute Coronary Syndrome. 2014 , 483-496	
1022	Optical coherence tomography and histopathology assessment after implantation of first- and second-generation drug-eluting stents in a porcine coronary model. 2014 , 78, 2665-73	12
1021	Edge vascular response after polymer-free vs. polymer-based paclitaxel-eluting stent implantation. 2014 , 78, 2657-64	1

1020	Innovations in vascular device surface engineering: a clinical review. 2014 , 2, 3-16	3
1019	An update on translational and early trials in coronary interventions. 2014 , 6, 433-444	
1018	Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial. 2014 , 15, 9	12
1017	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION. 2014 , 111, 1041-9	13
1016	First-in-Man Study of the Low-Dose Paclitaxel Using the COBRA-P Drug-Eluting Coronary Stent System With a Novel Biodegradable Coating in De Novo Coronary Lesions. 2014 , 84, 1101-1109	
1015	Clinical, angiographic, and intravascular ultrasound results of the VestSaync II trial. 2014 , 84, 1073-9	10
1014	Incidence of adverse cardiac events 5 years after polymer-free sirolimus eluting stent implantation: Results from the prospective Bad Berka Yukon Choice Registry. 2014 , 84, 1080-6	3
1013	Inhibition of neo-intimal hyperplasia in porcine coronary arteries utilizing a novel paclitaxel-coated scoring balloon catheter. 2014 , 84, 1089-98	18
1012	Polymer-free versus permanent polymer drug eluting stents in coronary artery disease: A meta-analysis of 10 RCTs with 6575 patients. 2015 , 1, 221-230	9
1011	Resultados iniciais e tardios de pacientes tratados com stent hbrido eluidor de sirolimus ou stent eluidor de everolimus. 2015 , 23, 114-118	
1010	ST-segment elevation myocardial infarction Ideal scenario for bioresorbable vascular scaffold implantation?. 2015 , 79, 263-70	14
1009	DrugMaterial Interactions, Materials Selection, and Manufacturing Methods. 2015 , 89-116	
1008	Vascular response after implantation of biolimus A9-eluting stent with bioabsorbable polymer and everolimus-eluting stents with durable polymer. Results of the optical coherence tomography analysis of the BIOACTIVE randomized trial. 2015 , 23, 28-37	
1007	Early and late outcomes of patients treated with hybrid sirolimus-eluting stent or everolimus-eluting stent. 2015 , 23, 114-118	
1006	Resposta vascular ap8s implante de stents liberadores de biolimus A9 com pol8mero bioabsorv8vel e stents liberadores de everolimus com pol8mero dur8vel. Resultados da an8lise de tomografia de coer8ncia 8ptica do estudo randomizado BIOACTIVE. 2015 , 23, 28-37	1
1005	Stent thrombosis caused by metal allergy complicated by protein S deficiency and heparin-induced thrombocytopenia: a case report and review of the literature. 2015 , 13, 25	5
1004	Optical coherence tomography assessment of the mechanistic effects of rotational and orbital atherectomy in severely calcified coronary lesions. 2015 , 86, 1024-32	70
1003	Long-Term Effects of Novel Combination Coating Anti-CD34 Antibody Applied on Sirolimus-Eluting Stents. 2015 , 28, 257-63	5

1002	Stent length as a potential indicator to select patients who may benefit from long-term dual antiplatelet therapy. 2015 , 7, 419-426	
1001	Gender disparity in the use of drug-eluting stents during percutaneous coronary intervention for acute myocardial infarction. 2015 , 86, 221-8	5
1000	Comparison of scanning electron microscopy and optical coherence tomography for imaging of coronary bifurcation stents. 2015 , 85, 1141-9	2
999	Detection and structural characterization of lipid-core plaques with intravascular NIRS-IVUS imaging. 2015 , 7, 519-535	0
998	Identification of Intrastent Pathology Associated With Late Stent Thrombosis Using Optical Coherence Tomography. 2015 , 28, 439-48	5
997	Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials. 2015 , 33, 253-63	8
996	Optical coherence tomography to evaluate coronary stent implantation and complications. 2015 , 26 Suppl 1, e55-68	5
995	Tailoring of the dopamine coated surface with VEGF loaded heparin/poly-L-lysine particles for anticoagulation and accelerate in situ endothelialization. 2015 , 103, 2024-34	14
994	Comparison between Plain Old Balloon Angioplasty and Drug-Eluting Stent Implantation for the Treatment of Stent Fracture. 2015 , 28, 365-73	3
993	Bioresorbable scaffolds in daily clinical routine: a practical review of all-comers results. 2015 , 30, 650-6	2
992	. 2015 ,	0
991	Neoatherosclerosis in the stent. 2015 , 11, 626-633	1
990	Diverse Findings in Calcified Thrombus Between Histopathology and In Vivo Imaging Including Intravascular Ultrasound, Optical Coherence Tomography, and Angioscopy. 2015 , 56, 661-3	7
989	Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes. 2015 , 8, 317-29	3
988	Nine-month angiographic and two-year clinical follow-up of novel biodegradable-polymer arsenic trioxide-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease. 2015 , 128, 768-73	5
987	The relationship between eosinophilia and slow coronary flow. 2015 , 11, 1187-91	8
986	Prevention of stent thrombosis: challenges and solutions. 2015 , 11, 93-106	23
985	Coronary artery bypass grafting versus percutaneous intervention in coronary revascularization: a historical perspective and review. 2015 , 57	

984	Evodiamine Attenuates PDGF-BB-Induced Migration of Rat Vascular Smooth Muscle Cells through Activating PPAR α 2015 , 16, 28180-93	22
983	Polymers for Cardiovascular Stent Coatings. 2015 , 2015, 1-11	39
982	Drug-eluting balloon: What do you need to know?. 2015 , 27, 189-197	
981	Drug-eluting stents with biodegradable polymer for the treatment of patients with diabetes mellitus: clinical outcome at 2 years in a large population of patients. 2015 , 8, 153-60	4
980	Randomized comparison of a sirolimus-eluting Orsiro stent with a biolimus-eluting Nobori stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome VII trial. 2015 , 170, 210-5	16
979	Some design considerations for polymer-free drug-eluting stents: a mathematical approach. 2015 , 18, 213-25	33
978	Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. 2015 , 36, 2147-59	266
977	Polymers in Cardiology. 2015 , 433-480	1
976	Reducing In-Stent Restenosis: Therapeutic Manipulation of miRNA in Vascular Remodeling and Inflammation. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2314-27	15.1 77
975	Contrast stainings outside the stents of the superficial femoral artery after polymer-free drug-eluting peripheral stents implantation. 2015 , 30, 293-8	0
974	Diagnosis and Evaluation of Stent Thrombosis with Optical Coherence Tomography. 2015 , 4, 295-307	
973	Impact of Strut Width in Periprocedural Myocardial Infarction: A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent. 2015 , 8, 900-9	39
972	Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. 2015 , 131, 74-81	74
971	Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial. 2016 , 17, 34-40	19
970	Etiology, Frequency, and Clinical Outcomes of Myocardial Infarction After Successful Drug-Eluting Stent Implantation: Two-Year Follow-Up From the ADAPT-DES Study. 2015 , 8, e002447	9
969	Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. 2015 , 8, e002230	95
968	Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. 2015 , 170, 641-651.e3	33
967	Coronary healing after stenting: wounds, faith, and the quest for the perfect stent. 2016 , 17, 12-4	

966	microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis. 2015 , 887, 53-77	65
965	Intravascular fibrin molecular imaging improves the detection of unhealed stents assessed by optical coherence tomography in vivo. 2017 , 38, 447-455	37
964	Seguridad y eficacia de nuevos modelos de stents liberadores de sirolimus en el modelo preclínico. 2015 , 68, 1118-1124	5
963	Effect of stromal cell derived factor-1 β release from heparin-coated Co-Cr stent substrate on the recruitment of endothelial progenitor cells. 2015 , 23, 1159-1167	8
962	A New Hemodynamic Ex Vivo Model for Medical Devices Assessment. 2015 , 29, 1648-55	3
961	Vascular restoration: Is there a window of opportunity?. 2015 , 85, 972-5	5
960	Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials. 2015 , 181, 331-9	15
959	Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. 2015 , 183, 190-7	3
958	Simple balloon dilation for drug-eluting in-stent restenosis: an optical coherent tomography analysis. 2015 , 16, 27-31	4
957	Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study. 2015 , 86, 1141-50	5
956	Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF. 2015 , 101, 50-7	8
955	Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus biolimus-eluting stent in the treatment of acute myocardial infarction). 2015 , 183, 190-7	117
954	Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation. 2015 , 8, e001878	55
953	Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. 2015 , 93, 22-7	31
952	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. 2015 , 385, 1527-35	92
951	Local delivery of paclitaxel in the treatment of peripheral arterial disease. 2015 , 45, 333-45	37
950	Histopathology of vascular response to drug-eluting stents: an insight from human autopsy into daily practice. 2015 , 30, 1-11	13
949	Evaluation of IVOCT imaging of coronary artery metallic stents with neointimal coverage. 2015 , 31, 463-70	0

948	Simultaneous occlusion of left anterior descending and left circumflex arteries by very late stent thrombosis: vascular response to drug-eluting stents assessed by intravascular ultrasound. 2015 , 30, 824-9	4
947	Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. 2015 , 8, 404-410	31
946	Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. 2015 , 8, e002427	72
945	Antiplatelet Therapy and Anticoagulation. 2015 , 109-130	
944	Biodegradable Stent Platforms: Are We Heading in the Right Direction?. 2015 , 31, 957-9	2
943	Metallic zinc exhibits optimal biocompatibility for bioabsorbable endovascular stents. 2015 , 56, 467-72	144
942	Safety and Efficacy of New Sirolimus-eluting Stent Models in a Preclinical Study. 2015 , 68, 1118-24	1
941	A Zr-based bulk metallic glass for future stent applications: Materials properties, finite element modeling, and in vitro human vascular cell response. 2015 , 25, 356-68	58
940	Prevention of Collagen-Induced Platelet Binding and Activation by Thermosensitive Nanoparticles. 2015 , 17, 1117-25	2
939	Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. 2015 , 8,	27
938	Coronary Angioscopy. 2015 ,	3
937	Magnesium alloys for vascular stents: the biological bases. 2015 , 16,	3
936	Effect of specific surface microstructures on substrate endothelialisation and thrombogenicity: Importance for stent design. 2015 , 59, 219-33	21
935	Incidence, clinical presentation, and predictors of early neoatherosclerosis after drug-eluting stent implantation. 2015 , 170, 591-7	20
934	Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 14-22	15.1 47
933	The butler did it! A very late stent thrombosis of TAXUS evaluated with Optical Coherence Tomography. 2015 , 187, 141-3	3
932	Optical coherence tomographic evaluation of the effect of cigarette smoking on vascular healing after sirolimus-eluting stent implantation. 2015 , 115, 751-7	3
931	Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis. 2015 , 108, 235-43	5

930	Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. 2015 , 8,		185
929	Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 791-801	15.1	169
928	Reducing Neointima Formation in a Swine Model with IVUS and Sirolimus Microbubbles. 2015 , 43, 2642-51		12
927	Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. 2015 , 23, 153-60		13
926	Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. 2015 , 20, 21		5
925	Vascular response after Zilver PTX stent implantation for superficial femoral artery lesions: serial optical coherence tomography findings at 6 and 12 months. 2015 , 22, 41-7		14
924	Dual antiplatelet therapy duration after the placement of a drug-eluting stent: what are the data?. 2015 , 17, 367		2
923	Preparation of Polymeric Prodrug Paclitaxel-Poly(lactic acid)-b-Polyisobutylene and Its Application in Coatings of a Drug Eluting Stent. 2015 , 7, 11263-71		21
922	Hydroxybutyl Chitosan Polymer-Mediated CD133 Antibody Coating of Metallic Stents to Reduce Restenosis in a Porcine Model of Atherosclerosis. 2015 , 20, 322-9		5
921	ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1. 2015 , 131, 1191-201		84
920	Shape-memory polymers for vascular and coronary devices. 2015 , 249-265		0
919	The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: chasing a mirage. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1311-1313	15.1	4
918	Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use. 2015 , 13, 1127-45		11
917	Continuation of Dual-Antiplatelet Therapy Following Percutaneous Revascularization with a Drug-Eluting Stent: What Duration Is Optimal?. 2015 , 17, 63		2
916	Antiplatelet therapy and exodontia. 2015 , 146, 851-6		11
915	Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1901-14	15.1	155
914	A comparison of drug eluting stent biocompatibility between third generation NOBORI biolimus A9-eluting stent and second generation XIENCE V everolimus-eluting stent in a porcine coronary artery model. 2015 , 16, 351-7		5
913	Effect of a novel peptide, WKYVMV- and sirolimus-coated stent on re-endothelialization and anti-restenosis. 2015 , 26, 251		15

912	Optical Coherence Tomography Findings in Bioresorbable Vascular Scaffolds Thrombosis. 2015 , 8, e002518	37
911	Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. 2015 , 373, 1905-15	441
910	Percutaneous Coronary Intervention Planning and Optimization with Optical Coherence Tomography. 2015 , 4, 251-284	1
909	Neointimal Coverage After Drug-Eluting Stent Implantation: Insights from Optical Coherence Tomography. 2015 , 4, 321-331	2
908	Effects of interfacial layer wettability and thickness on the coating morphology and sirolimus release for drug-eluting stent. 2015 , 460, 189-99	20
907	Controversies in Cardiology. 2015 ,	
906	Short-term outcomes in patients with acute coronary syndrome treated with direct bioresorbable scaffold deployment. 2015 , 16, 381-5	2
905	Bioresorbable Stents: Is This Where We Are Headed?. 2015 , 58, 342-55	11
904	Experimental assessment of effects of antiproliferative drugs of drug-eluting stents on endothelial cells. 2015 , 16, 344-7	1
903	Biodegradable polymer drug-eluting stents: ready for US prime time?. 2015 , 16, 323-5	
902	Comparison of long-term clinical outcomes between sirolimus- and paclitaxel-eluting stents in real-world clinical practice. 2015 , 30, 746-51	4
901	Midterm outcomes of bare-metal stenting after primary stenting for ST-segment elevated myocardial infarctions in the drug-eluting stent era: a propensity score-matched comparison with sirolimus-eluting stent. 2015 , 30, 234-43	2
900	Effect of oxide layer modification of CoCr stent alloys on blood activation and endothelial behavior. 2015 , 103, 629-40	18
899	Advanced Polymers in Medicine. 2015 ,	15
898	Multi-modality imaging for stent edge assessment. 2015 , 30, 162-8	2
897	Delayed inhaled carbon monoxide mediates the regression of established neointimal lesions. 2015 , 61, 1026-33	9
896	The relationship between eosinophil and cardiac syndrome X. 2015 , 21, 325-8	4
895	Cardiovascular OCT Imaging. 2015 ,	4

894	Are the findings of optical coherence tomography sufficient for the evaluation of the safety and efficacy of the next generation of drug eluting stents?. 2015 , 179, 127-8	
893	Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. 2015 , 179, 90-4	25
892	Biomaterials for Cardiac Regeneration. 2015 ,	3
891	Perioperative Hemostasis. 2015 ,	2
890	Natural history of low-intensity neointimal tissue after an everolimus-eluting stent implantation: a serial observation with optical coherence tomography. 2015 , 30, 136-9	8
889	Black hole restenosis after drug-eluting stent implantation for in-stent restenosis: potential mechanism and optimal strategy. 2015 , 30, 682-6	1
888	Stent coatings for blood compatibility. 2016 , 145-169	
887	Myocardial Ischemia and Its Complications. 2016 , 239-270	3
886	Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary Artery Disease: Results of the MANIPAL-FLEX Study. 2016 , 2016, 9324279	9
885	Biodegradable Polymers Influence the Effect of Atorvastatin on Human Coronary Artery Cells. 2016 , 17,	5
884	Drug diffusion and biological responses of arteries using a drug-eluting stent with nonuniform coating. 2016 , 9, 33-43	4
883	Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm. 2016 , 8, E1413-E1415	0
882	Coronary stent thrombosis: what have we learned?. 2016 , 8, 1398-405	7
881	Neoatherosclerosis after Drug-Eluting Stent Implantation: Roles and Mechanisms. 2016 , 2016, 5924234	5
880	Improved Biocompatibility of Novel Biodegradable Scaffold Composed of Poly-L-lactic Acid and Amorphous Calcium Phosphate Nanoparticles in Porcine Coronary Artery. 2016 , 2016, 1-8	10
879	Coronary stent technology: a narrative review. 2016 , 205, 277-81	12
878	The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence. 2016 , 17,	30
877	The Development of Coronary Artery Stents: From Bare-Metal to Bio-Resorbable Types. 2016 , 6, 168	24

876	Vitamin D Supplementation Reduces Intimal Hyperplasia and Restenosis following Coronary Intervention in Atherosclerotic Swine. 2016 , 11, e0156857	15
875	The benefits of drug-eluting stents in the treatment of coronary artery disease. 2016 , 9	1
874	Extreme late-phase observation using coronary angioscopy until 7 years after sirolimus-eluting stent implantation. 2016 , 27, 29-33	2
873	Quantitative analysis of the side-branch orifice after bifurcation stenting using en-face processing of OCT images: a comparison between Xience V and Resolute Integrity stents. 2016 , 27, 19-28	
872	Stent Coating Integrity of Durable and Biodegradable Coated Drug Eluting Stents. 2016 , 29, 483-490	20
871	The real world experience of the biodegradable polymer-coated sirolimus-eluting coronary stent system: Results From an "All-Comers" Clinical Experience. 2016 , 88, E93-8	4
870	Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry. 2016 , 87, 822-9	22
869	Diphenylalanine peptide nanotubes self-assembled on functionalized metal surfaces for potential application in drug-eluting stent. 2016 , 104, 2280-90	13
868	Optimal coating method for a dual-layer stent with sirolimus and alpha-lipoic acid in a porcine coronary restenosis model. 2016 , 24, 725-733	1
867	Temporal Trends in Strut-Level Optical Coherence Tomography Evaluation of Coronary Stent Coverage: A Systematic Review and Meta-Analysis. 2016 , 88, 1083-1093	14
866	Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta-analysis of randomized primary percutaneous coronary intervention trials. 2016 , 88, 38-48	32
865	Strategies to Extend the Life of Saphenous Vein Grafts. 2016 , 581-593	
864	Solely abluminal drug release from coronary stents could possibly improve reendothelialization. 2016 , 88, E59-66	8
863	Fractional flow reserve-guided paclitaxel-coated balloon treatment for de novo coronary lesions. 2016 , 88, 193-200	34
862	Early healing assessment with optical coherence tomography of everolimus-eluting stents with bioabsorbable polymer (synergy) at 3 and 6 months after implantation. 2016 , 88, E67-73	20
861	The interval between carotid artery stenting and open heart surgery is related to perioperative complications. 2016 , 87 Suppl 1, 564-9	2
860	Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. 2016 , 27, 777-783	3
859	Accelerated neutral atom beam (ANAB) technology for nanoscale surface processing. 2016 ,	

858	Intravascular Ultrasound and Virtual Histology. 2016 , 71-90		
857	Optical Coherence Tomography, Near-Infrared Spectroscopy, and Near-Infrared Fluorescence Molecular Imaging. 2016 , 91-106		
856	Drug Delivery Coatings for Coronary Stents. 2016 , 75-114		2
855	Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry. 2016 , 6, e010028		17
854	Thrombogenicity and hemocompatibility of biomaterials. 2015 , 11, 029601		31
853	Late Restenosis After Both First-Generation and Second-Generation Drug-Eluting Stent Implantations Occurs in Patients With Drug-Eluting Stent Restenosis. 2016 , 9,		6
852	Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2622-2632	15.1	60
851	Differential surface activation of the A1 domain of von Willebrand factor. 2016 , 11, 029803		7
850	Randomised comparison of drug-eluting versus bare-metal stenting in patients with non-ST elevation myocardial infarction. 2016 , 3, e000455		7
849	Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation. 2016 , 69, 1144-1151		1
848	Resultados del implante de armazn bioabsorbible de everolimus en segmentos largos atendiendo al concepto de solapamiento de armazones. 2016 , 69, 1144-1151		2
847	Direct oral anticoagulant use and stent thrombosis following an acute coronary syndrome: A potential new pharmacological option?. 2016 , 109, 359-69		0
846	MicroRNAs for Restenosis and Thrombosis After Vascular Injury. 2016 , 118, 1170-84		89
845	Comparison of two different drug-coated balloons for the treatment of in-stent restenosis: A long-term single-centre experience. 2016 , 17, 176-80		6
844	Frecuencia y caractersticas demogrficas de pacientes con diagnstico de trombosis de stents coronarios implantados en un hospital universitario entre enero de 2011 a diciembre de 2012. 2016 , 23, 87-95		
843	Fibrin clot formation and fibrinolysis in patients with a history of coronary stent thrombosis. 2016 , 143, 58-62		1
842	One-year outcomes following drug-eluting balloon use for coronary ostial restenosis. 2016 , 10, 25-28		2
841	Kounis syndrome revisited: Systemic mastocytosis and severe coronary artery disease. 2016 , 214, 510-1		3

840	Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics: The PANDA III Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2249-2258	15.1	29
839	Thin-cap fibroatheroma and large calcification at the proximal stent edge correlate with a high proportion of uncovered stent struts in the chronic phase. 2016 , 27, 376-84		9
838	Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes. 2016 , 23, e1876-e1889		9
837	Stent Polymers: Do They Make a Difference?. 2016 , 9,		43
836	A glimpse into first generation drug-eluting and bare metal stents ten years later with optical coherence tomography analysis. 2016 , 212, 129-30		1
835	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. 2016 , 105, 575-84		15
834	MicroRNAs as circulating biomarkers in acute coronary syndromes: A review. 2016 , 81, 15-21		22
833	Nanomaterial coatings applied on stent surfaces. 2016 , 11, 1309-26		21
832	Intravascular NIRF Molecular Imaging Approaches in Coronary Artery Disease. 2016 , 9, 1		8
831	Imaging of acquired coronary diseases: From children to adults. 2016 , 97, 571-80		4
830	Fabrication and characteristics of dual functionalized vascular stent by spatio-temporal coating. 2016 , 38, 143-52		22
829	Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. 2016 , 37, 1923-8		67
828	Failure Mechanisms and Neoatherosclerosis Patterns in Very Late Drug-Eluting and Bare-Metal Stent Thrombosis. 2016 , 9,		39
827	Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. 2016 , 15, 124		12
826	Clinical value of drug-coated balloon angioplasty for de novo lesions in patients with coronary artery disease. 2016 , 222, 113-118		31
825	Aspirin, Plavix, and Other Antiplatelet Medications: What the Oral and Maxillofacial Surgeon Needs to Know. 2016 , 28, 497-506		8
824	Pathology of Endovascular Stents. 2016 , 5, 391-403		11
823	The History of Coronary Stenting. 2016 , 5, 271-280		9

822	Differential angioscopic findings of neointimal coverage among first-, second-, and next generation drug-eluting stents. 2016 , 223, 450-451	5
821	Pathologies coronariennes acquises de l'enfant à l'adulte. 2016 , 97, 204-214	
820	Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting - A feasibility and safety study. 2016 , 225, 262-267	16
819	The Systems Biocompatibility of Coronary Stenting. 2016 , 5, 295-306	11
818	Evaluación morfológica y funcional seriada del balón recubierto de paclitaxel para lesiones de novo. 2016 , 69, 1026-1032	9
817	Angioscopic comparison of arterial repair after second-generation drug-eluting stent implantation into vulnerable and stable coronary plaques. 2016 , 221, 855-8	5
816	One-year outcomes of a BioMimetic Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in all-comers coronary artery disease patients: The meriT-3 study. 2016 , 68, 599-603	10
815	Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease. 2016 , 9,	10
814	Ex vivo assessment of neointimal characteristics after drug-eluting stent implantation: Optical coherence tomography and histopathology validation study. 2016 , 221, 1043-7	24
813	Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy. 2016 , 5, 331-347	6
812	Preclinical evaluation of a novel polyphosphazene surface modified stent. 2016 , 222, 217-225	19
811	Incidence and Morphological Predictors of Intrastent Coronary Thrombus After Drug-Eluting Stent Implantation (from a Multicenter Registry). 2016 , 117, 369-75	6
810	Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Arteries Below the Knee: 12-Month Clinical and Imaging Outcomes. 2016 , 9, 1721-8	30
809	Materials technology in drug eluting balloons: Current and future perspectives. 2016 , 239, 92-106	24
808	Safety and efficacy profile of bioresorbable-poly(lactide-polymer)-sirolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome. 2016 , 88, E173-E182	3
807	The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease. 2016 , 13, 1489-99	7
806	Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry. 2016 , 9, 1652-63	25
805	Impact of Insulin Resistance on Clinical Outcomes After Implantation of Drug-Eluting Stents. 2016 , 80, 592-3	

804	Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound. 2016 , 80, 450-60	51
803	Angioscopic Assessment of Stent Stability and Neointimal Coverage After Implantation of 2nd-Generation Drug-Eluting Stents - Comparison With Bare-Metal Stents and 1st-Generation Drug-Eluting Stents. 2016 , 80, 1895-7	
802	Nitric Oxide Releasing Coronary Stent: A New Approach Using Layer-by-Layer Coating and Liposomal Encapsulation. 2016 , 12, 6012-6023	35
801	Rescuing Impaired Re-endothelialization of Drug-Eluting Stents Using the Hepatocyte Growth Factor. 2016 , 36, 273-282	4
800	Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolimus-Eluting Combo Stent: The EGO-Combo Study. 2016 , 9,	20
799	Drug deposition in coronary arteries with overlapping drug-eluting stents. 2016 , 238, 1-9	22
798	Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial. 2016 , 9,	78
797	Early endothelialization associated with a biolimus A9 bioresorbable polymer stent in a porcine coronary model. 2017 , 32, 1244-1252	5
796	Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry. 2017 , 10, 1222-1229	21
795	Phenotypic switching prevention and proliferation/migration inhibition of vascular smooth muscle cells by the ruthenium nitrosyl complex trans-[Ru(NO)Cl(cyclam)](PF). 2017 , 69, 1155-1165	7
794	In vitro and in vivo degradation of rapamycin-eluting Mg-Nd-Zn-Zr alloy stents in porcine coronary arteries. 2017 , 80, 1-6	33
793	Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up. 2017 , 90, 31-37	12
792	Chronic total occlusion is associated with a higher incidence of malapposition and uncovered stent struts: OCT findings at 6 months following DES implantation. 2017 , 89, 582-591	8
791	Stent-mediated gene and drug delivery for cardiovascular disease and cancer: A brief insight. 2017 , 19, e2954	4
790	Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. 2017 , 376, 2319-2328	279
789	Effects of different components of the extracellular matrix on endothelialization. 2016 , 64, 867-874	5
788	Role of residual acute stent malapposition in percutaneous coronary interventions. 2017 , 90, 566-575	30
787	The effect of REDV/TiO coating coronary stents on in-stent restenosis and re-endothelialization. 2017 , 31, 911-922	10

786	Efficacy of everolimus-eluting stent implantation in patients with small coronary arteries (≤ 2.5 mm): outcomes of 3-year clinical follow-up. 2017 , 32, 796-803	4
785	Bioreactivity of stent material: Activation of platelets, coagulation, leukocytes and endothelial cell dysfunction in vitro. 2017 , 28, 529-539	14
784	Quantitative intravascular biological fluorescence-ultrasound imaging of coronary and peripheral arteries in vivo. 2017 , 18, 1253-1261	20
783	Is vascular response to bare metal stents in peripheral arteries different from that in coronary arteries?. 2017 , 15, 73-75	1
782	Effects of Tacrolimus or Sirolimus on the adhesion of vascular wall cells: Controlled in-vitro comparison study. 2017 , 67, 309-318	5
781	Revisiting the role of durable polymers in cardiovascular devices. 2017 , 15, 835-846	8
780	Emerging Technologies in Flow Diverters and Stents for Cerebrovascular Diseases. 2017 , 17, 96	6
779	Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled Trials. 2017 , 10, 1881-1890	9
778	Polymer-free amphiphilic-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus. 2017 , 245, 69-76	14
777	Dynamic neointimal pattern after drug-eluting stent implantation defined by optical coherence tomography. 2017 , 28, 557-563	1
776	Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?. 2017 , 28, 77-89	7
775	Should We Still Have Bare-Metal Stents Available in Our Catheterization Laboratory?. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 607-619	15.1 25
774	Biological effect of microengineered grooved stents on strut healing: a randomised OCT-based comparative study in humans. 2017 , 4, e000521	3
773	The promise of leaving nothing behind - And how to manage its failure. 2017 , 18, 473-474	
772	Tomografía de coherencia óptica de pacientes con trombosis del stent. 2017 , 70, 1050-1058	8
771	Seguridad y eficacia de nuevos modelos de stents liberadores de sirolimus con polímero biodegradable en el modelo preclínico. 2017 , 70, 1059-1066	1
770	Optical coherence tomography follow-up 18 months after titanium-nitride-oxide-coated versus everolimus-eluting stent implantation in patients with acute coronary syndrome. 2017 , 58, 1077-1084	0
769	Bilayered Nanoparticles with Sequential Release of VEGF Gene and Paclitaxel for Restenosis Inhibition in Atherosclerosis. 2017 , 9, 27522-27532	16

768	Drug-eluting stents in clinical routine: a 1-year follow-up analysis based on German health insurance administrative data from 2008 to 2014. 2017 , 7, e017460	2
767	Coronary balloon angioplasty, stents, and scaffolds. 2017 , 390, 781-792	109
766	Drug-eluting Stents versus bioabsorbierbare Scaffolds. 2017 , 17, 52-56	
765	Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications. 2017 , 58, 72-82	31
764	Clinical implications of blood-material interaction and drug eluting stent polymers in review. 2017 , 14, 707-716	11
763	MYBPH inhibits vascular smooth muscle cell migration and attenuates neointimal hyperplasia in a rat carotid balloon-injury model. 2017 , 359, 154-162	8
762	Nanomaterials for treating cardiovascular diseases: A review. 2017 , 2, 185-198	57
761	Very Late Pathological Responses to Cobalt-Chromium Everolimus-Eluting, Stainless Steel Sirolimus-Eluting, and Cobalt-Chromium Bare Metal Stents in Humans. 2017 , 6,	20
760	Local Hemodynamic Forces After Stenting: Implications on Restenosis and Thrombosis. 2017 , 37, 2231-2242	51
759	A comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: A systematic review and meta-analysis. 2017 , 7, 14997	7
758	Recent advances to accelerate re-endothelialization for vascular stents. 2017 , 8, 2041731417731546	50
757	Safety and Efficacy of New Biodegradable Polymer-based Sirolimus-Eluting Stents in a Preclinical Model. 2017 , 70, 1059-1066	0
756	Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study. 2017 , 28, 126-134	8
755	Long-term preclinical evaluation of bioabsorbable polymer-coated drug-eluting stent in a porcine model. 2017 , 25, 730-738	5
754	Bioabsorbable Scaffolds: Can the Problems of Dissolution Be Overcome?. 2017 , 138, 63-65	
753	Targeting AGGF1 (angiogenic factor with G patch and FHA domains 1) for Blocking Neointimal Formation After Vascular Injury. 2017 , 6,	15
752	Plasma activated coating immobilizes apolipoprotein A-I to stainless steel surfaces in its bioactive form and enhances biocompatibility. 2017 , 13, 2141-2150	6
751	A chemical stability study of trimethylsilane plasma nanocoatings for coronary stents. 2017 , 28, 15-32	8

750	Neointimal response to everolimus-eluting bioresorbable scaffolds implanted at bifurcating coronary segments: insights from optical coherence tomography. 2017 , 33, 169-175	0
749	Collagen-binding nanoparticles for extracellular anti-inflammatory peptide delivery decrease platelet activation, promote endothelial migration, and suppress inflammation. 2017 , 49, 78-88	12
748	Bioresorbable stents: Current and upcoming bioresorbable technologies. 2017 , 228, 931-939	69
747	Glycocalyx-Inspired Nitric Oxide-Releasing Surfaces Reduce Platelet Adhesion and Activation on Titanium. 2017 , 3, 68-77	44
746	Is a bare-metal stent still useful for improving the outcome of percutaneous coronary intervention? From the FU-Registry. 2017 , 69, 652-659	4
745	Effects of different fluid shear stress patterns on the in vitro degradation of poly(lactide-co-glycolide) acid membranes. 2017 , 105, 23-30	10
744	Comparison of prognostic significance of mean platelet volume/platelet count with GRACE for long-term prognosis in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. 2017 , 228, 335-340	14
743	Comparison of vascular responses after different types of second-generation drug-eluting stents implantation detected by optical coherence tomography. 2017 , 33, 177-186	3
742	Assessment of a Drug-Eluting Balloon for the Treatment of de novo Coronary Lesions Guided by Optical Coherence Tomography: Study Protocol for a Randomized Controlled Trial. 2017 , 136, 252-257	2
741	Evaluation of promoting effect of a novel Cu-bearing metal stent on endothelialization process from in vitro and in vivo studies. 2017 , 7, 17394	8
740	Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1T03 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months). 2017 , 10,	25
739	The dawn of neurosurgery in pre-conquest Mesoamerican territories. 2017 , 33, 1621-1629	2
738	On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel. 2017 , 117, 1644-1650	4
737	Near-Infrared Spectroscopy (NIRS): A Novel Tool for Intravascular Coronary Imaging. 2017 ,	1
736	Formation and Transformation of Neointima after Drug-eluting Stent Implantation: Insights from Optical Coherence Tomographic Studies. 2017 , 47, 823-832	9
735	Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning. 2017 , 12, 6343-6355	15
734	Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial. 2017 , 32, 933-941	6
733	Animal models of vascular stenting. 2017 , 24, 31-36	2

732	Coronary Artery Aneurysms: A Review of the Epidemiology, Pathophysiology, Diagnosis, and Treatment. 2017 , 4, 24	112
731	Regional anaesthesia and antithrombotic agents: instructions for use. 2017 , 83, 321 - 335	3
730	7.28 Drug Eluting Stents ?. 2017 , 548-590	
729	Development of Novel Drug-Eluting Stents for Acute Myocardial Infarction. 2017 , 53, 187-195	3
728	Coronary stents and vascular response to implantation: literature review. 2017 , 8, 137-148	22
727	The role of coronary angiography in the BRS era. 2017 , 23, 48-54	1
726	Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents. 2017 , 13, 139-154	16
725	Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives. 2017 , 9, S903-S913	38
724	Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer. 2017 , 47, 898-906	2
723	Mechanical behavior of polymer-based . metallic-based bioresorbable stents. 2017 , 9, S923-S934	42
722	Effectiveness and safety of the ABSORB bioresorbable vascular scaffold for the treatment of coronary artery disease: systematic review and meta-analysis of randomized clinical trials. 2017 , 9, S887-S897	5
721	A multicenter post-marketing evaluation of the Elixir DESolve Novolimus-eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. 2018 , 92, 1021-1027	18
720	Incidence and predictors of target lesion failure in a multiethnic Asian population receiving the SYNERGY coronary stent: A prospective all-comers registry. 2018 , 92, 1097-1103	10
719	Value of intravascular ultrasound in guiding coronary interventions. 2018 , 35, 520-533	4
718	Predictive Value of Mean Platelet Volume/Platelet Count for Prognosis in Acute Myocardial Infarction. 2018 , 59, 286-292	14
717	The Potential Effects of New Stent Platforms for Coronary Revascularization in Patients With Diabetes. 2018 , 34, 653-664	11
716	Hypersensitivity to Cardiovascular Implants: Stents. 2018 , 263-271	0
715	Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1676-1695	15.1 73

714	The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss. 2018 , 11, e006034	7
713	Preparation and characterization of gelatin/sericin/carboxymethyl chitosan medical tissue glue. 2018 , 16, 97-106	8
712	Transradial experience with bioresorbable vascular scaffolds: A case-matched study with metallic drug-eluting stents. 2018 , 19, 700-704	
711	Early Strut Coverage in Patients Receiving Drug-Eluting Stents and its Implications for Dual Antiplatelet Therapy: A Randomized Trial. 2018 , 11, 1810-1819	23
710	The evolution of coronary stents. 2018 , 16, 219-228	24
709	A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. 2018 , 11, 260-272	20
708	PET Molecular Targets and Near-Infrared Fluorescence Imaging of Atherosclerosis. 2018 , 20, 11	9
707	Initial pathological responses of second-generation everolimus-eluting stents implantation in Japanese coronary arteries: Comparison with first-generation sirolimus-eluting stents. 2018 , 71, 452-457	5
706	Hydrophilic surface modification of coronary stent using an atmospheric pressure plasma jet for endothelialization. 2018 , 32, 1083-1089	4
705	Recent alternative approaches of vascular drug-eluting stents. 2018 , 48, 153-165	4
704	Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents. 2018 , 71, 435-443	20
703	A propensity score-matched comparison of biodegradable polymer vs second-generation durable polymer drug-eluting stents in a real-world population. 2018 , 36, e12319	2
702	Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial. 2018 , 198, 25-32	7
701	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. 2018 , 60, 478-490	32
700	Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial. 2018 , 5, e000624	1
699	Bioresorbable Scaffold Stability and Mechanical Properties. 2018 , 641-658	1
698	Layered double hydroxide/poly-dopamine composite coating with surface heparinization on Mg alloys: improved anticorrosion, endothelialization and hemocompatibility. 2018 , 6, 1846-1858	47
697	Downregulation of microRNA-17-5p improves cardiac function after myocardial infarction via attenuation of apoptosis in endothelial cells. 2018 , 293, 883-894	24

696	Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. 2018 , 258, 42-49	9
695	Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries. 2018 , 33, 55-61	7
694	Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study. 2018 , 19, 329-338	3
693	Cardiac Computed Tomography for Planning Revascularization Procedures. 2018 , 33, 35-54	14
692	Maintaining Beliefs in the Face of Negative News: The Moderating Role of Experience. 2018 , 64, 804-824	31
691	Bilirubin coating attenuates the inflammatory response to everolimus-coated stents. 2018 , 106, 1486-1495	9
690	Late Incomplete stent apposition is associated with late/very late stent thrombosis: A meta-analysis. 2018 , 91, 365-375	7
689	Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. 2018 , 91, 859-866	35
688	Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite [®] drug-eluting stent: The ANCHOR study. 2018 , 91, 435-443	5
687	Current clinical applications of coronary optical coherence tomography. 2018 , 33, 1-10	23
686	Impact of lesion complexity on long-term vascular response to cobalt-chromium everolimus-eluting stent: five-year follow-up optical coherence tomography study. 2018 , 33, 341-350	2
685	Mesoderm/mesenchyme homeobox gene 1 promotes vascular smooth muscle cell phenotypic modulation and vascular remodeling. 2018 , 251, 82-89	16
684	OCT guidance during stent implantation in primary PCI: A randomized multicenter study with nine months of optical coherence tomography follow-up. 2018 , 250, 98-103	11
683	Neointimal coverage of jailed side branches in coronary bifurcation lesions: an optical coherence tomography analysis. 2018 , 29, 114-118	9
682	Five-year follow-up of the endothelial progenitor cell capturing stent versus the paclitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis. 2018 , 91, 1212-1218	4
681	Clinical outcomes of patients with coronary artery aneurysm after the first generation drug-eluting stent implantation. 2018 , 92, E235-E245	11
680	Nanomatrix Coated Stent Enhances Endothelialization but Reduces Platelet, Smooth Muscle Cell, and Monocyte Adhesion under Physiologic Conditions. 2018 , 4, 107-115	12
679	Very early neointimal coverage of new biodegradable polymer drug-eluting stent compared with durable polymer everolimus-eluting stent evaluated by optical frequency domain imaging. 2018 , 34, 515-522	4

678	Drug-eluting balloon: design, technology and clinical aspects. 2018 , 13, 032001	12
677	Definite stent thrombosis after drug-eluting stent implantation in coronary bifurcation lesions: A meta-analysis of 3,107 patients from 14 randomized trials. 2018 , 92, 680-691	6
676	Modelling drug release from polymer-free coronary stents with microporous surfaces. 2018 , 544, 392-401	10
675	Impact of previous drug-eluting stent restenosis in non-left main coronary artery lesions on long-term outcomes after left main coronary artery stenting: an observation from the AOI-LMCA registry. 2018 , 33, 350-359	
674	Stent Thrombosis. 2018 , 44, 46-51	6
673	Controlled release of paclitaxel using a drug-eluting stent through modulation of the size of drug particles in vivo. 2018 , 106, 2275-2283	1
672	Angiographic and clinical performance of polymer-free biolimus-eluting stent in patients with ST-segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study. 2018 , 91, 851-858	8
671	Imaging assessment of bioresorbable vascular scaffolds. 2018 , 33, 11-22	7
670	Improved Antithrombotic Function of Oriented Endothelial Cell Monolayer on Microgrooves. 2018 , 4, 1976-1985	10
669	Non-polymer drug-eluting coronary stents. 2018 , 8, 903-917	14
668	Optical Frequency Domain Imaging of Very Late Stent Thrombosis Following Bare-Metal Stent Implantation for Acute Myocardial Infarction. 2018 , 59, 209-212	1
667	Ultrathin strut biodegradable-polymer sirolimus-eluting stents: being wary or going with the flow?. 2018 , 10, 688-692	6
666	The Newest Generation of Drug-eluting Stents and Beyond. 2018 , 13, 54-59	67
665	Evaluation of safety and efficacy of biodegradable polymer-based sirolimus-eluting stent in a porcine coronary artery model. 2018 , 32, 71-77	
664	Refractory Vascular Wall Healing after Paclitaxel-Coated Nitinol Stent Implantation in the Femoropopliteal Artery: A High-Resolution Angioscopic Assessment. 2018 , 11, 373-376	2
663	Biodegradable polymer versus second-generation durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis. 2018 , 1, e93	2
662	Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering. 2018 , 9, 1329	17
661	Refining Coronary Stent Platforms in the Modern DES Era: Thinning, Eluting, Inhibiting, and Absorbing. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3298-3300	15.1 1

660	The Spectrum of Clinical Presentations and Management Options for the Treatment of Degenerative Atherothrombotic Disease of Saphenous Vein Grafts. 2018 , 377-398	
659	Outcomes of the amphilius-eluting polymer-free stent for chronic total occlusion treatment: a multicentre experience. 2018 , 19, 564-570	0
658	Structure of von Willebrand factor A1 on polystyrene determined from experimental and calculated sum frequency generation spectra. 2018 , 13, 06E411	7
657	Polymer-free drug-eluting stents. 2018 , 57-74	
656	Endothelial Function: A Short Guide for the Interventional Cardiologist. 2018 , 19,	16
655	Impact of current smoking on 2-year clinical outcomes between durable-polymer-coated stents and biodegradable-polymer-coated stents in acute myocardial infarction after successful percutaneous coronary intervention: Data from the KAMIR. 2018 , 13, e0205046	4
654	Eosinophilic inflammation in spontaneous coronary artery dissection: A potential therapeutic target?. 2018 , 121, 91-94	13
653	Correlation between pre-procedural plaque morphology and patterns of in-stent neointimal hyperplasia at 1-year follow-up in patients treated with new-generation drug-eluting stents: An optical coherence tomography based analysis. 2018 , 31, 737-746	2
652	Developing standards and test protocols for testing the hemocompatibility of biomaterials. 2018 , 51-76	8
651	Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. 2018 , 392, 1235-1245	74
650	Are all drug-eluting stents created equal?. 2018 , 392, 1172-1174	0
649	Evaluation of drug release from paclitaxel + hirudin-eluting balloons and the resulting vascular reactivity in healthy pigs. 2018 , 16, 3425-3432	
648	Stent Thrombosis: Implications for New Stent Designs and Dual Antiplatelet Therapy Duration. 2018 , 225-247	1
647	Open-labeled randomized controlled trial to evaluate the 1-year clinical outcomes of polymer-free sirolimus-eluting coronary stents as compared with biodegradable polymer-based sirolimus-eluting coronary stents. 2018 , 70 Suppl 3, S323-S328	1
646	Promoting vascular healing using nanofibrous ticagrelor-eluting stents. 2018 , 13, 6039-6048	7
645	Procedural advantages of a novel coronary stent design with ultra-thin struts and bioabsorbable abluminal polymer coating in an all-comers registry. 2018 , 14, 240-246	1
644	Comparison of endothelial cell attachment on surfaces of biodegradable polymer-coated magnesium alloys in a microfluidic environment. 2018 , 13, e0205611	3
643	Role of Allergic Inflammatory Cells in Coronary Artery Disease. 2018 , 138, 1736-1748	30

642	Early-Phase Vascular Healing of Bioabsorbable vs. Durable Polymer-Coated Everolimus-Eluting Stents in Patients With ST-Elevation Myocardial Infarction - 2-Week and 4-Month Analyses With Optical Coherence Tomography. 2018 , 82, 2594-2601	7
641	Latest STEMI treatment: a focus on current and upcoming devices. 2018 , 15, 807-817	8
640	Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation. 2018 , 16, 735-748	7
639	Stent Thrombosis. 2018 , 217-224	
638	Cardiovascular stents: overview, evolution, and next generation. 2018 , 7, 175-205	74
637	Interventional cardiology: from balloons to stents and back?. 2018 , 27, 928-934	1
636	Effectiveness and Safety of Biolimus A9Eluting stEnt in Patients with AcUTE Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study). 2018 , 59, 72-79	0
635	Role of oxidative stress in the process of vascular remodeling following coronary revascularization. 2018 , 268, 27-33	20
634	In vitro and in vivo evaluation of a novel polymer-free everolimus-eluting stent by nitrogen-doped titanium dioxide film deposition. 2018 , 91, 615-623	6
633	Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. 2018 , 39, 2448-2456	28
632	Application of underdamped Langevin dynamics simulations for the study of diffusion from a drug-eluting stent. 2018 , 507, 231-239	5
631	Polymer-free versus permanent polymer-coated drug eluting stents for the treatment of coronary artery disease: A meta-analysis of randomized trials. 2018 , 31, 608-616	3
630	Lower on-treatment platelet reactivity during everolimus-eluting stent implantation contributes to the resolution of post-procedural intra-stent thrombus: serial OCT observation in the PRASFIT-Elective study. 2018 , 33, 1423-1433	
629	Impact of out-stent plaque characteristics on vascular response after second generation drug-eluting stent implantation: iMAP-intravascular ultrasound and angioscopic study. 2018 , 19, 83-87	
628	Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. 2018 , 39, 2460-2468	35
627	High-Density Lipoproteins and Apolipoprotein A-I Improve Stent Biocompatibility. 2018 , 38, 1691-1701	11
626	Short term clinical outcomes of Everolimus-eluting stents in patients with stable angina pectoris. 2018 , 34, 235-239	2
625	Percutaneous coronary intervention: balloons, stents and scaffolds. 2018 , 107, 55-63	7

624	Non-Inferiority of Resolute Integrity Drug-Eluting Stent to Benchmark Xience Drug-Eluting Stent. 2018 , 82, 2284-2291	1
623	Rhombic-Shaped Channel Stent with Enhanced Drug Capacity and Fatigue Life. 2017 , 9,	4
622	Randomized Comparison of Strut Coverage between Ticagrelor and Clopidogrel in Acute Myocardial Infarction at 3-Month Optical Coherence Tomography. 2018 , 59, 624-632	5
621	Polymer coatings for biocompatibility and reduced nonspecific adsorption. 2018 , 155-198	3
620	Bioabsorbable Drug-Eluting Stent Versus Bare Metal Stent in Iliac Artery Evaluated by Optical Coherence Tomography: An In Vivo Study in Porcine. 2018 , 52, 512-519	
619	First-in-Man Trial of SiO Inert-Coated Bare Metal Stent System in Native Coronary Stenosis - The AXETIS FIM Trial. 2018 , 82, 477-485	2
618	Treatment of Coronary Bifurcation Lesions. 2018 , 745-776	1
617	Dual-Layer Coated Drug-Eluting Stents with Improved Degradation Morphology and Controlled Drug Release. 2018 , 26, 641-649	2
616	Fundamentals of bioresorbable stents. 2018 , 75-97	2
615	Overview of cardiovascular stent designs. 2018 , 3-26	5
614	The comparison of early healing 1-month after PCI among CoCr-everolimus-eluting stent (EES), biodegradable polymer (BP)-EES and BP-sirolimus-eluting stent: Insights from OFDI and coronary angiography. 2018 , 20, 40-45	3
613	High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial. 2018 , 32, 567-576	5
612	Everolimus-eluting bioabsorbable vascular scaffolds (BVS) versus everolimus-eluting metallic stents (EES) at 3 years: Systematic review and meta-analysis. 2018 , 1, e10008	
611	Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials. 2018 , 18, 170	11
610	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. 2018 , 20, F1-F74	17
609	Randomized Prospective Comparison of Everolimus-Eluting vs. Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention - 3-Year Clinical Outcomes of the EXCELLENT Randomized Trial. 2018 , 82, 1566-1574	4
608	Endothelial cell activation is attenuated by everolimus via transcriptional and post-transcriptional regulatory mechanisms after drug-eluting coronary stenting. 2018 , 13, e0197890	13
607	Postpercutaneous Interventions: Endothelial Repair. 2018 , 591-596	

606 Stents and the Endothelium. **2018**, 597-608

605 Major coronary evaginations following implantation of bioresorbable vascular scaffolds - Clinical and OCT characteristics. **2019**, 20, 485-491

604 A meta-analysis of randomized controlled trials to compare long-term clinical outcomes of bioabsorbable polymer and durable polymer drug-eluting stents. **2019**, 5, 105-113 9

603 Design Principles in Biomaterials and Scaffolds. **2019**, 505-522 6

602 Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?. **2019**, 20, 228-234 2

601 Computational modelling of magnesium stent mechanical performance in a remodelling artery: Effects of multiple remodelling stimuli. **2019**, 35, e3247 5

600 Nitric oxide releasing lipid bilayer tethered on titanium and its effects on vascular cells. **2019**, 80, 811-819 9

599 Clinical outcomes and complications of treatment with supraflex stent in patients with coronary artery disease: One-year follow-up. **2019**, 29, 8231 3

598 Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis. **2019**, 97, 1219-1229 6

597 Magmaris®resorbable magnesium scaffold: state-of-art review. **2019**, 15, 267-279 13

596 Single arm retrospective study of bioresorbable vascular scaffolds to treat patients with severe infrapopliteal arterial disease. **2019**, 94, 1028-1033 8

595 Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. **2019**, 8, e013607 11

594 Real-World Use Of Ultrathin-Strut Biodegradable Polymer-Coated Sirolimus-Eluting Stents In Patients With Coronary Artery Disease: 6-Month Clinical Outcomes. **2019**, 15, 439-447 1

593 Elevated level of miR-17 along with decreased levels of TIMP-1 and IL-6 in plasma associated with the risk of in-stent restenosis. **2019**, 13, 423-429 3

592 In Vitro Thrombogenicity Testing of Biomaterials. **2019**, 8, e1900527 25

591 Progress in Drug-Eluting Stent Technology: Have We Come to the End of the Road?. **2019**, 12, 1661-1664 0

590 Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents. **2019**, 12, e008152 30

589 Endothelialization of cardiovascular devices. **2019**, 99, 53-71 33

588	Magnesium Based Biodegradable Metallic Implant Materials: Corrosion Control and Evaluation of Surface Coatings. 2019 , 9, 3-27	1
587	Migration versus proliferation as contributor to in vitro wound healing of vascular endothelial and smooth muscle cells. 2019 , 376, 58-66	7
586	Design and rationale of a randomized noninferiority trial to evaluate the SurVeil drug-coated balloon in subjects with stenotic lesions of the femoropopliteal artery - the TRANSCEND study. 2019 , 209, 88-96	2
585	Clinical Outcomes One Year and Beyond After Combination Sirolimus-Eluting Endothelial Progenitor Cell Capture Stenting During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. 2019 , 20, 739-743	
584	Biodegradable vs. permanent polymer drug-eluting stents: the need for a new nomenclature to classify drug-eluting stent technology. 2019 , 40, 2616-2619	3
583	Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall Healing after IMplantation of drug Eluting peripheral stent in Japanese patients with the Infra inguinal lesion: serial angioscopic observation). 2019 , 35, 1777-1784	3
582	Hemocompatibility of biodegradable Zn-0.8 wt% (Cu, Mn, Li) alloys. 2019 , 104, 109896	29
581	A prospective, multicenter, randomized OCT study of early neointimal condition at first and second months after BuMA Supreme stent versus XIENCE stent implantation in high-bleeding-risk coronary artery disease patients: study protocol for a randomized controlled trial. 2019 , 20, 335	
580	Future Perspectives of PLGA Nanospheres for Advanced DDSs and Continuous Preparation Systems for Spherical Crystallizers. 2019 , 107-118	
579	Risk Factors and Long-Term Clinical Outcomes of Second-Generation Drug-Eluting Stent Thrombosis. 2019 , 12, e007822	17
578	Spherical Crystallization as a New Platform for Particle Design Engineering. 2019 ,	
577	2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. 2019 , 12, 1679-1687	6
576	Novel Stent Technologies in Search of a TARGET: Balancing Needs for Patient and Market?. 2019 , 12, 1688-1690	
575	Real World Experience of a Biodegradable Polymer Sirolimus-Eluting Stent (Yukon Choice PC Elite) in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: A Multicentric Observational Study (The Elite India Study). 2019 , 7, 1103-1109	2
574	Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial. 2019 , 4, 659-669	32
573	Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study. 2019 , 6, e000941	3
572	Comparative Effectiveness and Safety of Polymer-Free Biolimus-Eluting Stent and Durable Polymer Everolimus-Eluting Stent in All-Corner Patients Who Underwent Percutaneous Coronary Interventions. 2019 , 124, 195-204	6
571	XLIMus drug eluting stent: A randomized controlled Trial to assess endothelialization. The XLIMIT trial. 2019 , 23, 100363	1

570	Delivery of Cell-Specific Aptamers to the Arterial Wall with an Occlusion Perfusion Catheter. 2019 , 16, 360-366	4
569	Hyaluronic Acid Nanoparticle Composite Films Confer Favorable Time-Dependent Biofunctions for Vascular Wound Healing. 2019 , 5, 1833-1848	9
568	Augmented re-endothelialization and anti-inflammation of coronary drug-eluting stent by abluminal coating with magnesium hydroxide. 2019 , 7, 2499-2510	16
567	Long-term prevention of capsular opacification after lens-refilling surgery in a rabbit model. 2019 , 97, e860-e870	4
566	Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries. 2019 , 13, 1753944719826335	6
565	The "Oculo-Appositional Reflex": Should Optical Coherence Tomography-Detected Stent Malapposition Be Corrected?. 2019 , 8, e012262	3
564	Newer-generation Metallic Stents: Design, Performance Characteristics, and Outcomes. 2019 , 8, 95-109	1
563	Feasibility of Implanting 50-60 mm-Tapered Drug Eluting Stents in Chronic Total Occlusions. 2019 , 20, 1117-1122	1
562	The negative affectivity dimension of Type D personality is associated with in-stent neoatherosclerosis in coronary patients with percutaneous coronary intervention: An optical coherence tomography study. 2019 , 120, 20-28	8
561	Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis. 2019 , 108, 1059-1068	8
560	Five-year outcomes after first- and second-generation drug-eluting stent implantation in all patients undergoing percutaneous coronary intervention. 2019 , 74, 169-174	4
559	Assessment of strut coverage of everolimus-eluting platinum chromium stent 2 weeks after implantation by optical coherence tomography. 2019 , 34, 1258-1265	3
558	Preclinical In-Vivo Evaluation and Screening of Zinc Based Degradable Metals for Endovascular Stents. 2019 , 71, 1436-1446	11
557	Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months' results from the S-FLEX UK registry. 2019 , 9, e026578	4
556	Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study. 2019 , 2019, 3146848	4
555	Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials. 2019 , 33, 557-566	6
554	The Current Literature on Bioabsorbable Stents: a Review. 2019 , 21, 54	19
553	Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents: An updated meta-analysis. 2019 , 98, e15217	3

552	Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond?. 2019 , 8,	10
551	A comparison of the impact of current smoking on 2-year major clinical outcomes of first- and second-generation drug-eluting stents in acute myocardial infarction: Data from the Korea Acute Myocardial Infarction Registry. 2019 , 98, e14797	4
550	Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR. 2019 , 34, 237-250	5
549	A serial 3- and 9-year optical coherence tomography assessment of vascular healing response to sirolimus- and paclitaxel-eluting stents. 2019 , 35, 9-21	0
548	Polymer-free versus durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis. 2019 , 38, 13-21	9
547	Polysaccharide Based Scaffolds for Soft Tissue Engineering Applications. 2018 , 11,	206
546	Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Final five-year results of the patient-level pooled analysis from the TARGET I and TARGET II trials. 2019 , 93, 818-824	3
545	Comparison of the vessel healing process after everolimus-eluting stent and bare metal stent implantations in patients with ST-elevation myocardial infarction. 2019 , 34, 572-582	1
544	The effects of stenting on coronary endothelium from a molecular biological view: Time for improvement?. 2019 , 23, 39-46	36
543	One-year clinical outcomes of patients treated with polymer-free amphilius-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis. 2019 , 94, 61-69	5
542	Method for Combined Observation of Serial Sections of Stented Arteries Embedded in Resin by Light Microscopy and Transmission Electron Microscopy. 2019 , 47, 401-407	2
541	Non-coding RNAs in vascular remodeling and restenosis. 2019 , 114, 49-63	27
540	Update on pathological platelet activation in coronary thrombosis. 2019 , 234, 2121-2133	17
539	Fully bioresorbable vascular scaffolds: lessons learned and future directions. 2019 , 16, 286-304	78
538	Predictors of stent thrombosis and their implications for clinical practice. 2019 , 16, 243-256	62
537	Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilius-Eluting Stent. 2019 , 139, 67-77	24
536	Bioresorbable polymer-coated thin strut sirolimus-eluting stent vs durable polymer-coated everolimus-eluting stent in daily clinical practice: Propensity matched one-year results from interventional cardiology network registry. 2019 , 93, E362-E368	3
535	Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. 2019 , 5, 105-116	25

534	Hybrid-stenting with metallic and bioresorbable drug-eluting stents 2-year clinical outcomes in KUM ABSORB registry. 2019 , 93, 71-78	1
533	Optical Coherence Tomography Tissue Coverage and Characterization with Grey-Scale Signal Intensity Analysis After Bifurcation Stenting with a New Generation Bioabsorbable Polymer Drug-Eluting Stent. 2020 , 21, 277-285	
532	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy. 2020 , 95, 89-96	3
531	Functionalization with a VEGFR2-binding antibody fragment leads to enhanced endothelialization of a cardiovascular stent in vitro and in vivo. 2020 , 108, 213-224	4
530	Impact of strut thickness and number of crown and connectors on clinical outcomes on patients treated with second-generation drug eluting stent. 2020 , 96, 1417-1422	8
529	Different vascular healing process between bioabsorbable polymer-coated everolimus-eluting stents versus bioresorbable vascular scaffolds via optical coherence tomography and coronary angiography (the ENHANCE study: ENdothelial Healing Assessment with Novel Coronary Technology). 2020 , 95, 142-153	4
528	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. 2020 , 300, 93-98	3
527	Cardiovascular OCT Imaging. 2020 ,	2
526	Assessment of Vascular Patency and Inflammation with Intravascular Optical Coherence Tomography in Patients with Superficial Femoral Artery Disease Treated with Zilver PTX Stents. 2020 , 21, 101-107	0
525	Development of a Bioactive Polymeric Drug Eluting Coronary Stent Coating Using Electrospraying. 2020 , 48, 271-281	12
524	Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. 2020 , 95, 522-529	3
523	The effect of the debulking by excimer laser coronary angioplasty on long-term outcome compared with drug-coating balloon: insights from optical frequency domain imaging analysis. 2020 , 35, 403-412	5
522	Drug-eluting coronary stents: insights from preclinical and pathology studies. 2020 , 17, 37-51	72
521	Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II-III and BIOFLOW II trials. 2020 , 300, 60-65	8
520	Polymer-Free vs. Polymer-Coated Drug-Eluting Stents for the Treatment of Coronary Artery Disease: A Meta-Analysis of 16 Randomized Trials. 2020 , 21, 745-753	7
519	Vulnerable struts with CRE8, Biomatrix and Xience stents assessed with OCT and their correlation with clinical variables at 6-month follow-up: the CREBX-OCT study. 2020 , 36, 217-230	3
518	The REMEDEE trial: 5-Year results on a novel combined sirolimus-eluting and endothelial progenitor cells capturing stent. 2020 , 95, 1076-1084	3
517	Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention. 2020 , 34, e23013	16

516	Spatiotemporal dual-delivery of therapeutic gas and growth factor for prevention of vascular stent thrombosis and restenosis. 2020 , 19, 100546	8
515	Cut-off value of strut-vessel distance for the resolution of acute incomplete stent apposition in the early phase using serial optical coherence tomography after cobalt-chromium everolimus-eluting stent implantation. 2020 , 75, 641-647	2
514	Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial. 2020 , 96, 1399-1406	11
513	Anti-restenotic and anti-thrombotic effect of polymer-free N-TiO ₂ film-based tacrolimus-eluting stent in a porcine model. 2020 , 22, 100777	4
512	Medium-Term Bioresorbable Scaffold Outcomes Utilising Data From an Australian Clinical Quality Registry. 2020 , 29, 1440-1448	
511	Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model. 2020 , 31, 230-236	
510	Antiplatelet drugs: a review of pharmacology and the perioperative management of patients in oral and maxillofacial surgery. 2020 , 102, 9-13	6
509	Design of biodegradable, implantable devices towards clinical translation. 2020 , 5, 61-81	188
508	Clinical outcomes of complex lesions treated with an abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent. 2020 , 96, 1023-1028	2
507	Adverse events beyond 1 year after percutaneous coronary intervention. 2020 , 35, 687-696	2
506	Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients: LEADERS-FREE and ONYX ONE. 2020 , 9, 441-449	
505	Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial. 2020 , 31, 485-492	6
504	The role of extracellular vesicles in neointima formation post vascular injury. 2020 , 76, 109783	3
503	Stent Thrombosis After Percutaneous Coronary Intervention: From Bare-Metal to the Last Generation of Drug-Eluting Stents. 2020 , 38, 639-647	7
502	The role of intravascular ultrasound in percutaneous coronary intervention of complex coronary lesions. 2020 , 10, 1371-1388	2
501	Development and Biodegradation of Biomimetic Zwitterionic Phosphorylcholine Chitosan Coating on Zn1Mg Alloy. 2020 , 12, 54445-54458	5
500	Health Care Monitoring and Treatment for Coronary Artery Diseases: Challenges and Issues. 2020 , 20,	3
499	Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants. 2020 , 258, 120291	24

498	The co-deposition coating of collagen IV and laminin on hyaluronic acid pattern for better biocompatibility on cardiovascular biomaterials. 2020 , 196, 111307	4
497	Design, Characterization, and 3D Printing of Cardiovascular Stents with Zero Poisson's Ratio in Longitudinal Deformation. 2020 ,	6
496	Vitamin D attenuates HMGB1-mediated neointimal hyperplasia after percutaneous coronary intervention in swine. 2020 , 474, 219-228	2
495	Perspectives on smart stents with sensors: From conventional permanent to novel bioabsorbable smart stent technologies. 2020 , 3, e10116	5
494	Hybrid intervention approach to coronary artery and valvular heart disease. 2020 , 33, 520-523	0
493	Analysis of vascular inflammation against bioresorbable Zn-Ag based alloys. 2020 , 3, 6779-6789	3
492	Comparison Between Optical Frequency Domain Imaging and Intravascular Ultrasound for Percutaneous Coronary Intervention Guidance in Biolimus A9-Eluting Stent Implantation: A Randomized MISTIC-1 Non-Inferiority Trial. 2020 , 13, e009314	3
491	ImpaCt of an Optimal Implantation Strategy on Absorb Long-Term Outcomes: The CIAO Registry. 2021 , 30, 1-8	0
490	Nanospheres encapsulated everolimus delivery into arterial wall-the tissue pharmacokinetics and vascular response experimental study. 2021 , 98, 914-922	0
489	In-Stent Restenosis in the United States: Time to Enrich its Treatment Armamentarium. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1532-1535	15.1 2
488	The state-of-the-art coronary stent with crystallized sirolimus: the MiStent technology and its clinical program. 2021 , 17, 593-607	0
487	The role of intracoronary imaging in translational research. 2020 , 10, 1480-1507	1
486	Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice. 2021 , 74, 584-590	
485	A Smart Stent for Monitoring Eventual Restenosis: Computational Fluid Dynamic and Finite Element Analysis in Descending Thoracic Aorta. 2020 , 8, 81	4
484	Target Lesion Failure With Current Drug-Eluting Stents: Evidence From a Comprehensive Network Meta-Analysis. 2020 , 13, 2868-2878	9
483	Assessment of a pro-healing stent in an animal model of early neoatherosclerosis. 2020 , 10, 8227	1
482	Are we curing one evil with another? A translational approach targeting the role of neoatherosclerosis in late stent failure. 2020 , 22, C15-C25	
481	Combinatorial therapy of sirolimus and heparin by nanocarrier inhibits restenosis after balloon angioplasty. 2020 , 15, 1205-1220	2

480	Targeting and deep-penetrating delivery strategy for stented coronary artery by magnetic guidance and ultrasound stimulation. 2020 , 67, 105188	9
479	Drug-eluting bioresorbable scaffolds in cardiovascular disease, peripheral artery and gastrointestinal fields: a clinical update. 2020 , 17, 931-945	2
478	Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. 2020 , 13, 1391-1402	61
477	Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial. 2020 , 13, e008737	7
476	Clinical Prognosis Associated With the Use of Overlapping Stents With Homogenous Versus Heterogeneous Pharmacological Characteristics for the Treatment of Diffuse Coronary Artery Disease. 2020 , 21, 1355-1359	
475	Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE Trial. 2020 , 9,	0
474	Vascular autophagy in health and disease. 2020 , 115, 41	45
473	Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. 2020 , 2020, 3872704	5
472	Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. 2020 , 312, 42-47	3
471	Long-Term Efficacy of Biodegradable Metal-Polymer Composite Stents After the First and the Second Implantations into Porcine Coronary Arteries. 2020 , 12, 15703-15715	30
470	The Cre8 amphiphilic-eluting stent for the treatment of coronary artery disease: safety and efficacy profile. 2020 , 17, 267-275	4
469	Nitric Oxide-Producing Cardiovascular Stent Coatings for Prevention of Thrombosis and Restenosis. 2020 , 8, 578	8
468	Clinical and surgical aspects of medical materials biocompatibility. 2020 , 219-250	1
467	The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. 2020 , 28, 208-212	2
466	Iron Oxide Nanoparticles as Imaging and Therapeutic Agents for Atherosclerosis. 2020 , 46, 553-562	9
465	Histopathologic and physiologic effect of bifurcation stenting: current status and future prospects. 2020 , 17, 189-200	4
464	Coronary arteritis: a case series. 2020 , 4, 1-6	2
463	A case report of Kounis syndrome presenting with a rash, very late stent thrombosis and coronary evaginations. 2020 , 4, 1-5	1

462	Pathology and Multimodality Imaging of Acute and Chronic Femoral Stenting in Humans. 2020 , 13, 418-427	1
461	The Orsiro Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stent: A Review of Current Evidence. 2020 , 21, 540-548	5
460	Three-year follow up of biodegradable polymer cobalt-chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: Pooled analysis of CREDIT II and CREDIT III trials. 2020 , 95 Suppl 1, 565-571	2
459	Mechanical and physio-biological properties of peptide-coated stent for re-endothelialization. 2020 , 24, 4	2
458	Microneedle drug eluting balloon for enhanced drug delivery to vascular tissue. 2020 , 321, 174-183	18
457	Microstructure and properties of biodegradable MgZn-Nd alloy micro-tubes prepared by an improved method. 2020 , 835, 155369	2
456	Effect of neointimal tissue morphology on vascular response to balloon angioplasty in lesions with in-stent restenosis after drug-eluting stent deployment: an optical coherence tomography analysis. 2020 , 35, 1193-1200	4
455	Inpatient Randomization to Study Strut Coverage in Polymer-Free Versus Biodegradable-Polymer Sirolimus-Eluting Stent Implantations. 2020 , 13, 899-900	1
454	Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy. 2020 , 17, 383-390	3
453	Supporting evidence from optical coherence tomography for shortening dual antiplatelet therapy after drug-eluting stents implantation. 2020 , 18, 261-267	2
452	Randomised comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch: the Nordic-Baltic Bifurcation Study IV. 2020 , 7, e000947	5
451	Nanosized copper(ii) oxide/silica for catalytic generation of nitric oxide from S-nitrosothiols. 2020 , 8, 4267-4277	7
450	Comparison of neointimal coverage between ultrathin biodegradable polymer-coated sirolimus-eluting stents and durable polymer-coated everolimus-eluting stents: 6 months optical coherence tomography follow-up from the TAXCO study. 2021 , 97, 423-430	4
449	Five-year follow-up of patients who underwent everolimus-eluting bioresorbable scaffold implantation. 2021 , 97, 56-62	
448	Short- and mid-term influence of drug-coated stent implantation on structural and functional vascular healing response: An optical coherence tomography and acetylcholine testing study. 2021 , 97, E186-E193	0
447	Cardiovascular applications of magnetic particles. 2021 , 518, 167428	5
446	Self-assembled nanosheets on NiTi alloy facilitate endothelial cell function and manipulate macrophage immune response. 2021 , 78, 110-120	3
445	Difference of vascular healing between bioabsorbable-polymer and durable-polymer new generation drug-eluting stents: an optical coherence tomographic analysis. 2021 , 37, 1131-1141	3

- 444 Fluid targeted delivery of functionalized magneto-responsive nanocomposite particles to a ferromagnetic stent. **2021**, 519, 167489 3
- 443 Two-year follow-up of bioresorbable vascular scaffolds in severe infra-popliteal arterial disease. **2021**, 29, 355-362 2
- 442 The role of nanomaterials and nanostructured surfaces for improvement of biomaterial peculiarities in vascular surgery: a review. 1-10
- 441 Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges. **2021**, 19, 801-816 3
- 440 Diagnostic accuracy of optical coherence tomography for the identification of in-stent fibroatheroma following stent implantation: an ex vivo histological validation study. **2021**, 37, 1503-1509
- 439 An ultralow dose paclitaxel coated drug balloon with an outer protective sheath for peripheral arterial disease treatment. **2021**, 9, 2428-2435 1
- 438 Structure-function relation in the coronary artery tree: theory and applications in interventional cardiology. **2021**, 545-554
- 437 Coronary drug-eluting stents: Still room for improvement?. **2021**, 107-127
- 436 Drug-eluting stent thrombosis: current and future perspectives. **2021**, 36, 158-168 10
- 435 Local blood flow parameters and atherosclerosis in coronary artery bifurcations. **2021**, 193-202
- 434 A systematic review and meta-analysis of bioresorbable vascular scaffolds for below-the-knee arterial disease. **2021**, 40, 42-51 2
- 433 Procedural optimization of drug-coated balloons in the treatment of coronary artery disease. **2021**, 98, E43-E52 3
- 432 Inflammation as a determinant of healing response after coronary stent implantation. **2021**, 37, 791-801 2
- 431 Emergent biomechanical factors predicting vulnerable coronary atherosclerotic plaque rupture. **2021**, 361-380 1
- 430 Citric acid functionalized nitinol stent surface promotes endothelial cell healing. **2021**, 109, 1549-1559 1
- 429 Vascular endothelial and smooth muscle cell galvanotactic response and differential migratory behavior. **2021**, 399, 112447 0
- 428 Influence of dual antiplatelet therapy duration on neointimal condition after second-generation drug-eluting stent implantation. **2021**, 1 0
- 427 The incidence, natural history, and predictive factors for tissue protrusion after drug-eluting stent implantation. **2021**, 98, E62-E68

- 426 Second generation drug-eluting stents: a focus on safety and efficacy of current devices. **2021**, 19, 107-127 2
- 425 The Biolimus A9-coated BioFreedom stent: from clinical efficacy to real-world evidence. **2021**, 17, 239-255 1
- 424 Coronary revascularization in patients with stable coronary disease and diabetes mellitus. **2021**, 18, 14791641211002469
- 423 Thirty-day and 5-year results of percutaneous coronary intervention for in-stent restenotic chronic total occlusion lesions: Data from 2,659 consecutive patients. **2021**, 97 Suppl 2, 1016-1024
- 422 Polymer blends and polymer composites for cardiovascular implants. **2021**, 146, 110249 18
- 421 Pathological findings after third- and second-generation everolimus-eluting stent implantations in coronary arteries from autopsy cases and an atherosclerotic porcine model. **2021**, 11, 6281
- 420 Outcomes with drug-coated balloons vs. drug-eluting stents in small-vessel coronary artery disease. **2021**, 35, 76-76 3
- 419 Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. **2021**, 10, 0
- 418 Biodegradable polymer-coated versus durable polymer-coated sirolimus-eluting stents: the final 5-year outcomes of the I-LOVE-IT 2 trial. **2021**, 16, e1518-e1526 4
- 417 Anti-Thrombogenicity Study of a Covalently-Attached Monolayer on Stent-Grade Stainless Steel. **2021**, 14, 0
- 416 Biosafety and efficacy evaluation of a biodegradable magnesium-based drug-eluting stent in porcine coronary artery. **2021**, 11, 7330 2
- 415 Angiographic and clinical outcomes of patients implanted with ultrathin, biodegradable polymer sirolimus-eluting stents versus durable polymer drug-eluting stents for percutaneous coronary intervention: an updated meta-analysis based on randomized controlled trials. **2021**, 62, 175-187
- 414 Vascular Responses to First-Generation Sirolimus-Eluting Stents and Bare-Metal Stents Beyond 10 Years. **2021**, 3, 201-210
- 413 Contemporary Management of Isolated Ostial Side Branch Disease: An Evidence-based Approach to Medina 001 Bifurcations. **2021**, 16, e06 1
- 412 Outcomes of patients treated with a biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stents after rotational atherectomy. **2021**, 110, 1574-1585 0
- 411 A Microneedles Balloon Catheter for Endovascular Drug Delivery. **2021**, 6, 2100037 1
- 410 Five-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer. **2021**, 100, e25765
- 409 Angioscopic findings of a first-generation drug-eluting stent occurring very late stent thrombosis 13 years after implantation. **2021**, 1 0

408	Critical evaluation of stents in coronary angioplasty: a systematic review. 2021 , 20, 46	1
407	Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2413-2431	15.1 4
406	Evaluation of a Targeted Drug-Eluting Intravascular Nanotherapy to Prevent Neointimal Hyperplasia in an Atherosclerotic Rat Model. 2021 , 1, 2000093	
405	Do we really understand how drug eluted from stents modulates arterial healing?. 2021 , 601, 120575	3
404	Prognostic Impact of Calcified Plaque Morphology After Drug Eluting Stent Implantation - An Optical Coherence Tomography Study. 2021 , 85, 2019-2028	5
403	Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Everolimus-Eluting Stents (ISAR-TEST 5) trial. 2021 , 110, 1501-1508	1
402	Primary Percutaneous Coronary Intervention in Patients With Type 2 Diabetes With Late/Very Late Stent Thrombosis and Lesions: A Single-Center Observational Cohort Study of Clinical Outcomes and Influencing Factors. 2021 , 8, 653467	1
401	Intracoronary optical coherence tomography: state of the art and future directions. 2021 , 17, e105-e123	14
400	Thin- versus thick-strut polymer-free biolimus-eluting stents: the BioFreedom QCA randomised trial. 2021 , 17, 233-239	1
399	Late neointimal volume reduction is observed following biodegradable polymer-based drug eluting stent in porcine model. 2021 , 34, 100792	
398	Continuous observation of twinning and dynamic recrystallization in ZM21 magnesium alloy tubes during locally heated dieless drawing. 2021 ,	1
397	Highly Efficient Photocatalytic Anti-Bacterial Ag Doped Titanium Dioxide Nanofilms with Combination of Reactive Oxygen Species and Ag Ions Releasing for Application of Vascular Implants. 2021 , 8, 2100892	0
396	Target Lesion Lipid Content Detected by Near-Infrared Spectroscopy After Stenting and the Risk of Subsequent Target Lesion Failure. 2021 , 41, 2181-2189	1
395	Outcomes of the novolimus-eluting bioresorbable vascular scaffold in real world clinical practice. 2021 , 69, 261-268	2
394	The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome. 2021 , 10,	3
393	Aneurysmal degeneration of fluoropolymer-coated paclitaxel-eluting stent in the superficial femoral artery: a rising concern. 2021 , 4, 56	1
392	Roles of MicroRNAs in Peripheral Artery In-Stent Restenosis after Endovascular Treatment. 2021 , 2021, 9935671	0
391	Evoluci3n de pacientes tratados con armazones coronarios bioabsorbibles liberadores de everolimus tras su disoluci3n completa. 2021 , 74, 584-590	2

390	Preclinical Evaluation of the Temporary Drug-Coated Spur Stent System in Porcine Peripheral Arteries. 2021 , 28, 938-949	0
389	Review on the numerical investigations of mass transfer from drug eluting stent. 2021 , 41, 1057-1070	1
388	Some Perspectives on Hypersensitivity to Coronary Stents. 2021 , 14, 4327-4336	2
387	Comparison of 6-month vascular healing response after bioresorbable polymer versus durable polymer drug-eluting stent implantation in patients with acute coronary syndromes: A randomized serial optical coherence tomography study. 2021 , 98, E677-E686	1
386	Coronary Stenting: Reflections on a 35-Year Journey. 2021 ,	0
385	Assessment Framework for Recognizing Clinical Deterioration in Patients With ACS Undergoing PCI. 2021 , 41, 18-28	
384	Stent strut streamlining and thickness reduction promote endothelialization. 2021 , 18, 20210023	2
383	Endothelial Barrier Function After Stenting: Science Fiction or Relevant Endpoint?. 2021 , 29, 95-96	
382	Endothelial Recovery in Bare Metal Stents and Drug-Eluting Stents on a Single-Cell Level. 2021 , 41, 2277-2292	1
381	COBRA PzF Coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies?. 2021 ,	0
380	EFFECTS OF COATING PROPERTIES ON CONTROLLED DELIVERY FROM AN EMBEDDED DRUG-ELUTING STENT: A SIMULATION STUDY. 2021 , 29, 687-717	2
379	Real-World Clinical Outcomes of Indigenous Biodegradable Polymer Drug-Eluting Stents. 2021 , 13, e17886	
378	Precision delivery of liquid therapy into the arterial wall for the treatment of peripheral arterial disease. 2021 , 11, 18676	0
377	Drug-eluting stents. 2021 , 483-502	
376	The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy. 2021 , 13,	5
375	Final 5-Year Results in Randomized Japanese Patients Implanted With a Thin-Strut, Bioabsorbable, Polymer-Coated, Everolimus-Eluting SYNERGY Stent (From the EVOLVE II Study). 2020 , 3, 9-17	0
374	Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry. 2020 , 96, 1213-1221	1
373	Stents: Safety and Efficacy. 2014 , 115-141	1

372	Immunological and Phenotypic Considerations in Supplementing Cardiac Biomaterials with Cells. 2015 , 239-273	2
371	Advanced Stents for Cardiovascular Applications. 2016 , 407-426	3
370	Coronary Stents. 2019 , 1-13	1
369	Revascularization for Coronary Artery Disease: Principle and Challenges. 2020 , 1177, 75-100	5
368	Intimal Hyperplasia. 2010 , 69-88	1
367	Bare Metal and Drug-Eluting Coronary Stents. 2012 , 171-196	3
366	Restenosis. 2012 , 421-431	1
365	Qualitative and Quantitative Coronary Angiography. 2012 , 757-775	7
364	Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent). 2017 , 10, 1215-1221	64
363	Impact of different coronary angioscopic findings on arterial healing one year after bioresorbable-polymer and second-generation durable-polymer drug-eluting stent implantation. 2020 , 76, 371-377	3
362	Smart releasing electrospun nanofibers-poly: L.lactide fibers as dual drug delivery system for biomedical application. 2020 , 16, 015022	7
361	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. 2021 , 42, 339-351	24
360	Invasive Imaging and Haemodynamics. 2009 , 237-280	2
359	Noncardiac surgery for patients with coronary artery stents: timing is everything. 2008 , 109, 573-5	21
358	Comparison of coronary angioscopic findings 8 months after stent implantation between two kinds of biodegradable polymer-coated and one durable polymer-coated drug-eluting stent. 2021 , 32, 91-95	2
357	A review of bioresorbable scaffolds: hype or hope?. 2017 , 58, 512-515	4
356	A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. 2014 , 124, 4102-14	132
355	In-stent restenosis exacerbated by drug-induced severe eosinophilia after second-generation drug-eluting stent implantation. 2014 , 15, 397-400	7

354	Myocardial bridging is a potential risk factor of very late stent thrombosis of drug eluting stent. 2012 , 18, HY9-12	7
353	Automated stent coverage analysis in intravascular OCT (IVOCT) image volumes using a support vector machine and mesh growing. 2019 , 10, 2809-2828	9
352	3,3'-Diindolylmethane suppresses vascular smooth muscle cell phenotypic modulation and inhibits neointima formation after carotid injury. 2012 , 7, e34957	9
351	Nanoporous CREG-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. 2013 , 8, e60735	14
350	Association of localized hypersensitivity and in-stent neoatherosclerosis with the very late drug-eluting stent thrombosis. 2014 , 9, e113870	11
349	Stents Eluting 6-Mercaptopurine Reduce Neointima Formation and Inflammation while Enhancing Strut Coverage in Rabbits. 2015 , 10, e0138459	6
348	Targeting In-Stent-Stenosis with RGD- and CXCL1-Coated Mini-Stents in Mice. 2016 , 11, e0155829	13
347	Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent. 2017 , 12, e0170964	6
346	Effect of a Non-polymer Titanium Dioxide Thin Film-Coated Stent with Heparin in a Porcine Coronary Restenosis Model. 2017 , 3, 17-23	1
345	Early Phase Arterial Reaction Following Drug-Eluting and Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. 2015 , 56, 389-94	7
344	Very late stent thrombosis in late stent malapposition after sirolimus-eluting stent implantation. 2007 , 48, 591-6	11
343	Neointimal calcification after stenting and chronic kidney disease. 2013 , 54, 341-7	6
342	Delivery of Nanoparticles for the Treatment of Cardiovascular Diseases. 018-021	2
341	A feasibility study of using biodegradable magnesium alloy in glaucoma drainage device. 2018 , 11, 135-142	7
340	A novel polymer-free ciglitazone-coated vascular stent: in vivo and ex vivo analysis of stent endothelialization in a rabbit iliac artery model. 2016 , 7, 57571-57580	1
339	Intracoronary near-infrared spectroscopy-role and clinical applications. 2020 , 10, 1508-1516	4
338	Sirolimus-eluting coronary stents: a review. 2007 , 3, 191-201	39
337	Clopidogrel: the data, the experience, and the controversies. 2012 , 12, 361-74	6

336	Stent Thrombosis after Rescue Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction. 2015 , 9, 127-32	1
335	A Case Report of a DES-Implanted Patient : Continuation of Antiplatelet Therapy Would Prevent Stent Thrombosis after Surgery. 2011 , 31, 986-989	1
334	The Ultimaster coronary stent system: 5-year worldwide experience. 2020 , 16, 251-261	5
333	Abluminus DES+ for the treatment of coronary artery disease in patients with diabetes mellitus. 2020 , 16, 613-623	2
332	Benchside testing of drug-eluting stent surface and geometry. 2010 , 2, 159-175	15
331	Corrected and republished from: Regional anesthesia and antithrombotic agents: instructions for use. 2020 , 86, 341-353	2
330	Clinical applications of fractional flow reserve in bifurcation lesions. 2012 , 9, 278-84	9
329	The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study. 2010 , 25, 154-61	15
328	Perioperative management of antiplatelet therapy in patients with cardiovascular disease. 2008 , 31,	2
327	Evaluation of prolonged safety and efficacy of biodegradable polymer coated sirolimus-eluting coronary stent system: 1-year outcomes of the INDOLIMUS Registry. 2015 , 5, 249-53	1
326	Coronary artery aneurysms following drug eluting stents implantation: A retrospective analysis from series of cases at tertiary care cardiac centre over three years. 2019 , 7, 110	1
325	Safety and Efficacy of a Novel Everolimus-Eluting Stent System in Real-World Patients with Coronary Artery Disease: A Report of Preliminary Outcomes. 2016 , 06, 458-467	1
324	Histopathologic evaluation of nitinol self-expanding stents in an animal model of advanced atherosclerotic lesions. 2010 , 5, 737-44	11
323	Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial. 2017 , 12, 1623-1631	18
322	Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. 2017 , 12, 1747-1756	90
321	Characteristics of early versus late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study. 2017 , 13, 294-302	34
320	Impact of bioresorbable versus permanent polymer on longterm vessel wall inflammation and healing: a comparative drug-eluting stent experimental study. 2018 , 13, 1670-1679	7
319	Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model. 2017 , 13, e1096-e1098	23

318	Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents. 2017 , 13, 1336-1344	10
317	State of the art: coronary artery stents - past, present and future. 2017 , 13, 706-716	41
316	Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents. 2019 , 14, 1685-1693	19
315	Benefit of a new provisional stenting strategy, the re-proximal optimisation technique: the rePOT clinical study. 2018 , 14, e325-e332	26
314	Randomised evaluation of a novel biodegradable polymer-based sirolimus-eluting stent in ST-segment elevation myocardial infarction: the MASTER study. 2019 , 14, e1836-e1842	11
313	Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study. 2018 , 14, 780-788	13
312	Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial. 2018 , 14, 915-923	31
311	Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial. 2018 , 14, e343-e351	17
310	Prevalence of neoatherosclerosis in sirolimus-eluting stents in a very late phase after implantation. 2018 , 14, e1316-e1323	3
309	Intravascular ultrasound findings of the Fantom sirolimus-eluting bioresorbable scaffold at six- and nine-month follow-up: the FANTOM II study. 2018 , 14, e1215-e1223	4
308	Thromboresistance and functional healing in the COBRA PzF stent versus competitor DES: implications for dual antiplatelet therapy. 2019 , 15, e342-e353	16
307	Incidence and predictors of outcomes after a first definite coronary stent thrombosis. 2020 , 16, e344-e350	6
306	First-in-human evaluation of a novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial. 2020 , 16, e133-e140	5
305	Preclinical investigation of neoatherosclerosis in magnesium-based bioresorbable scaffolds versus thick-strut drug-eluting stents. 2020 , 16, e922-e929	1
304	Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. 2015 , 10, 1425-31	14
303	Drug-eluting stents and bare metal stents in patients with NSTEMI-ACS: 2-year outcome from the randomised BASKET-PROVE trial. 2014 , 10, 58-64	7
302	Flow disturbances in stent-related coronary evaginations: a computational fluid-dynamic simulation study. 2014 , 10, 113-23	11
301	Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. 2014 , 10, 38-46	86

300	Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. 2014 , 10, 212-23	8
299	An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents. 2014 , 10, 224-30	13
298	Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug eluting balloon in Coronary artery rEstenosis) randomised clinical trial. 2014 , 10, 439-48	46
297	Coronary stents seeded with human trophoblastic endovascular progenitor cells show accelerated strut coverage without excessive neointimal proliferation in a porcine model. 2014 , 10, 709-16	8
296	Comparison of vascular response between durable and biodegradable polymer-based drug-eluting stents in a porcine coronary artery model. 2014 , 10, 717-23	23
295	Vascular healing and integration of a fully bioresorbable everolimus-eluting scaffold in a rabbit iliac arterial model. 2014 , 10, 833-41	20
294	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial. 2015 , 11, 272-9	28
293	Pathological aspects of bioresorbable stent implantation. 2015 , 11 Suppl V, V159-65	14
292	Impact of local flow haemodynamics on atherosclerosis in coronary artery bifurcations. 2015 , 11 Suppl V, V18-22	27
291	Biological effect on restenosis and vascular healing of encapsulated paclitaxel nanocrystals delivered via coated balloon technology in the familial hypercholesterolaemic swine model of in-stent restenosis. 2016 , 12, 1164-1173	5
290	Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). 2007 , 3, 206-12	24
289	A novel ultra-thin bare metal stent (BMS): results from a worldwide registry. 2007 , 3, 249-55	5
288	Efficiency and safety of the sirolimus eluting stent in complex coronary artery lesions after cessation of dual antiplatelet therapy: fifteen months clinical outcome of the randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. 2007 , 3, 309-14	3
287	Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). 2007 , 3, 350-8	110
286	Endothelial progenitor cells, late stent thrombosis and delayed re-endothelialisation. 2008 , 3, 518-25	2
285	First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. 2008 , 3, 574-9	55
284	Optical coherence tomography to assess malapposition in overlapping drug-eluting stents. 2008 , 3, 580-3	42
283	Have we been misled by the ESC DES firestorm?. 2008 , 3, 535-7	14

282	Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. 2008 , 4, 59-63	39
281	Lower levels of in-stent late loss are not associated with the risk of stent thrombosis in patients receiving drug-eluting stents. 2008 , 4, 124-32	16
280	The neointimal response to stents eluting tacrolimus from a degradable coating depends on the balance between polymer degradation and drug release. 2008 , 4, 139-47	11
279	One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial. 2008 , 4, 200-7	11
278	Intrepid™Trapidil Eluting Stent. 2008 , 4, 405-411	2
277	Meeting report ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007. 2009 , 4, 427-436	2
276	Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry. 2009 , 5, 57-66	9
275	Very late changes in the dilated lesion following coronary balloon angioplasty: a 17 year serial quantitative angiographic study. 2009 , 5, 121-6	7
274	Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. 2009 , 5, 157-65	55
273	Reproducibility of quantitative optical coherence tomography for stent analysis. 2009 , 5, 224-32	91
272	Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. 2009 , 5, 255-64	19
271	Optical coherence tomography assessment of a new dedicated bifurcation stent. 2009 , 5, 544-51	21
270	First use in patients of a combined near infra-red spectroscopy and intra-vascular ultrasound catheter to identify composition and structure of coronary plaque. 2010 , 5, 755-6	45
269	Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. 2009 , 5 Suppl F, F58-64	46
268	OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings. 2009 , 5 Suppl F, F65-71	20
267	The bioabsorption process: tissue and cellular mechanisms and outcomes. 2009 , 5 Suppl F, F28-35	44
266	Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent. 2009 , 5 Suppl F, F36-42	8
265	Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial. 2010 , 6, 63-68	12

264	Optical coherence tomography (OCT) strut-level analysis of drug-eluting stents (DES) in human coronary bifurcations. 2010 , 6, 69-77	32
263	Strut apposition after coronary stent implantation visualised with optical coherence tomography. 2010 , 6, 86-93	16
262	Polymer-free cerivastatin-eluting stent shows superior neointimal inhibition with preserved vasomotor function compared to polymer-based paclitaxel-eluting stent in rabbit iliac arteries. 2010 , 6, 126-133	14
261	A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. 2010 , 6, 195-205	37
260	The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. 2010 , 6, 233-239	39
259	Intravascular ultrasound, angioscopic and histopathological characterisation of heterogeneous patterns of restenosis after sirolimus-eluting stent implantation: insights into potential "thromborestenosis" phenomenon. 2010 , 6, 380-7	35
258	Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating. 2010 , 6, 630-7	34
257	Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. 2010 , 6, 562-7	41
256	Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry. 2011 , 6, 831-7	8
255	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. 2011 , 6, 928-35	16
254	A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients. 2011 , 6, 949-54	14
253	Atheroma and coronary bifurcations: before and after stenting. 2010 , 6 Suppl J, J24-30	13
252	Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial. 2011 , 7, 64-73	7
251	Optical coherence tomography at follow-up after percutaneous coronary intervention: relationship between procedural dissections, stent strut malapposition and stent healing. 2011 , 7, 353-61	22
250	Paclitaxel-iodopromide coated balloon followed by "bail-out" bare metal stent in porcine iliofemoral arteries: first report on biological effects in peripheral circulation. 2011 , 7, 362-8	12
249	Final proximal post-dilatation is necessary after kissing balloon in bifurcation stenting. 2011 , 7, 597-604	73
248	Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. 2011 , 7, 730-7	60
247	In vitro and in vivo characterisation of biodegradable polymer-based drug-eluting stent. 2011 , 7, 835-43	16

246	Clinical long-term outcome after implantation of titanium nitride-oxide coated stents compared with paclitaxel- or sirolimus-eluting stents: propensity-score matched analysis. 2012 , 7, 1043-50	3
245	Drug-coated balloons in peripheral arterial disease. 2011 , 7 Suppl K, K70-6	5
244	Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug eLuting balloon in Coronary artery rEstenosis) study. 2011 , 7 Suppl K, K100-5	4
243	Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. 2012 , 8, 109-16	46
242	Vascular responses to a biodegradable polymer (polylactic acid) based biolimus A9-eluting stent in porcine models. 2012 , 8, 743-51	16
241	Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study. 2013 , 8, 1006-11	64
240	Randomised comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis. 2014 , 9, 1389-97	19
239	First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the meriT-1 trial. 2013 , 9, 493-500	23
238	Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months?. 2013 , 9, 620-8	68
237	Peri-stent contrast staining and very late stent thrombosis after sirolimus-eluting stent implantation: an observation from the RESTART (REgistry of Stent Thrombosis for review And Re-evaluaTion) angiographic substudy. 2013 , 9, 831-40	9
236	Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. 2013 , 9, 936-44	43
235	Comparison of paclitaxel-eluting vs. everolimus-eluting stents implanted simultaneously in different lesions of the same coronary artery: 12-month follow-up with optical coherence tomography. 2013 , 9, 952-8	3
234	Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. 2015 , 11, 926-34	46
233	A Y-shaped bifurcation-dedicated stent for the treatment of de novo coronary bifurcation lesions: an IVUS analysis from the BRANCH trial. 2015 , 10, e1-8	107
232	Delayed coverage of drug-eluting stents after interventional revascularisation of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry. 2016 , 11, 1004-12	13
231	Permanent and biodegradable polymer coatings in the absence of antiproliferative drugs in a porcine model of coronary artery stenting. 2016 , 11, 1020-6	10
230	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. 2016 , 11, 1372-9	52
229	DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial. 2016 , 12, e1336-e1342	12

228	Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry. 2016 , 12, e137-43	6
227	Drug-eluting stents and acute myocardial infarction: A lethal combination or friends?. 2014 , 6, 929-38	2
226	Bioresorbable Scaffolds: Current Technology and Future Perspectives. 2020 , 11,	8
225	Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR). 2019 , 26, 469-476	5
224	First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Syndromes (Katowice-Zabrze Registry). 2016 , 106, 373-81	7
223	Comparison of 9-Month Angiographic Follow-Up and Long-Term Clinical Outcomes of Biodegradable Polymer Drug-Eluting Stents and Second-Generation Durable Polymer Drug-Eluting Stents in Patients Undergoing Single Coronary Artery Stenting. 2020 , 36, 97-104	5
222	Direct Adsorption of Anti-CD34 Antibodies on the Nano-Porous Stent Surface to Enhance Endothelialization. 2016 , 32, 273-80	5
221	Human Umbilical Vein Endothelial Cell Interaction with Fluorine-Incorporated Amorphous Carbon Films. 2012 , 51, 090129	4
220	Clinical outcomes of ultrathin biodegradable polymer-coated sirolimus-eluting stents in an all-comer population: One-year results from the T-FLEX registry including high-risk subgroups. 2021 , 25, 706-715	0
219	Microneedle-mediated therapy for cardiovascular diseases. 2021 , 12, 472	2
218	Outcomes of intravascular ultrasound versus optical coherence tomography guided percutaneous coronary angiography: A meta regression-based analysis. 2021 ,	1
217	A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three Drug-Eluting Stents in Three Coronary Arteries. 2008 , 38, 564	3
216	Anti-platelet treatment for acute coronary syndrome in Japan. 2008 , 19, 504-509	
215	Drug-eluting stents: insights into safety and indications. 2008 , 28, 114-9	
214	[Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations]. 2008 , 149, 483-91	
213	Why don't we return to bare metal stents?. 2008 , 4, 36-41	
212	The Role of Percutaneous Coronary Revascularization in Advanced Ischemic Heart Disease. 2009 , 69-83	
211	De Gruyter. 2009 , 81,	

- 210 Formulation of nanoparticle-eluting stents by a cationic electrodeposit coating technology: Efficient and safe nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. **2009**, 17, 159-164 1
- 209 Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction. **2010**, 219-233
- 208 Carotid Stenting and Angioplasty. **2010**, 167-186
- 207 A practical approach to IVUS for in-stent restenosis and thrombosis. **2009**, 96-102
- 206 Surgery Against Cancer of Gastrointestinal Tract and Perioperative Management in Patients Receiving Drug-Eluting Coronary Stent Implantation. **2010**, 43, 882-892 1
- 205 Manejo de los antiagregantes en el perioperatorio. **2010**, 123-140
- 204 Optical Coherence Tomography for Coronary Imaging. 195-205
- 203 Modern Coronary Stenting. 23-39
- 202 Drug-Eluting Stent. **2010**, 114-122
- 201 Primary Percutaneous Coronary Intervention. **2010**, 65-77
- 200 Coronary Stent Technology. 330-344
- 199 Stent selection in patients with acute coronary syndromes and unstable coronary lesions. **2010**, 2, 545-557 1
- 198 Coronary artery stenting. **2010**, 412-428
- 197 Intravascular Photoacoustic and Ultrasound Imaging: From Tissue Characterization to Molecular Imaging to Image-Guided Therapy. **2011**, 787-816 1
- 196 Antithrombotic therapy in patients at risk for coronary stent thrombosis undergoing non-cardiac surgery. **2010**, 52, 25-30
- 195 ABSORB BVS Implantation in Bifurcation Lesions - Current Evidence and Practical Recommendations. **2014**, 9, 84-88
- 194 Lessons for the treatment of bifurcation lesions: from nowadays to the future. **2011**, 3, 55-65 1
- 193 Zotarolimus Eluting Stent Clinical Studies. 519-527

192 Novel Drug Eluting Stent Systems. 539-555

191 Principles of Intra-Coronary Optical Coherence Tomography. 172-178

190 Coronary Artery Disease: Development and Progression. **2012**, 21-28

0

189 Perioperative Management of Oral Anticoagulants and Antiplatelet Agents. 161-177

188 Drug-Coated Balloons. **2012**, 197-202

187 Development and implementation of an advanced coronary angiography and intervention database system. **2012**, 53, 35-42

3

186 Sirolimus-Versus Zotarolimus-Eluting Stents in Acute Coronary Syndromes With C Type Left Anterior Descending Artery Lesions: A Three-Year Clinical Follow-Up. **2012**, 3, 116-122

185 Percutaneous Coronary Intervention in Acute ST Segment Elevation Myocardial Infarction. **2012**, 237-262

184 Treatment of Coronary Artery Bifurcation Lesions. **2013**, 555-574

183 Challenges in the management of postpartum spontaneous coronary artery dissection. **2012**, 4, 371-386

1

182 Intracoronary Stenting Strategies. **2013**, 497-529

181 Percutaneous Coronary Intervention. 205-242

180 Continuation of dual anti-platelet therapy after drug-eluting stents in primary angioplasty beyond 12 months. **2012**, 1, 53

179 Antithrombotic therapy for atherothrombotic disease. **2013**, 24, 30-37

178 Application of Invasive Intracoronary Imaging Devices to Clinical Use. **2013**, 19, 315-321

177 Assessing Safety of CABG in the Era Post Primary PCI, an Outcome Analysis of STEMI Population. **2013**, 03, 15-22

176 Quadratic ODE and PDE Models of Drug Release Kinetics from Biodegradable Polymers. **2013**, 13-24

175 A case of very late stent thrombosis after sirolimus-eluting stent implantation in a patient with provoked severe coronary spasm. **2013**, 03, 6-8

- 174 Clinical Outcomes of Stent Thrombosis after Drug-Eluting Coronary Stent Implantation. **2013**, 13, 880-892 3
- 173 Bioresorbable Scaffolds. **2014**, 9, 175-179 1
- 172 Seven Years Follow-Up of Biodegradable Polymer Coated Paclitaxel-Eluting Infinium Coronary Stent in Saudi Arabia. **2014**, 05, 216-224
- 171 Severe coronary spasm following implantation of biodegradable polymer Biolimus-eluting stent in an elderly patient. **2014**, 21, 101-105
- 170 Cardiac disease and anaesthesia. **2014**, 235-260
- 169 Intravascular Molecular Imaging of Proteolytic Activity. **2015**, 79-106
- 168 Growth Factor Delivery Matrices for Cardiovascular Regeneration. **2015**, 159-214
- 167 [Value of the optical coherence tomography in the treatment guided of the stent failure. Case report]. **2014**, 84, 305-9
- 166 Stent Thrombosis. **2015**, 147-165
- 165 Late Stent Change. **2015**, 137-146
- 164 What Is the Optimal Stent Design Interventionalist's View. **2015**, 307-331
- 163 Nine-Months Clinical Outcome of Biodegradable Polymer Coated Sirolimus-eluting Stent System: A Multi-Centre "Real-World" Experience. **2015**, 9, OC23-6
- 162 Angioscopy and Coronary Endothelial Function. **2015**, 95-105 1
- 161 Vascular Pathology and Interventional Treatments. **2015**, 303-325
- 160 Drug-Eluting Stents and Coronary Artery Disease. **2015**, 495-524
- 159 Risk of Stent Stenosis after Implanting a First-Generation Drug-Eluting Stent and Drug Balloon Angioplasty. **2015**, 88, 690
- 158 A Case of Peri-stent Contrast Staining Nine Months after Nobori Biolimus A9-Eluting Stent Implantation. **2015**, 7, 23-30
- 157 What Is the Optimal Stent Design? The Pathologist's Opinion. **2015**, 287-305

- 156 Coronary Angioscopic Insights into Several Drug-Eluting Stents of Different Platforms. **2015**, 163-179
- 155 A Polymer Coated Cicaprost-Eluting Stent Increases Neointima Formation and Impairs Vessel Function in the Rabbit Iliac Artery. **2016**, 07, 226-235
- 154 Stents: Endovascular. 7586-7600
- 153 Cuff-Induced Neointimal Formation in Mouse Models. **2016**, 21-41
- 152 Can Platforms Affect the Safety and Efficacy of Drug-Eluting Stents in the Era of Biodegradable Polymers?: A Meta-Analysis of 34,850 Randomized Individuals. **2016**, 11, e0151259
- 151 Bioresorbable scaffolds for the treatment of in-stent restenosis: an alternative to double metal layers?. **2016**, 11, 1451-3
- 150 Characteristics of Coronary Lesions in Small Vessel Disease Treated with Elective Stenting in Patients with Type 2 Diabetes Mellitus. **2016**, 1, 55-61
- 149 Bioresorbable vascular scaffolds - Magic of the ephemeral?. **2016**, 15, 127-134 2
- 148 Urgent Surgery Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy of Non-vitamin K Antagonist Oral Anticoagulant, Aspirin, and Clopidogrel. **2017**, 169-182
- 147 Usefulness of coronary spasm provocation test in patients received coronary stents. **2017**, 23, 139-145
- 146 Acute and Chronic Vascular Effects of Percutaneous Coronary Interventions. **2017**, 111-117
- 145 Coronary Aneurysm Formation After Bioresorbable Vascular Scaffold Implantation Resulting in Acute Myocardial Infarction. **2017**, 18, 541-548 1
- 144 Stents: Endovascular. **2017**, 1465-1479
- 143 Abbott: Current and next generation ABSORB scaffold. **2017**, 484-490
- 142 Endeavours to define optimal antithrombotic therapy after percutaneous coronary intervention. **2017**, 13, e1386-e1391
- 141 Everolimus-eluting bioresorbable vascular scaffolds for the left anterior descending coronary artery disease: 12-month follow up. **2018**, 13, 41
- 140 A Review of the Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent in the Treatment of Coronary Artery Disease. **2019**, 13, 17 2
- 139 Platelet Reactivity in Patients with Coronary Stenting Treated with Dual Antiplatelet Therapy and after Withdrawal of Clopidogrel: Impact of Bioactive Titanium Stent versus Everolimus-coated Stent. **2019**, 65-82

- 138 Current concepts regarding drug dosing for peripheral stents. **2019**, 60, 439-449
- 137 One-year outcomes of a NeoHexa sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease patients: Results from NeoRegistry in India. **2019**, 11, 200-208 ○
- 136 Hydrogel Coatings for Heart Stents. 1-14
- 135 Capturing Endothelial Cells by Coronary Stents - From Histology to Clinical Outcomes. **2019**, ○
- 134 Emerging therapies in coronary balloon angioplasty, stenting, and bioabsorbable scaffolds. **2020**, 527-557
- 133 Right Coronary Artery Pseudoaneurysm With Hemopericardium: A Rare Complication of Percutaneous Coronary Intervention. **2020**, 12, e8567
- 132 Comparison of Neointimal Response between Durable-Polymer Everolimus-Eluting Stent and Bioabsorbable-Polymer Everolimus-Eluting Stent for Severely Calcified Lesions Requiring Rotational Atherectomy. **2020**, 61, 665-672 ○
- 131 Recent advances in cardiovascular stent for treatment of in-stent restenosis: Mechanisms and strategies. **2021**, 37, 12-29 2
- 130 Intracoronary tenecteplase for stent thrombosis. **2021**,
- 129 Stent thrombosis in acute coronary syndromes: Patient-related factors and operator-related factors. **2020**, 24, 274-279 2
- 128 Impact of ultra-long sirolimus-eluting stents on coronary artery lesions: one-year results of real-world FLEX-LONG Study. **2020**, 111, 529-535 ○
- 127 Efficacy and Safety of Dual-Drug-Eluting Stents for de Novo Coronary Lesions in South Korea-The Effect Trial. **2020**, 10, ○
- 126 Chitosan as a biomaterial for implantable drug delivery. **2022**, 133-158
- 125 Very Late Stent Thrombosis. **2020**, 125-137
- 124 The Effect Of Smoking On Platelet Reactivity Assessed By P2Y12 Platelet Function Testing In Patient With Clopidogrel Therapy.
- 123 Coronary Stents and Metal Allergy. **2020**, 1-13
- 122 Extremely Late In-Stent Thrombosis 12 Years After Implantation of a Drug-Eluting Stent. **2020**, 12, e9053 ○
- 121 Research Utility of Optical Coherence Tomography (OCT). 220-238

120	Coronary Stents and Metal Allergy. 2021 , 1171-1183	0
119	Ultrathin biodegradable polymer sirolimus-eluting stent versus contemporary durable polymer everolimus-eluting stent for percutaneous coronary intervention: a meta-analysis of randomized trials. 2021 , 32, 459-465	1
118	REabsorbable vs. DUrable Polymer Drug-Eluting Stents in All-Comer PatiEnts: the REDUCE registry. 2021 , 32, 281-287	0
117	Update on stents: recent studies on the TAXUS stent system in small vessels. 2007 , 3, 481-90	3
116	Retractable-needle catheters: an update on local drug delivery in coronary interventions. 2008 , 35, 419-24	
115	Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells. 2010 , 37, 194-201	22
114	Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review. 2010 , 37, 343-6	8
113	Simultaneous very late stent thrombosis in multiple coronary arteries. 2012 , 39, 630-4	5
112	Effectiveness of Two-Year versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis after Drug-Eluting Stent Implantation. 2012 , 7, 47-52	2
111	Controversies in the use & implementation of drug-eluting stent technology. 2012 , 136, 926-41	
110	Intravascular near-infrared fluorescence molecular imaging of atherosclerosis. 2013 , 3, 217-31	14
109	The twelve-month outcome of biolimus eluting stent with biodegradable polymer compared with an everolimus eluting stent with durable polymer. 2011 , 3, 113-6	18
108	OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-month vs. 6-month Approach. 2012 , 4, 81-4	2
107	What is the clinical benefit of neutrophil-lymphocyte ratio in cardiovascular patients?. 2014 , 6, 131-2	1
106	Very late outcomes of drug-eluting stents coated with biodegradable polymers: insights from the 5-year follow-up of the randomized PAIN trial. 2014 , 4, 480-6	5
105	Poly-l-lactic acid/amorphous calcium phosphate bioabsorbable stent causes less inflammation than poly-l-lactic acid stent in coronary arteries. 2014 , 7, 5317-23	5
104	Early surgery after coronary revascularization: a fine line between bleeding and thrombosis. 2015 , 11, 14-23	
103	Effect of enoxaparin on clinical events after percutaneous coronary intervention. 2015 , 8, 10815-24	

102	Mechanism of in-stent restenosis after second-generation drug-eluting stents (DES): is it different from bare-metal stents and first-generation DES?. 2015 , 7, E599-602	4
101	Three-Year Clinical Outcomes of a Polymer-Free Paclitaxel-Eluting Microporous Stent in Real-World Practice: Final Results of the Safety and Efficacy Registry of the Yinyi Stent (SERY-I). 2017 , 33, 28-33	2
100	Neoatherosclerosis and Late Thrombosis After Percutaneous Coronary Intervention: Translational Cardiology and Comparative Medicine from Bench to Bedside. 2017 , 90, 463-470	4
99	Incremental age-related one-year MACCE after acute myocardial infarction in the drug-eluting stent era (from KAMIR-NIH registry). 2018 , 15, 574-584	2
98	Double-vessel very late stent thrombosis following Resolute Onyx zotarolimus eluting stents implantation in an octogenarian. 2018 , 15, 639-643	2
97	Comparison of Long-Term Safety and Efficacy of Bioresorbable Scaffolds between Patients with and without Diabetes Mellitus. 2021 , 37, 138-145	
96	Nanoparticles-reinforced poly-l-lactic acid composite materials as bioresorbable scaffold candidates for coronary stents: Insights from mechanical and finite element analysis. 2022 , 125, 104977	1
95	Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry. 2021 , 21, 537	
94	New Ultrasound-Controlled Paclitaxel Releasing Balloon vs. Asymmetric Drug-Eluting Stent in Primary ST-Segment Elevation Myocardial Infarction - A Prospective Randomized Trial. 2021 ,	0
93	Optical coherence tomographic insights of very late stent thrombosis of a second-generation drug-eluting stent: a case report.. 2021 , 5, ytab490	
92	Type IV myocardial infarction associated with acute stent thrombosis in the early period after revascularization in a patient with new coronavirus infection COVID-19. 2021 , 99, 369-374	
91	Overcoming challenges in refining the current generation of coronary stents. 2021 ,	
90	Adventitial histopathological changes after coronary stenting in a porcine model. 2020 , 65, 465-472	
89	A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better?. 2021 , 15, 84	1
88	JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease.. 2022 , 86,	3
87	Debulking strategies in revascularization of diseased saphenous vein bypass grafts. 2022 , 377-412	
86	Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients.. 2022 , 53, 671	1
85	Treatment and Outcome of Patients With Coronary Artery Ectasia: Current Evidence and Novel Opportunities for an Old Dilemma.. 2021 , 8, 805727	3

84	Target and non-target vessel related events at 10 years post percutaneous coronary intervention.. 2022 , 1	0
83	A Comparative Analysis of Two Biolimus-Eluting Biodegradable Stents: Evaluation of the Equivalence of 6 Months Versus 12 Months of DAPT Following Biolimus-Eluting Stent Implantation in Acute Coronary Syndrome (EQUUS). 2022 , 1, 61	
82	Diabetes and restenosis.. 2022 , 21, 23	5
81	In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches.. 2022 , 12,	4
80	Effects of Aggressive PSP Strategy for Coronary Bioresorbable Vascular Scaffolds Implantation.. 2022 ,	
79	Analysis of Functionalized Ferromagnetic Memory Alloys from the Perspective of Developing a Medical Vascular Implant.. 2022 , 14,	1
78	A primary lung cancer patient who underwent lobectomy after one month of dual antiplatelet therapy following coronary stent deployment. 2022 , 36, 150-155	
77	Coronary Bifurcation Stenting: Review of Current Techniques and Evidence.. 2022 ,	
76	A nitric oxide-eluting and REDV peptide-conjugated coating promotes vascular healing.. 2022 , 284, 121478	2
75	Real-World Long-Term Clinical Outcomes of Ultrathin Strut Biodegradable Polymer Drug-Eluting Stents in Korean ST-Segment-Elevation Myocardial Infarction (STEMI) Patients with or without Acute Heart Failure Undergoing Primary Percutaneous Coronary Intervention.. 2021 , 10,	
74	Simultaneous Multi-Vessel Very Late Stent Thrombosis in Acute ST-Segment Elevation Myocardial Infarction.. 2021 , 2021, 2658094	0
73	An implantable Artificial Atherosclerotic Plaque as a Novel Approach for Drug Transport Studies on Drug-eluting Stents. 2021 , e2101570	
72	Assessment of the State of the Implanted Stents with the Method of Optical Coherence Tomography in 6 Months after Implantation in the Area of Recanalized Chronic Occlusions of Coronary Arteries. 2020 , 217-232	
71	Clinical Outcomes of Drug-Coated Balloon Treatment After Successful Revascularization of Chronic Total Occlusions.. 2022 , 9, 821380	2
70	A Senolytic-Eluting Coronary Stent for the Prevention of In-Stent Restenosis.. 2022 ,	1
69	Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds-Insights From an All-Comer Registry.. 2022 , 9, 856930	1
68	Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial.. 2022 , 101161CIRCINTERVENTIONS121011569	0
67	Chapter 4. Biological Consequences of the BloodSurface Interaction. 136-183	

- 66 The Predictive Value of the Perivascular Adipose Tissue CT Fat Attenuation Index for Coronary In-stent Restenosis.. **2022**, 9, 822308 0
- 65 Long-Term Clinical Outcomes Between Biodegradable and Durable Polymer Drug-Eluting Stents: A Nationwide Cohort Study.. **2022**, 9, 873114
- 64 Can an ultrathin strut stent design and a polymer free, proendothelializing probucol matrix coating improve early strut healing? The FRIENDLY-OCT trial. An intra-patient randomized study with OCT, evaluating early strut coverage of a novel probucol coated polymer-free and ultra-thin strut sirolimus-eluting stent compared to a biodegradable polymer sirolimus-eluting stent.. **2022**, 1 1
- 63 Efficacy and Safety of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Peripheral Artery Disease: A Single-Arm Meta-Analysis.. **2022**, 15266028221091899 0
- 62 Optical Coherence Tomography, Near-Infrared Spectroscopy, and Near-Infrared Fluorescence Molecular Imaging. **2022**, 107-125
- 61 Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the Euro Bifurcation Club registry.. **2022**, 0
- 60 Impact of Drug-Eluting Stent-associated Coronary Artery Spasm on 3-Year Clinical Outcomes: A Propensity Score Matching Analysis.. **2022**,
- 59 Evaluation of Efficacy and Safety of Paclitaxel and Cilostazol Dual Drug-eluting Coronary Stents. 1,
- 58 Effect of Variable Diffusivity on Solute Transfer with Reference to Stent. **2023**, 187-200
- 57 Comparative study of neointimal coverage between titanium-nitric oxide-coated and everolimus-eluting stents in acute coronary syndromes. **2022**,
- 56 A Randomized Comparison of the Healing Response Between the Firehawk Stent and the Xience Stent in Patients With ST-Segment Elevation Myocardial Infarction at 6 Months of Follow-Up (TARGET STEMI OCT China Trial): An Optical Coherence Tomography Study. **2022**, 9, 1 1
- 55 Management of in-stent restenosis. **2022**, 18, e103-e123 2
- 54 Predictive Value Analysis of in-Stent Restenosis Within Three Years in Older Acute Coronary Syndrome Patients: A Two-Center Retrospective Study. **2022**, 28, 107602962211078 0
- 53 Myocardial ischemia and its complications. **2022**, 407-445
- 52 Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist). **2022**, 11, 2094 0
- 51 Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside. 2
- 50 Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?. 2
- 49 Bioengineering Extracellular Vesicles for the Treatment of Cardiovascular Diseases. 2200087 0

48	Coronary In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2022 , 80, 348-372	15.1	3
47	Fully implantable batteryless soft platforms with printed nanomaterial-based arterial stiffness sensors for wireless continuous monitoring of restenosis in real time. 2022 , 46, 101557		2
46	PolymerMetal Composite Healthcare Materials: From Nano to Device Scale. 2022 , 6, 218		0
45	Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk. 2022 ,		0
44	Estudio comparativo de la cobertura neointimal entre los stents con recubrimiento de titanio-óxido nítrico y los liberadores de everolimus en el síndrome coronario agudo. 2022 ,		0
43	An intricate interplay between stent drug dose and release rate dictates arterial restenosis. 2022 , 349, 992-1008		1
42	Clinical rationale and experimental feasibility of the first national drug-eluting stent platform. 2020 , 9, 52-62		0
41	Development of Biodegradable Polymeric Stents for the Treatment of Cardiovascular Diseases. 2022 , 12, 1245		5
40	Drug-Eluting, Bioresorbable Cardiovascular Stents-Challenges and Perspectives.		0
39	Resection of a synovial cell sarcoma by cardiac autotransplantation: A case report. 2022 ,		0
38	Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent. 2022 , 2022, 1-9		0
37	Timing and predictors of definite stent thrombosis in comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention and therapeutic hypothermia (ST-OHCA study). 2022 , 18, 740-748		0
36	The factors influencing the efficiency of drug-coated balloons. 9,		1
35	Stent Thrombosis After Percutaneous Coronary Intervention. 2022 , 11, 465-473		0
34	Advancements and Opportunities in Characterizing Patient-Specific Wall Shear Stress Imposed by Coronary Artery Stenting. 2022 , 7, 325		0
33	Heterogeneous vascular response after implantation of bare nitinol self-expanding stents in the swine femoropopliteal artery.		0
32	Cell proliferation. 2022 ,		0
31	Structural and temporal dynamics analysis on drug-eluting stents: History, research hotspots and emerging trends. 2023 , 23, 170-186		1

- 30 Long-term clinical outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer sirolimus-eluting stents. **2018**, 4, 77-86 ○
- 29 Repair effect of the poly (D,L-lactic acid) nanoparticle containing tauroursodeoxycholic acid-eluting stents on endothelial injury after stent implantation. 9, ○
- 28 Three-Year Clinical Outcomes of a Thin-Strut Biodegradable-Polymer Everolimus-Eluting Stent in Patients With Acute Coronary Syndrome. 2, ○
- 27 Contemporary Drug-Eluting Stents and Vascular Response. 60-68 ○
- 26 Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention. **2022**, 27, 8144 1
- 25 Bifurcation strategies using second-generation drug-eluting stents on clinical outcomes in diabetic patients. 9, ○
- 24 A Randomized Controlled Trial of a Biodegradable Polymer, Microcrystalline Sirolimus-Eluting Stent (MiStent) versus Another Biodegradable Polymer Sirolimus-Eluting Stent (TIVOLI): The DESSOLVE-C Trial. Publish Ahead of Print, ○
- 23 Progression and interventional therapy of a coronary pseudoaneurysm ̄ case report. ○
- 22 Nanoparticle Drug Eluting Stents for Treatment of Coronary Re-stenosis in unsteady non-Newtonian magneto-hemodynamics: Computational fluid dynamic simulation. ○
- 21 Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial. **2023**, 16, ○
- 20 Determinants and long-term outcomes of largely uncovered struts in thin-struts drug-eluting stents assessed by optical coherence tomography. **2022**, 100, ○
- 19 Polymer Free Amphilimus Drug Eluting Stent for Infrapopliteal Arterial Disease in Patients with Critical Limb Ischemia: A New Device in the Armamentarium. **2023**, 59, 39 ○
- 18 Evolution of Drug-Eluting Stent Drug Elution Profile: Is a Crystalline Drug Form the Ideal Solution?. 55-67 ○
- 17 Optical Coherence Tomography-Guided Percutaneous Coronary Intervention. **2023**, ○
- 16 Nanoparticle Drug Eluting Stents for Treatment of Coronary Re-stenosis in unsteady non-Newtonian magneto-hemodynamics: Computational fluid dynamic simulation. ○
- 15 A retrospective study from a single center to compare outcomes in 79 patients with in-stent restenosis treated with paclitaxel-coated balloon angioplasty or drug-eluting stent implantation. **2023**, 75, ○
- 14 How Bioresorbable Vascular Can Be Beneficial for Patients in the Long-Term. 2-14 ○
- 13 Migration of endothelial cells on the surface of anodized Ni-Ti stent strut. 5, ○

- 12 Is Stent Thrombosis a Genetic Disease?. **2023**, 2, 100194
- 11 OCTOPUS [Optical coherence tomography plaque and stent analysis software. **2023**, 9, e13396
- 10 Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence. **2023**, 12, 1238
- 9 The outcome of ultrathin-strut biodegradable polymer-coated sirolimus-eluting stents in coronary artery disease patients [A feasibility study. **2023**, 24, 1
- 8 Five-year outcomes of biodegradable versus second-generation durable polymer drug-eluting stents used in complex percutaneous coronary intervention. **2023**, 136, 322-330
- 7 Preclinical Evaluation of an Everolimus-Eluting Bioresorbable Vascular Scaffold Via a Long-Term Rabbit Iliac Artery Model. **2023**, 20, 239-249
- 6 Management of In-stent Restenosis. 8, 142-155
- 5 The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy. **2023**, 100629
- 4 Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in NonST-Elevation Coronary Syndromes and Multivessel Disease: A Systematic Review and Meta-Analysis. **2023**, 195, 70-76
- 3 Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt from Recent Trials, a Literature Review. **2023**, 12, 2833
- 2 Stent strut thickness and outcome in chronic total coronary occlusions: The thinner the better?. **2023**,
- 1 Long-term Outcomes for Drug-eluting Balloons versus Drug-eluting Stents in the Treatment of Small Vessel Coronary Artery Disease: A Systematic Review and Meta-analysis. 18,